Document_And_Entity_Informatio
Document And Entity Information (USD $) | 12 Months Ended | ||
Jul. 31, 2014 | Oct. 01, 2014 | Jan. 31, 2014 | |
Document and Entity Information [Abstract] | ' | ' | ' |
Entity Registrant Name | 'ENZO BIOCHEM INC | ' | ' |
Document Type | '10-K | ' | ' |
Current Fiscal Year End Date | '--07-31 | ' | ' |
Entity Common Stock, Shares Outstanding | ' | 44,504,000 | ' |
Entity Public Float | ' | ' | $107,702,000 |
Amendment Flag | 'false | ' | ' |
Entity Central Index Key | '0000316253 | ' | ' |
Entity Current Reporting Status | 'Yes | ' | ' |
Entity Voluntary Filers | 'No | ' | ' |
Entity Filer Category | 'Accelerated Filer | ' | ' |
Entity Well-known Seasoned Issuer | 'No | ' | ' |
Document Period End Date | 31-Jul-14 | ' | ' |
Document Fiscal Year Focus | '2014 | ' | ' |
Document Fiscal Period Focus | 'FY | ' | ' |
CONSOLIDATED_BALANCE_SHEETS
CONSOLIDATED BALANCE SHEETS (USD $) | Jul. 31, 2014 | Jul. 31, 2013 |
In Thousands, unless otherwise specified | ||
ASSETS | ' | ' |
Cash and cash equivalents | $17,455 | $9,007 |
Accounts receivable, net of allowance for doubtful accounts of $2,142 in 2014 and $2,707 in 2013 | 12,470 | 12,288 |
Inventories | 8,690 | 8,805 |
Prepaid expenses | 2,121 | 2,456 |
Total current assets | 40,736 | 32,556 |
Property, plant, and equipment, net | 7,730 | 8,617 |
Goodwill | 7,452 | 7,452 |
Intangible assets, net | 8,108 | 9,943 |
Other | 385 | 390 |
Total assets | 64,411 | 58,958 |
LIABILITIES AND STOCKHOLDERS’ EQUITY | ' | ' |
Loan payable | 3,013 | 3,264 |
Accounts payable - trade | 8,245 | 8,481 |
Accrued liabilities | 12,917 | 11,776 |
Other current liabilities | 790 | 331 |
Total current liabilities | 24,965 | 23,852 |
Deferred taxes | 183 | 200 |
Other liabilities | 2,313 | 774 |
Total liabilities | 27,461 | 24,826 |
Commitments and contingencies | ' | ' |
Stockholders’ equity: | ' | ' |
Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding | ' | ' |
Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued: 44,239,183 at July 31, 2014 and 40,569,393 at July 31, 2013 | 443 | 406 |
Additional paid-in capital | 317,160 | 304,288 |
Accumulated deficit | -282,397 | -272,420 |
Accumulated other comprehensive income | 1,744 | 1,858 |
Total stockholders’ equity | 36,950 | 34,132 |
Total liabilities and stockholders’ equity | $64,411 | $58,958 |
CONSOLIDATED_BALANCE_SHEETS_Pa
CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $) | Jul. 31, 2014 | Jul. 31, 2013 |
In Thousands, except Share data, unless otherwise specified | ||
Allowance for doubtful accounts (in Dollars) | $2,142 | $2,707 |
Preferred Stock, par value (in Dollars per share) | $0.01 | $0.01 |
Preferred Stock, shares authorized | 25,000,000 | 25,000,000 |
Preferred Stock, shares issued | 0 | 0 |
Preferred Stock, shares outstanding | 0 | 0 |
Common Stock, par value (in Dollars per share) | $0.01 | $0.01 |
Common Stock, shares authorized | 75,000,000 | 75,000,000 |
Common Stock, shares issued | 44,239,183 | 40,569,393 |
CONSOLIDATED_STATEMENTS_OF_OPE
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) | 12 Months Ended | ||
In Thousands, except Per Share data, unless otherwise specified | Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 |
Revenues: | ' | ' | ' |
Clinical laboratory services | $58,689 | $55,889 | $59,403 |
Product revenues | 32,850 | 32,526 | 37,722 |
Royalty and license fee income | 4,408 | 5,292 | 5,958 |
Total revenues | 95,947 | 93,707 | 103,083 |
Operating expenses: | ' | ' | ' |
Cost of clinical laboratory services | 38,948 | 38,251 | 36,305 |
Cost of product revenues | 15,320 | 16,584 | 19,668 |
Research and development | 3,141 | 3,889 | 6,293 |
Selling, general, and administrative | 41,801 | 43,654 | 47,928 |
Provision for uncollectible accounts receivable | 3,063 | 4,496 | 5,104 |
Legal fee expense | 6,954 | 5,813 | 3,724 |
Legal settlements, net | -3,100 | ' | ' |
Impairment charges | ' | ' | 24,540 |
Total operating expenses | 106,127 | 112,687 | 143,562 |
Operating loss | -10,180 | -18,980 | -40,479 |
Other income (expense): | ' | ' | ' |
Interest | -208 | -54 | 21 |
Other | 194 | 5 | 77 |
Foreign exchange gain (loss) | 289 | 80 | -540 |
Loss before income taxes | -9,905 | -18,949 | -40,921 |
(Provision) benefit for income taxes | -72 | 712 | 1,652 |
Net loss | ($9,977) | ($18,237) | ($39,269) |
Net loss per common share: | ' | ' | ' |
Basic and diluted (in Dollars per share) | ($0.23) | ($0.46) | ($1.01) |
Weighted average common shares outstanding: | ' | ' | ' |
Basic and diluted (in Shares) | 42,561 | 39,607 | 38,798 |
CONSOLIDATED_STATEMENTS_OF_COM
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 |
Net loss | ($9,977) | ($18,237) | ($39,269) |
Other comprehensive income (loss): | ' | ' | ' |
Foreign currency translation adjustments | -114 | 253 | -2,188 |
Comprehensive loss | ($10,091) | ($17,984) | ($41,457) |
CONSOLIDATED_STATEMENTS_OF_STO
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $) | Common Stock [Member] | Treasury Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Accumulated Other Comprehensive Income (Loss) [Member] | Total |
In Thousands, except Share data | ||||||
Balance at Jul. 31, 2011 | $390 | ($6,387) | $305,833 | ($214,914) | $3,793 | $88,715 |
Balance (in Shares) at Jul. 31, 2011 | 39,045,837 | 450,014 | ' | ' | ' | ' |
Net (loss) for the year ended | ' | ' | ' | -39,269 | ' | -39,269 |
Vesting of restricted stock | 2 | ' | ' | ' | ' | 2 |
Vesting of restricted stock (in Shares) | 174,638 | ' | ' | ' | ' | ' |
Share-based compensation charges | ' | ' | 719 | ' | ' | 719 |
Issuance of treasury stock for employee 401(k) plan match | ' | 3,313 | -2,664 | ' | ' | 649 |
Issuance of treasury stock for employee 401(k) plan match (in Shares) | ' | -233,458 | ' | ' | ' | ' |
Issuance of common stock for services | 3 | ' | 470 | ' | ' | 473 |
Issuance of common stock for services (in Shares) | 275,000 | ' | ' | ' | ' | ' |
Foreign currency translation adjustments | ' | ' | ' | ' | -2,188 | -2,188 |
Balance at Jul. 31, 2012 | 395 | -3,074 | 304,358 | -254,183 | 1,605 | 49,101 |
Balance (in Shares) at Jul. 31, 2012 | 39,495,475 | 216,556 | ' | ' | ' | ' |
Net (loss) for the year ended | ' | ' | ' | -18,237 | ' | -18,237 |
Vesting of restricted stock | 2 | ' | ' | ' | ' | 2 |
Vesting of restricted stock (in Shares) | 157,784 | ' | ' | ' | ' | ' |
Share-based compensation charges | ' | ' | 545 | ' | ' | 545 |
Net proceeds from Issuance of common stock | 9 | ' | 1,816 | ' | ' | 1,825 |
Net proceeds from Issuance of common stock (in Shares) | 906,715 | ' | ' | ' | ' | 906,715 |
Issuance of treasury stock for employee 401(k) plan match | ' | 3,074 | -2,458 | ' | ' | 616 |
Issuance of treasury stock for employee 401(k) plan match (in Shares) | ' | -216,556 | ' | ' | ' | ' |
Issuance of common stock for employee 401(k) plan match | ' | ' | 27 | ' | ' | 27 |
Issuance of common stock for employee 401(k) plan match (in Shares) | 9,419 | ' | ' | ' | ' | 9,419 |
Foreign currency translation adjustments | ' | ' | ' | ' | 253 | 253 |
Balance at Jul. 31, 2013 | 406 | ' | 304,288 | -272,420 | 1,858 | 34,132 |
Balance (in Shares) at Jul. 31, 2013 | 40,569,393 | ' | ' | ' | ' | ' |
Net (loss) for the year ended | ' | ' | ' | -9,977 | ' | -9,977 |
Vesting of restricted stock | 1 | ' | ' | ' | ' | 1 |
Vesting of restricted stock (in Shares) | 82,968 | ' | ' | ' | ' | ' |
Share-based compensation charges | ' | ' | 594 | ' | ' | 594 |
Net proceeds from Issuance of common stock | 34 | ' | 11,508 | ' | ' | 11,542 |
Net proceeds from Issuance of common stock (in Shares) | 3,421,176 | ' | ' | ' | ' | ' |
Issuance of options in lieu of payment of cash bonuses | ' | ' | 136 | ' | ' | 136 |
Issuance of common stock for employee 401(k) plan match | 2 | ' | 634 | ' | ' | 636 |
Issuance of common stock for employee 401(k) plan match (in Shares) | 165,646 | ' | ' | ' | ' | 165,646 |
Foreign currency translation adjustments | ' | ' | ' | ' | -114 | -114 |
Balance at Jul. 31, 2014 | $443 | ' | $317,160 | ($282,397) | $1,744 | $36,950 |
Balance (in Shares) at Jul. 31, 2014 | 44,239,183 | ' | ' | ' | ' | ' |
CONSOLIDATED_STATEMENTS_OF_STO1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parentheticals) (USD $) | 12 Months Ended | |
In Thousands, unless otherwise specified | Jul. 31, 2014 | Jul. 31, 2013 |
Issuance of common stock, expenses | $357 | $224 |
Common Stock [Member] | ' | ' |
Issuance of common stock, expenses | 357 | 224 |
Additional Paid-in Capital [Member] | ' | ' |
Issuance of common stock, expenses | $357 | $224 |
CONSOLIDATED_STATEMENTS_OF_CAS
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 |
Cash flows from operating activities: | ' | ' | ' |
Net loss | ($9,977) | ($18,237) | ($39,269) |
Adjustments to reconcile net loss to net cash used in operating activities: | ' | ' | ' |
Depreciation and amortization of property, plant and equipment | 2,131 | 2,615 | 2,817 |
Amortization of intangible assets | 1,840 | 1,990 | 1,660 |
Provision for uncollectible accounts receivable | 3,063 | 4,496 | 5,104 |
Deferred income tax (benefit) | -18 | -759 | -1,762 |
Share-based compensation charges | 594 | 545 | 719 |
Share-based 401(k) employer match expense | 636 | 643 | 649 |
Deferred revenue recognized | ' | ' | -400 |
Foreign exchange (gain) loss | -304 | -127 | 538 |
Impairment charges | ' | ' | 24,540 |
Changes in operating assets and liabilities: | ' | ' | ' |
Accounts receivable | -3,224 | -2,606 | -4,210 |
Inventories | 159 | 60 | 199 |
Prepaid expenses | 336 | -97 | 356 |
Accounts payable - trade | -226 | -514 | 1,031 |
Accrued liabilities, other current liabilities and other liabilities | 3,293 | 1,975 | 2,056 |
Total adjustments | 8,280 | 8,221 | 33,297 |
Net cash used in operating activities | -1,697 | -10,016 | -5,972 |
Cash flows from investing activities: | ' | ' | ' |
Capital expenditures | -838 | -988 | -1,364 |
Maturities of short term investments | ' | ' | 58,497 |
Purchases of short term investments | ' | ' | -48,497 |
Decrease (increase) in security deposits and other | 5 | 17 | -25 |
Earn-out payment | ' | ' | -1,150 |
Net cash (used in) provided by investing activities | -833 | -971 | 7,461 |
Cash flows from financing activities: | ' | ' | ' |
Net proceeds from issuance of common stock | 11,542 | 1,825 | ' |
Proceeds from borrowings under Credit Agreement | 78,814 | 13,360 | ' |
Repayments under Credit Agreement | -79,065 | -10,096 | ' |
Installment loan payments | -374 | -274 | -154 |
Net cash provided by (used in) financing activities | 10,917 | 4,815 | -154 |
Effect of exchange rate changes on cash and cash equivalents | 61 | 103 | -420 |
Increase (decrease) in cash and cash equivalents | 8,448 | -6,069 | 915 |
Cash and cash equivalents - beginning of year | 9,007 | 15,076 | 14,161 |
Cash and cash equivalents - end of year | $17,455 | $9,007 | $15,076 |
Summary_of_significant_account
Summary of significant accounting policies | 12 Months Ended | ||||||||||||||||||||||||||
Jul. 31, 2014 | |||||||||||||||||||||||||||
Accounting Policies [Abstract] | ' | ||||||||||||||||||||||||||
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] | ' | ||||||||||||||||||||||||||
Note 1 - Summary of significant accounting policies | |||||||||||||||||||||||||||
Nature of business | |||||||||||||||||||||||||||
Enzo Biochem, Inc. (the “Company”) is an integrated life science and biotechnology company engaged in research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally. The Company is conducting research and development activities in the development of therapeutic products based on the Company’s technology platform of genetic modulation and immune modulation. The Company also operates a clinical laboratory that offers and provides diagnostic medical testing services in the New York, New Jersey and Eastern Pennsylvania medical communities. The Company operates in three segments (see Note 15). | |||||||||||||||||||||||||||
Principles of consolidation | |||||||||||||||||||||||||||
The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) and include the accounts of the Company and its wholly-owned subsidiaries, Enzo Clinical Labs, Inc., Enzo Life Sciences, Inc. (and its wholly-owned foreign subsidiaries), Enzo Therapeutics, Inc. and Enzo Realty LLC (“Realty”). All intercompany transactions and balances have been eliminated. | |||||||||||||||||||||||||||
Use of Estimates | |||||||||||||||||||||||||||
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying footnotes. Actual results could differ from those estimates. | |||||||||||||||||||||||||||
Foreign Currency Translation/Transactions | |||||||||||||||||||||||||||
The Company has determined that the functional currency for its foreign subsidiaries is the local currency. For financial reporting purposes, assets and liabilities denominated in foreign currencies are translated at current exchange rates and profit and loss accounts are translated at weighted average exchange rates. Resulting translation gains and losses are included as a separate component of stockholders’ equity as accumulated other comprehensive income or loss. Gains or losses resulting from transactions entered into in other than the functional currency are recorded as foreign exchange gains and losses in the consolidated statements of operations. | |||||||||||||||||||||||||||
Cash and cash equivalents | |||||||||||||||||||||||||||
Cash and cash equivalents consist of demand deposits with banks and highly liquid money market funds.. At July 31, 2014 and 2013, the Company had cash and cash equivalents in foreign bank accounts of $1.1 million and $1.5 million, respectively. | |||||||||||||||||||||||||||
Fair Values of Financial Instruments | |||||||||||||||||||||||||||
The recorded amounts of the Company’s cash and equivalents, receivables, loan payable, accounts payable and accrued liabilities approximate their fair values principally because of the short-term nature of these items. | |||||||||||||||||||||||||||
Concentration of credit risk | |||||||||||||||||||||||||||
Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents and accounts receivable. | |||||||||||||||||||||||||||
The Company believes the fair value of the aforementioned financial instruments approximates the cost due to the immediate or short-term nature of these items. | |||||||||||||||||||||||||||
Concentration of credit risk with respect to the Company’s Life Sciences segment is mitigated by the diversity of the Company’s clients and their dispersion across many different geographic regions. To reduce risk, the Company routinely assesses the financial strength of these customers and, consequently, believes that its accounts receivable credit exposure with respect to these customers is limited. | |||||||||||||||||||||||||||
The Company believes that the concentration of credit risk with respect to the Clinical Labs accounts receivable is mitigated by the diversity of third party payers that insure individuals. To reduce risk, the Company routinely assesses the financial strength of these payers and, consequently, believes that its accounts receivable credit risk exposure, with respect to these payers, is limited. While the Company also has receivables due from the Federal Medicare program, the Company does not believe that these receivables represent a credit risk since the Medicare program is funded by the federal government and payment is primarily dependent on our submitting the appropriate documentation. | |||||||||||||||||||||||||||
Accrual for Self-Funded Medical | |||||||||||||||||||||||||||
Accruals for self-funded medical insurance are determined based on a number of assumptions and factors, including historical payment trends, claims history and current estimates. These estimated liabilities are not discounted. If actual trends differ from these estimates, the financial results could be impacted. | |||||||||||||||||||||||||||
Revenue Recognition - Product revenues | |||||||||||||||||||||||||||
Revenues from product sales are recognized when the products are shipped and title transfers, the sales price is fixed or determinable and collectability is reasonably assured. | |||||||||||||||||||||||||||
Royalties | |||||||||||||||||||||||||||
Royalty revenues are recorded in the period earned. Royalties received in advance of being earned are recorded as deferred revenues. | |||||||||||||||||||||||||||
Clinical laboratory services | |||||||||||||||||||||||||||
Revenues from the Clinical Labs segment are recognized upon completion of the testing process for a specific patient and reported to the ordering physician. These revenues and the associated accounts receivable are based on gross amounts billed or billable for services rendered, net of a contractual adjustment, which is the difference between amounts billed to payers and the expected reimbursable settlements from such payers. | |||||||||||||||||||||||||||
The following table summarizes the Clinical Lab segment’s net revenues and revenue percentages by revenue category: | |||||||||||||||||||||||||||
Years Ended July 31, | |||||||||||||||||||||||||||
2014 | 2013 | 2012 | |||||||||||||||||||||||||
Revenue category | Amount | % | Amount | % | Amount | % | |||||||||||||||||||||
Third-party payers | $ | 29,509 | 50 | $ | 26,014 | 47 | $ | 29,616 | 50 | ||||||||||||||||||
Medicare | 12,815 | 22 | 12,497 | 22 | 12,658 | 21 | |||||||||||||||||||||
Patient self-pay | 11,204 | 19 | 12,172 | 22 | 11,895 | 20 | |||||||||||||||||||||
HMO’s | 5,161 | 9 | 5,206 | 9 | 5,234 | 9 | |||||||||||||||||||||
Total | $ | 58,689 | 100 | % | $ | 55,889 | 100 | % | $ | 59,403 | 100 | % | |||||||||||||||
The Company provides services to certain patients covered by various third-party payers, including the Federal Medicare program. Laws and regulations governing Medicare are complex and subject to interpretation for which action for noncompliance includes fines, penalties and exclusion from the Medicare programs (See Note 14). | |||||||||||||||||||||||||||
Other than the Medicare program, one provider whose programs are included in the “Third-party payers” and “Health Maintenance Organizations” (“HMO’s”) categories represent approximately 25%, 22% and 21% of the Clinical Labs segment net revenue for the years ended July 31, 2014, 2013 and 2012 respectively. | |||||||||||||||||||||||||||
Contractual Adjustment | |||||||||||||||||||||||||||
The Company’s estimate of contractual adjustment is based on significant assumptions and judgments, such as its interpretation of payer reimbursement policies, and bears the risk of change. The estimation process is based on the experience of amounts approved as reimbursable and ultimately settled by payers, versus the corresponding gross amount billed to the respective payers. The contractual adjustment is an estimate that reduces gross revenue based on gross billing rates to amounts expected to be approved and reimbursed. Gross billings are based on a standard fee schedule the Company sets for all third-party payers, including Medicare, HMO’s and managed care providers. The Company adjusts the contractual adjustment estimate quarterly, based on its evaluation of current and historical settlement experience with payers, industry reimbursement trends, and other relevant factors which include the monthly and quarterly review of: 1) current gross billings and receivables and reimbursement by payer, 2) current changes in third party arrangements and 3) the growth of in-network provider arrangements and managed care plans specific to our Company. | |||||||||||||||||||||||||||
During the years ended July 31, 2014, 2013 and 2012, the contractual adjustment percentages, determined using current and historical reimbursement statistics, were approximately 86%, 85% and 85%, respectively, of gross billings. | |||||||||||||||||||||||||||
Accounts Receivable and Allowance for Doubtful Accounts | |||||||||||||||||||||||||||
Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period of the related revenue. | |||||||||||||||||||||||||||
For the Clinical Labs segment, the allowance for doubtful accounts represents amounts that the Company does not expect to collect after the Company has exhausted its collection procedures. The Company estimates its allowance for doubtful accounts in the period the related services are billed and adjusts the estimate in future accounting periods as necessary. It bases the estimate for the allowance on the evaluation of historical collection experience, the aging profile of accounts receivable, payer mix and other relevant factors. | |||||||||||||||||||||||||||
During the years ended July 31, 2014 and 2013, the Company determined an allowance for doubtful accounts for customers whose accounts receivable have been outstanding less than 210 days and either fully reserved or wrote off 100% of accounts receivable over 210 days, as it determined based on historical trends that those accounts were uncollectible, except for certain fully reserved balances, principally related to Medicare. These accounts have not been written off because the payer’s filing date deadline has not occurred or the collection process has not been exhausted. The Company adjusts the historical collection analysis for recoveries, if any, on an ongoing basis. | |||||||||||||||||||||||||||
The Company’s ability to collect outstanding receivables from third-party payers is critical to its operating performance and cash flows. The primary collection risk lies with uninsured patients or patients for whom primary insurance has paid but a patient portion remains outstanding. The Company also assesses the current state of its billing functions in order to identify any known collection issues and to assess the impact, if any, on the allowance estimates which involves judgment. The Company believes that the collectability of its receivables is directly linked to the quality of its billing processes, most notably, those related to obtaining the correct information in order to bill effectively for the services provided. Should circumstances change (e.g. shift in payer mix, decline in economic conditions or deterioration in aging of receivables), our estimates of net realizable value of receivables could be reduced by a material amount. | |||||||||||||||||||||||||||
The Clinical Labs segment’s net receivables are detailed by billing category and as a percent to its total net receivables. At July 31, 2014 and 2013, approximately 60% of the Company’s net accounts receivable relates to its Clinical Labs business, which operates in the New York, New Jersey, and Eastern Pennsylvania medical communities. | |||||||||||||||||||||||||||
The Life Sciences segment’s accounts receivable includes royalties receivable of $1.0 million and $1.2 million, as of July 31, 2014 and 2013, respectively, due from QIAGEN Gaithersburg Inc. (“Qiagen”) (see Note 12). | |||||||||||||||||||||||||||
The following is a table of the Company’s net accounts receivable by segment. | |||||||||||||||||||||||||||
31-Jul-14 | 31-Jul-13 | ||||||||||||||||||||||||||
Net accounts receivable by segment | Amount | % | Amount | % | |||||||||||||||||||||||
Clinical Labs (by billing category) | |||||||||||||||||||||||||||
Third party payers | $ | 3,499 | 46 | $ | 3,395 | 46 | |||||||||||||||||||||
Patient self-pay | 2,193 | 29 | 2,696 | 37 | |||||||||||||||||||||||
Medicare | 1,558 | 21 | 930 | 13 | |||||||||||||||||||||||
HMO’s | 280 | 4 | 300 | 4 | |||||||||||||||||||||||
Total Clinical Labs | 7,530 | 100 | % | 7,321 | 100 | % | |||||||||||||||||||||
Total Life Sciences | 4,940 | 4,967 | |||||||||||||||||||||||||
Total accounts receivable – net | $ | 12,470 | $ | 12,288 | |||||||||||||||||||||||
Changes in the Company’s allowance for doubtful accounts are as follows: | |||||||||||||||||||||||||||
31-Jul-14 | 31-Jul-13 | ||||||||||||||||||||||||||
Beginning balance | $ | 2,707 | $ | 3,273 | |||||||||||||||||||||||
Provision for doubtful accounts | 3,063 | 4,496 | |||||||||||||||||||||||||
Write-offs | (3,628 | ) | (5,062 | ) | |||||||||||||||||||||||
Ending balance | $ | 2,142 | $ | 2,707 | |||||||||||||||||||||||
Inventories | |||||||||||||||||||||||||||
The Company values inventory at the lower of cost (first-in, first-out) or market. Work-in-process and finished goods inventories consist of material, labor, and manufacturing overhead. Write downs of inventories to market value are based on a review of inventory quantities on hand and estimated sales forecasts based on sales history and anticipated future demand. Unanticipated changes in demand could have a significant impact on the value of our inventory and require additional write downs of inventory which would impact our results of operations. | |||||||||||||||||||||||||||
Property, plant and equipment | |||||||||||||||||||||||||||
Property, plant and equipment is stated at cost, and depreciated on the straight-line basis over the estimated useful lives of the various asset classes as follows: building and building improvements: 15 - 30 years, and laboratory machinery and equipment and office furniture and computer equipment which range from 3 - 10 years. Leasehold improvements are amortized over the term of the related leases or estimated useful lives of the assets, whichever is shorter. | |||||||||||||||||||||||||||
Goodwill and Intangible Assets | |||||||||||||||||||||||||||
Goodwill represents the excess of the cost of an acquisition over the fair value of the net assets acquired. | |||||||||||||||||||||||||||
Intangible assets (exclusive of patents), arose primarily from acquisitions, and primarily consist of customer relationships, trademarks, licenses, and website and database content. Finite-lived intangible assets are amortized according to their estimated useful lives, which range from 4 to 15 years. Indefinite-lived intangibles are not amortized and are evaluated each reporting period to determine whether events and circumstances continue to support their having an indefinite life. Indefinite-lived intangibles found to no longer have an indefinite life are evaluated for impairment and are then amortized over their remaining useful life as finite-lived intangible assets. Patents represent capitalized legal costs incurred in pursuing patent applications. When such applications result in an issued patent, the related capitalized costs are amortized over a ten year period or the life of the patent, whichever is shorter, using the straight-line method. The Company reviews its issued patents and pending patent applications, and if it determines to abandon a patent application or that an issued patent no longer has economic value, the unamortized balance in deferred patent costs relating to that patent is immediately expensed. | |||||||||||||||||||||||||||
Impairment testing for Goodwill and Long-Lived Assets | |||||||||||||||||||||||||||
The Company tests goodwill and indefinite-lived intangible assets annually as of the first day of the fourth quarter, or more frequently if indicators of potential impairment exist. In assessing goodwill and indefinite-lived intangible assets for impairment, the Company has the option to first perform a qualitative assessment to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit or intangible asset is less than its carrying amount. If the Company determines that it is not more likely that not that the fair value of a reporting unit or intangible asset is less than its carrying amount, the Company is not required to perform any additional tests in assessing goodwill and indefinite-lived intangible assets for impairment. For goodwill, if the Company concludes otherwise or elects not to perform the qualitative assessment, then it is required to perform the first step of a two-step quantitative impairment review process. The first step of the quantitative impairment test requires the identification of the reporting units and comparison of the fair value of each of these reporting units to their respective carrying value. If the carrying value of the reporting unit is less than its fair value, no impairment exists and the second step is not performed. If the carrying value of the reporting unit is higher than its fair value, the second step must be performed to compute the amount of the goodwill impairment, if any. In the second step, the impairment is computed by comparing the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized for the excess. For indefinite-lived intangible assets, if the Company concludes otherwise or elects not to perform the qualitative assessment, then the fair value of the intangible asset is compared to its carrying value, and impairment is recognized for the excess of the carrying value over the fair value, if any. | |||||||||||||||||||||||||||
The Company performed a qualitative assessment in 2014 and a quantitative assessment in 2013 and concluded there were no impairments. The Company performed a quantitative assessment in fiscal 2012 and concluded goodwill and indefinite-lived intangible assets had been impaired (see Note 2). | |||||||||||||||||||||||||||
The Company reviews the recoverability of the carrying value of long-lived assets (including intangible assets with finite lives) for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. Should indicators of impairment exist, the carrying values of the assets are evaluated in relation to the operating performance and future undiscounted cash flows of the underlying business. The net book value of an asset is adjusted to fair value if its expected future undiscounted cash flow is less than its book value. There were 0 impairments in 2014, 2013 or 2012, exclusive of goodwill and indefinite-lived intangibles in 2012. | |||||||||||||||||||||||||||
Comprehensive loss | |||||||||||||||||||||||||||
Comprehensive loss consists of the Company’s consolidated net loss and foreign currency translation adjustments. Foreign currency translation adjustments included in comprehensive loss were not tax effected as investments in international affiliates are deemed to be permanent. Accumulated other comprehensive income is a separate component of stockholders’ equity and consists of the cumulative foreign currency translation adjustments. | |||||||||||||||||||||||||||
Shipping and Handling Costs | |||||||||||||||||||||||||||
Shipping and handling costs associated with the distribution of finished goods to customers are recorded in cost of goods sold. | |||||||||||||||||||||||||||
Research and Development | |||||||||||||||||||||||||||
Research and development costs are charged to expense as incurred. | |||||||||||||||||||||||||||
Advertising | |||||||||||||||||||||||||||
All costs associated with advertising are expensed as incurred. Advertising expense, included in Selling, general and administrative expense, approximated $440, $302 and $237 for the years ended July 31, 2014, 2013 and 2012, respectively. | |||||||||||||||||||||||||||
Income Taxes | |||||||||||||||||||||||||||
The Company accounts for income taxes under the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The liability method requires that any tax benefits recognized for net operating loss carry forwards and other items be reduced by a valuation allowance when it is more likely than not that the benefits may not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. | |||||||||||||||||||||||||||
It is the Company’s policy to provide for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. At July 31, 2014, the Company believes it has appropriately accounted for any unrecognized tax benefits. To the extent the Company prevails in matters for which a liability for an unrecognized tax benefit is established or is required to pay amounts in excess of the liability, the Company’s effective tax rate in a given financial statement period may be affected. | |||||||||||||||||||||||||||
Segment Reporting | |||||||||||||||||||||||||||
The Company follows accounting pronouncements which establish standards for reporting information on operating segments in interim and annual financial statements. An enterprise is required to separately report information about each operating segment that engages in business activities from which the segment may earn revenues and incur expenses, whose separate operating results are regularly reviewed by the chief operating decision maker regarding allocation of resources and performance assessment and which exceed specific quantitative thresholds related to revenue and profit or loss. The Company’s operating activities are reported in three segments (see Note 15). | |||||||||||||||||||||||||||
Net income (loss) per share | |||||||||||||||||||||||||||
Basic net income (loss) per share represents net income (loss) divided by the weighted average number of common shares outstanding during the period. The dilutive effect of potential common shares, consisting of outstanding stock options and unvested restricted stock, is determined using the treasury stock method. Diluted weighted average shares outstanding for fiscal 2014, 2013 and 2012 do not include the potential common shares from stock options and unvested restricted stock because to do so would have been antidilutive and as such is the same as basic weighted average shares outstanding. The number of potential common shares (“in the money options”) and unvested restricted stock excluded from the calculation of diluted earnings per share for the years ended July 31, 2014, 2013, and 2012 was 159,000, 32,000, and 0, respectively. | |||||||||||||||||||||||||||
For the years ended July 31, 2014, 2013 and 2012, the effect of approximately 604,000, 727,000 and 736,000 respectively, of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. The following table sets forth the computation of basic and diluted net loss per share for the years ended July 31: | |||||||||||||||||||||||||||
2014 | 2013 | 2012 | |||||||||||||||||||||||||
Net loss | $ | (9,977 | ) | $ | (18,237 | ) | $ | (39,269 | ) | ||||||||||||||||||
Weighted-average common shares outstanding - Basic | 42,561 | 39,607 | 38,798 | ||||||||||||||||||||||||
Add: effect of dilutive stock options and restricted stock | — | — | — | ||||||||||||||||||||||||
Weighted-average common shares outstanding - Diluted | 42,561 | 39,607 | 38,798 | ||||||||||||||||||||||||
Net loss per share: | |||||||||||||||||||||||||||
Basic and diluted | $ | (0.23 | ) | $ | (0.46 | ) | $ | (1.01 | ) | ||||||||||||||||||
Share-Based Compensation | |||||||||||||||||||||||||||
The Company records compensation expense associated with stock options and restricted stock based upon the fair value of stock based awards as measured at the grant date. The expense is recorded by amortizing the fair values on a straight line basis over the vesting period, adjusted for estimated forfeitures. | |||||||||||||||||||||||||||
For the years ended July 31, 2014, 2013 and 2012, share-based compensation expense relating to the fair value of stock options, restricted shares and restricted stock units was approximately $594, $545, and $719, respectively (see Note 10). 0 excess tax benefits were recognized for the year ended July 31, 2014, 2013 and 2012. | |||||||||||||||||||||||||||
The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statement of operations for the years ended July 31: | |||||||||||||||||||||||||||
2014 | 2013 | 2012 | |||||||||||||||||||||||||
Cost of clinical laboratory services | $ | 9 | $ | 10 | $ | 10 | |||||||||||||||||||||
Research and development | 1 | 2 | 4 | ||||||||||||||||||||||||
Selling, general and administrative | 584 | 533 | 705 | ||||||||||||||||||||||||
$ | 594 | $ | 545 | $ | 719 | ||||||||||||||||||||||
As of July 31, 2014, there was $462 of total unrecognized compensation cost related to non-vested share-based payment arrangements granted under the Company’s incentive stock plans, which will be recognized over a weighted average remaining life of approximately fourteen months. | |||||||||||||||||||||||||||
Effect of new accounting pronouncements | |||||||||||||||||||||||||||
In May 2014, the Financial Accounting Standards Board issued ASU No. 2014-09, Revenue from Contracts with Customers: Topic 606, or ASU 2014-09. ASU 2014-09 amends the guidance for revenue recognition to replace numerous, industry-specific requirements and converges areas under this topic with those of the International Financial Reporting Standards. ASU 2014-09 implements a five-step process for customer contract revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include the capitalization and amortization of certain contract costs, ensuring the time value of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The amendments in ASU 2014-09 are effective for reporting periods beginning after December 15, 2016, and early adoption is prohibited. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. We are currently assessing the impact the adoption of ASU 2014-09 will have on the Company’s combined consolidated financial statements. | |||||||||||||||||||||||||||
In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of Unrecognized Tax Benefit When a Net Operating Loss Carryforward, A Similar Tax Loss, or a Tax Credit Carryforward Exists (A Consensus the FASB Emerging Issues Task Force). ASU 2013-11 requires an entity to present an unrecognized tax benefit as a reduction of a deferred tax asset for a net operating loss carryforward, or similar tax loss or tax credit carryforward, rather than as a liability when the uncertain tax position would reduce the net operating loss or other carryforward under the tax law of the applicable jurisdiction and the entity intends to use the deferred tax asset for that purpose. This amendment is effective prospectively but allows optional retrospective adoption (for all periods presented). We do not expect the adoption of this standard to have a material impact on our consolidated financial statements. | |||||||||||||||||||||||||||
In August 2014, the FABS issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. ASU 2014-15 will explicitly require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. We are currently evaluating the impact of the adoption of ASU 2014-15. |
Goodwill_and_intangible_assets
Goodwill and intangible assets | 12 Months Ended | |||||||||||||||||||||||||
Jul. 31, 2014 | ||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | ' | |||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Text Block] | ' | |||||||||||||||||||||||||
Note 2 - Goodwill and intangible assets | ||||||||||||||||||||||||||
Goodwill | ||||||||||||||||||||||||||
The Company’s net carrying amount of goodwill is in the Clinical Labs segment as of July 31, 2014 and 2013 and is $7,452. | ||||||||||||||||||||||||||
As a result of a decline in the Company’s market capitalization, relating to the decline in the Company’s stock price of 44% from May 1 to July 31, 2012, declining results in the fiscal 2012 fourth quarter and results from the completion of the refocusing of the Enzo Life Sciences reporting unit, the Company determined that these impairment factors required the completion of an interim impairment test as of July 31, 2012. Based upon the results of the interim impairment test as of July 31, 2012, the carrying value of the Enzo Life Sciences reporting unit was determined to be higher than its fair value and, accordingly, the Company performed a step-two impairment analysis. The results of the step-two impairment analysis for the Enzo Life Sciences reporting unit indicated that goodwill was fully impaired. As a result of the analysis, the Company recognized a total non-cash impairment charge of $18.8 million ($18.0 net of related taxes) as of July 31, 2012. The impairment charge did not impact the Company’s consolidated cash flows, liquidity, and capital resources. The fair value of the Enzo Clinical Lab reporting unit was higher than its carrying value and therefore a step-two analysis was not required. | ||||||||||||||||||||||||||
Intangible assets | ||||||||||||||||||||||||||
The Company’s change in the net carrying amount of intangible assets, all in the Life Sciences segment is as follows: | ||||||||||||||||||||||||||
Gross | Accumulated | Net | ||||||||||||||||||||||||
Amortization | ||||||||||||||||||||||||||
31-Jul-12 | $ | 27,904 | (16,124 | ) | 11,780 | |||||||||||||||||||||
Amortization expense | — | (1,990 | ) | (1,990 | ) | |||||||||||||||||||||
Foreign currency translation | 310 | (157 | ) | 153 | ||||||||||||||||||||||
31-Jul-13 | $ | 28,214 | (18,271 | ) | 9,943 | |||||||||||||||||||||
Amortization expense | — | -1,840 | (1,840 | ) | ||||||||||||||||||||||
Foreign currency translation | 264 | (259 | ) | 5 | ||||||||||||||||||||||
31-Jul-14 | $ | 28,478 | (20,370 | ) | 8,108 | |||||||||||||||||||||
Intangible assets, all finite-lived, consist of the following: | ||||||||||||||||||||||||||
31-Jul-14 | 31-Jul-13 | |||||||||||||||||||||||||
Gross | Accumulated | Net | Gross | Accumulated | Net | |||||||||||||||||||||
Amortization | Amortization | |||||||||||||||||||||||||
Patents | $ | 11,027 | $ | (10,775 | ) | $ | 252 | $ | 11,027 | $ | (10,587 | ) | $ | 440 | ||||||||||||
Customer relationships | 12,602 | (6,565 | ) | 6,037 | 12,446 | (5,448 | ) | 6,998 | ||||||||||||||||||
Website and acquired content | 1,037 | (1,037 | ) | — | 1,026 | (980 | ) | 46 | ||||||||||||||||||
Licensed technology and other | 537 | (434 | ) | 103 | 513 | (382 | ) | 131 | ||||||||||||||||||
Trademarks, gives effect for impairment charge and reclassification to finite-lived as of May 1, 2012 | 3,275 | (1,559 | ) | 1,716 | 3,202 | (874 | ) | 2,328 | ||||||||||||||||||
Total | $ | 28,478 | $ | (20,370 | ) | $ | 8,108 | $ | 28,214 | $ | (18,271 | ) | $ | 9,943 | ||||||||||||
At July 31, 2014 information with respect to the intangibles acquired is as follows: | ||||||||||||||||||||||||||
Useful life | Weighted average | |||||||||||||||||||||||||
assigned | remaining useful life | |||||||||||||||||||||||||
Customer relationships | 8-15 years | 6 years | ||||||||||||||||||||||||
Trademarks | 5 years | 3 years | ||||||||||||||||||||||||
Other intangibles | 4-5 years | 1 years | ||||||||||||||||||||||||
At July 31, 2014, the weighted average useful life of intangible assets was approximately five years. | ||||||||||||||||||||||||||
Estimated amortization expense related to these finite-lived intangible assets for the five succeeding fiscal years ending July 31 is as follows: | ||||||||||||||||||||||||||
2015 | 1,630 | |||||||||||||||||||||||||
2016 | 1,620 | |||||||||||||||||||||||||
2017 | 1,508 | |||||||||||||||||||||||||
2018 | 1,141 | |||||||||||||||||||||||||
2019 | 827 | |||||||||||||||||||||||||
Amortization expense for the years ended July 31, 2014, 2013, and 2012 was $1,840, $1,990, and $1,660, respectively. | ||||||||||||||||||||||||||
In connection with the annual assessment of the then indefinite-lived intangibles as of May 1, 2012, the Company determined the estimated fair value of trademarks, relating to the Enzo Life Science reporting unit, were less than their carrying values by $5.7 million primarily due to declines in projected revenues and in connection with future plans resulting from a strategic review. As a result of this impairment, which included a change in the future branding strategy, the useful life of the trademarks was reassessed and determined to have an estimated economic life of 5 years. A non-cash impairment charge of $5.7 million, ($4.4 million net of related taxes) was recorded for the trademark impairment in the fourth quarter of fiscal 2012. As a result of the reclassification of trademarks from indefinite lived to a 5 year life, annual amortization of trademarks is estimated to be $0.6 million per year. 0 impairment was determined to exist at May 1, 2014 or 2013. | ||||||||||||||||||||||||||
The aggregate goodwill and indefinite lived-intangible impairment charge recorded in the fiscal 2012 fourth quarter was $24.5 million, ($22.4 million net of related taxes). These charges did not affect consolidated cash flows, current liquidity or capital resources. |
Supplemental_disclosure_for_st
Supplemental disclosure for statement of cash flows | 12 Months Ended |
Jul. 31, 2014 | |
Supplemental Cash Flow Elements [Abstract] | ' |
Cash Flow, Supplemental Disclosures [Text Block] | ' |
Note 3 - Supplemental disclosure for statement of cash flows | |
In the years ended July 31, 2014, 2013, and 2012, income taxes paid by the Company approximated $44, $46, and $70 respectively. | |
In the years ended July 31, 2014, 2013, and 2012, interest paid by the Company approximated $208, $69, and $5 respectively. | |
During fiscal 2014 and 2013, the Company financed $392 and $365, respectively, in machinery and transportation equipment under installment loans. | |
During fiscal 2014, the Company did not enter into any capital lease agreements. During fiscal 2013, the Company entered into a capital lease for machinery and equipment with a cost basis of $765. | |
During fiscal 2014, the Company recorded $136 in additional paid in capital and reduced accrued liabilities by the same amount for options issued in lieu of cash payment of certain incentive compensation awards. |
Inventories
Inventories | 12 Months Ended | ||||||||
Jul. 31, 2014 | |||||||||
Inventory Disclosure [Abstract] | ' | ||||||||
Inventory Disclosure [Text Block] | ' | ||||||||
Note 4 - Inventories | |||||||||
Inventories consisted of the following at July 31: | |||||||||
2014 | 2013 | ||||||||
Raw materials | $ | 1,092 | $ | 922 | |||||
Work in process | 2,460 | 2,628 | |||||||
Finished products | 5,138 | 5,255 | |||||||
$ | 8,690 | $ | 8,805 | ||||||
Property_plant_and_equipment
Property, plant, and equipment | 12 Months Ended | ||||||||
Jul. 31, 2014 | |||||||||
Property, Plant and Equipment [Abstract] | ' | ||||||||
Property, Plant and Equipment Disclosure [Text Block] | ' | ||||||||
Note 5 - Property, plant, and equipment | |||||||||
At July 31, 2014 and 2013 property, plant, and equipment consist of: | |||||||||
2014 | 2013 | ||||||||
Building and building improvements | $ | 4,834 | $ | 4,751 | |||||
Machinery and equipment (includes asset under capital lease - see Note 9) | 7,125 | 6,922 | |||||||
Office furniture and computer equipment | 16,834 | 16,390 | |||||||
Leasehold improvements | 4,835 | 4,759 | |||||||
33,628 | 32,822 | ||||||||
Accumulated depreciation and amortization | (26,610 | ) | (24,917 | ) | |||||
7,018 | 7,905 | ||||||||
Land and land improvements | 712 | 712 | |||||||
$ | 7,730 | $ | 8,617 | ||||||
Income_taxes
Income taxes | 12 Months Ended | ||||||||||||
Jul. 31, 2014 | |||||||||||||
Income Tax Disclosure [Abstract] | ' | ||||||||||||
Income Tax Disclosure [Text Block] | ' | ||||||||||||
Note 6 - Income taxes | |||||||||||||
The (provision) benefit for income taxes for fiscal years ended July 31 is as follows: | |||||||||||||
2014 | 2013 | 2012 | |||||||||||
Current (provision) benefit: | |||||||||||||
Federal | $ | — | $ | — | $ | — | |||||||
State and local | (68 | ) | (46 | ) | (49 | ) | |||||||
Foreign | (22 | ) | (1 | ) | (61 | ) | |||||||
Deferred benefit | 18 | 759 | 1,762 | ||||||||||
(Provision) benefit for income taxes | $ | (72 | ) | $ | 712 | $ | 1,652 | ||||||
Deferred tax assets and liabilities arise from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements. The components of deferred tax assets (liabilities) as of July 31 are as follows: | |||||||||||||
2014 | 2013 | ||||||||||||
Deferred tax assets: | |||||||||||||
Federal tax carryforward losses | $ | 35,352 | $ | 34,836 | |||||||||
Provision for uncollectible accounts receivable | 753 | 920 | |||||||||||
State and local tax carry forward losses | 2,604 | 3,791 | |||||||||||
Accrued royalties | 144 | 143 | |||||||||||
Stock compensation | 190 | 317 | |||||||||||
Depreciation | 618 | 625 | |||||||||||
Research and development and other tax credit carryforwards | 1,085 | 1,013 | |||||||||||
Foreign tax carryforward losses | 1,207 | 772 | |||||||||||
Intangibles | 2,970 | 2,980 | |||||||||||
Inventory | 2,194 | 1,249 | |||||||||||
Accrued expenses | 3,103 | 1,622 | |||||||||||
Other, net | 15 | 19 | |||||||||||
Deferred tax assets | 50,235 | 48,287 | |||||||||||
Deferred tax liabilities: | |||||||||||||
Deferred patent costs | (135 | ) | (132 | ) | |||||||||
Prepaid expenses | (671 | ) | (695 | ) | |||||||||
Unrealized foreign exchange | (118 | ) | — | ||||||||||
Other, net | (29 | ) | (37 | ) | |||||||||
Deferred tax liabilities | (953 | ) | (864 | ) | |||||||||
Net deferred tax assets (liabilities) before valuation allowance | 49,282 | 47,423 | |||||||||||
Less: valuation allowance | (49,465 | ) | (47,623 | ) | |||||||||
Net deferred tax liabilities | $ | (183 | ) | $ | (200 | ) | |||||||
At July 31, 2014, the Company had net deferred tax liabilities of approximately $0.2 million which consists primarily of identifiable intangible assets and cumulative tax deductions in excess of book expenses recognized by foreign subsidiaries. | |||||||||||||
Net deferred tax liabilities are included in the consolidated balance sheets as of July 31 as follows: | |||||||||||||
2014 | 2013 | ||||||||||||
Deferred taxes: | |||||||||||||
Current | $ | — | $ | — | |||||||||
Non-current | 183 | 200 | |||||||||||
$ | 183 | $ | 200 | ||||||||||
The Company recorded a valuation allowance during the year ended July 31, 2014 and 2013 equal to domestic and certain foreign net deferred tax assets. The Company believes that the valuation allowance is necessary as it is not more likely than not that the deferred tax assets will be realized in the foreseeable future based on positive and negative evidence available at this time. This conclusion was reached because of uncertainties relating to future taxable income, in terms of both its timing and its sufficiency, which would enable the Company to realize the deferred tax assets. The change in the valuation allowance was $1.8 million and $6.4 million for fiscal years 2014 and 2013, respectively. | |||||||||||||
As of July 31, 2014, the Company had U.S. federal net operating loss carryforwards of approximately $103.2 million. The U.S. federal tax loss carryforwards, if not fully utilized, expire between 2018 and 2034. Utilization is dependent on generating sufficient taxable income prior to expiration of the tax loss carryforwards. In addition, the Company has research and development tax credit carryforwards of approximately $1.0 million which expire between 2025 and 2034. As of July 31, 2014, the Company had foreign loss carryforwards of approximately $6.0 million. | |||||||||||||
The components of loss before income taxes consisted of the following for the years ended July 31: | |||||||||||||
2014 | 2013 | 2012 | |||||||||||
United States operations | $ | (8,702 | ) | $ | (15,419 | ) | $ | (31,817 | ) | ||||
International operations | (1,203 | ) | (3,530 | ) | (9,104 | ) | |||||||
Loss before taxes | $ | (9,905 | ) | $ | (18,949 | ) | $ | (40,921 | ) | ||||
The benefit (provision) for income taxes were at rates different from U.S. federal statutory rates for the following reasons for the years ended July 31: | |||||||||||||
2014 | 2013 | 2012 | |||||||||||
Federal statutory rate | 34 | % | 34 | % | 34 | % | |||||||
Penalties and other expenses not deductible for income tax return purposes | (6.6 | ) | (0.9 | ) | (0.5 | ) | |||||||
State income taxes, net of benefit of federal tax deduction | 0.2 | 2.5 | 0.9 | ||||||||||
Change in valuation allowance | (16.5 | ) | (32.7 | ) | (23.2 | ) | |||||||
Impairment of goodwill | — | — | (7.1 | ) | |||||||||
State tax law change | (12.3 | ) | — | — | |||||||||
Other | 0.5 | 0.9 | (0.1 | ) | |||||||||
(0.7 | )% | 3.8 | % | 4 | % | ||||||||
U.S. federal income taxes have not been provided on approximately $304 of undistributed earnings at the Company’s foreign subsidiaries at July 31, 2014, because it is the Company’s intent to keep the earnings reinvested. As of July 31, 2014, the Company has 0 liabilities for uncertain tax positions. It is the Company’s policy to record interest and penalties as a component of tax expense. The Company files income tax returns in the U.S. Federal jurisdiction, various U.S. state jurisdictions and several foreign jurisdictions. With few exceptions, the years that remain subject to examination are years July 31, 2011 through 2013. |
Loan_Payable
Loan Payable | 12 Months Ended |
Jul. 31, 2014 | |
Debt Disclosure [Abstract] | ' |
Debt Disclosure [Text Block] | ' |
Note 7 - Loan Payable | |
On June 7, 2013, the Company entered into a secured Revolving Loan and Security Agreement (the “Credit Agreement”) among the Company and certain of its subsidiaries, with Enzo Therapeutics as a guarantor, and Healthcare Finance Group, LLC. The Credit Agreement, which expires in December 2016, provides for borrowings against eligible US receivables, as defined, of the Clinical Lab and Life Science segments up to $8.0 million at defined eligibility percentages and provides for additional borrowings of $4.0 million for increased eligible assets. Debt issuance costs of $281 are being amortized over the life of the Credit Agreement. If the amount of borrowings outstanding under the revolving credit facility exceeds the borrowing base then in effect, or the Lender requires a reserve, the Company will be required to repay such borrowings in an amount sufficient to eliminate such excess. Interest on advances, payable monthly, is based on the three month LIBOR rate, with a floor of 1.25% plus an applicable margin of 4.0%, In the event of any default, the interest rate may be increased 3.0% over the current rate. The facility also carries a non-utilization fee of 0.50% per annum, payable monthly, on the unused portion of the credit line. The Credit Agreement requires a minimum borrowing of $2.0 million. At July 31, 2014 and 2013, the borrowings under the Credit Agreement related to the Clinical Labs and Life Sciences receivables aggregated $3.0 million and $3.3 million, respectively, with an additional availability of $2.7 million at July 31, 2014. | |
The Company’s obligations under the Credit Agreement are secured by primarily all the unencumbered U.S. assets of the Company, excluding buildings and intellectual property which the Lender has a negative pledge, and the capital stock of subsidiaries. The Credit Agreement includes customary affirmative and negative covenants and events of default and requires maximum levels of cash usage and minimum levels of liquidity, as defined, and provides for increased liquidity levels if operating results are not achieved. Negative covenants include among others, limitations on additional debt, liens, loans or investments, distributions, asset sales and affiliate transactions. Events of default include, non-payment of principal and interest on debt outstanding, non-performance of covenants, material change in business, breach of representations, bankruptcy and insolvency, material judgments and changes in control. As of July 31, 2013, the Company received a waiver from the Lender for non-compliance with a financial covenant and the lender modified various financial covenants relating to fiscal 2014. As of July 31, 2014, the Company is in compliance with the financial covenants. |
Accrued_Liabilities_Other_Curr
Accrued Liabilities, Other Current Liabilities and Other Liabilities | 12 Months Ended | ||||||||
Jul. 31, 2014 | |||||||||
Payables and Accruals [Abstract] | ' | ||||||||
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | ' | ||||||||
Note 8 - Accrued Liabilities, Other Current Liabilities and Other Liabilities | |||||||||
At July 31 accrued liabilities consist of: | |||||||||
2014 | 2013 | ||||||||
Legal | $ | 4,721 | $ | 3,104 | |||||
Payroll, benefits, severance and commissions | 4,959 | 4,794 | |||||||
Research and development | 400 | 721 | |||||||
Professional fees | 638 | 863 | |||||||
Other | 2,199 | 2,294 | |||||||
$ | 12,917 | $ | 11,776 | ||||||
At July 31 other current liabilities consist of: | |||||||||
2014 | 2013 | ||||||||
Accrued legal settlement – see Note 14 | $ | 400 | $ | — | |||||
Installment loans - see Note 9 | 241 | 182 | |||||||
Capital lease obligations - see Note 9 | 149 | $ | 149 | ||||||
$ | 790 | $ | 331 | ||||||
Self-Insured Medical Plan | |||||||||
The Company self-funds medical insurance coverage for certain of its U.S. based employees. The risk to the Company is being limited through the use of individual and aggregate stop loss insurance. As of July 31, 2014 and 2013, the Company has established a reserve of $0.2 million, which is included in accrued liabilities, for claims that have been reported but not paid and incurred but not reported. The reserve is based upon the Company’s historical payment trends, claim history and current estimates. |
Other_liabilities
Other liabilities | 12 Months Ended | ||||||||
Jul. 31, 2014 | |||||||||
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract] | ' | ||||||||
Other Liabilities Disclosure [Text Block] | ' | ||||||||
Note 9 - Other liabilities | |||||||||
At July 31 Other liabilities consist of: | |||||||||
2014 | 2013 | ||||||||
Accrued legal settlement – see Note 14 | $ | 1,600 | — | ||||||
Capital lease obligation | $ | 344 | $ | 505 | |||||
Installment loans | 369 | 269 | |||||||
$ | 2,313 | $ | 774 | ||||||
The capital lease obligation and installment loans are for machinery and equipment used in the Clinical Labs segment. Amortization of the asset recorded under the capital lease is included in depreciation expense. At July 31, 2014, the accumulated amortization on the capital lease was $330. | |||||||||
Future minimum lease and loan payments are as follows: | |||||||||
Capital lease | Installment | ||||||||
loans | |||||||||
2015 | 149 | 241 | |||||||
2016 | 200 | 200 | |||||||
2017 | 191 | 160 | |||||||
2018 | — | 9 | |||||||
Total payments | 540 | 610 | |||||||
Less: imputed interest | (47 | ) | — | ||||||
Payments net of interest | 493 | 610 | |||||||
Less: current portion | (149 | ) | (241 | ) | |||||
Other liabilities - net | $ | 344 | $ | 369 | |||||
The weighted average interest rate on our short term borrowings during fiscal 2014 was 2.87%. The weighted average interest rate on our short term borrowings during fiscal 2013 was 4.5%. |
Stockholders_Equity
Stockholders' Equity | 12 Months Ended | ||||||||||||||||||||||||
Jul. 31, 2014 | |||||||||||||||||||||||||
Stockholders' Equity Note [Abstract] | ' | ||||||||||||||||||||||||
Stockholders' Equity Note Disclosure [Text Block] | ' | ||||||||||||||||||||||||
Note 10 - Stockholders’ equity | |||||||||||||||||||||||||
Controlled Equity Offering | |||||||||||||||||||||||||
On March 28, 2013, the Company entered into a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”). Under the Sales Agreement, the Company may offer and sell, from time to time, through Cantor, shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), having an aggregate offering price of up to $20.0 million (the “Shares”). The Company will pay Cantor a commission of 3.0% of the aggregate gross proceeds received under the Sale Agreement. The Company is not obligated to make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the Shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Cantor or the Company, as permitted therein. The Shares were initially issued pursuant to the Company’s Registration Statement which was declared effective on August 5, 2010 and the prospectus supplement, dated March 28, 2013, and more recently under a current registration statement declared effective August 13, 2013 and the prospectus supplement dated August 1, 2013, filed by the Company with the Securities and Exchange Commission. During fiscal 2013, the Company sold an aggregate of 906,715 shares of common stock under the Sales Agreement at an average price of $2.26 per share and received proceeds aggregating $1,825, net of expenses of the offering and commissions of $224. For the year ended July 31, 2014, the Company sold an aggregate of 3,421,176 shares of common stock under the Sales Agreement at an average price of $3.48 per share and received proceeds of approximately $11.5 million, net of expenses of $357. | |||||||||||||||||||||||||
Common stock | |||||||||||||||||||||||||
In fiscal 2014, the Company issued 165,646 shares of common for its employees’ 401(k) matching contributions obligation. The Company recorded an expense of $636 for the match, representing the fair value of the shares at the date of issuance. | |||||||||||||||||||||||||
In fiscal 2013, the Company issued 9,419 shares of common stock for its employees’ 401(k) matching contributions obligation. The Company recorded an expense of $27 for the match representing the fair value of the shares at the date of issuance. | |||||||||||||||||||||||||
In June 2012, the Company issued 275,000 shares of common stock at a fair value of $0.5 million for services performed. | |||||||||||||||||||||||||
Treasury stock | |||||||||||||||||||||||||
In fiscal 2013, the Company issued 216,556 shares from treasury stock to match a portion of its employees’ 401(k) contributions. The Company recorded an expense of $616 for the match, reducing treasury stock by $3,074 for the average acquisition cost of such shares and adjusting additional paid in capital by $2,458. | |||||||||||||||||||||||||
In fiscal 2012, the Company issued 233,458 shares from treasury stock for its employees’ 401(k) matched contributions obligation. The Company recorded an expense of $649 for the match, reducing treasury stock by $3,313 for the average acquisition cost of such shares and adjusting additional paid in capital by $2,664. | |||||||||||||||||||||||||
Incentive stock plans | |||||||||||||||||||||||||
The Company has an incentive stock option and restricted (non-vested) stock award plan (the “2005 Plan”), under which the Company may grant options and restricted stock (non-vested) awards for up to 1,000,000 common shares under the 2005 Plan. 0 additional awards may be granted under the 2005 Plan. On January 14, 2011, the Company’s stockholders approved the adoption of the 2011 Incentive Plan (the “2011 Plan”) which provides for the issuance of equity awards, including among others, options, restricted stock and restricted stock units for up to 3,000,000 Common Shares. The exercise price of options granted under the 2011 Plan, and consistent with other Plans, is equal to or greater than fair market value of the Common Stock on the date of grant. Unless terminated earlier by the Board of Directors, the 2011 Plan will terminate at the earliest of; (a) such time as 0 shares of Common Stock remain available for issuance under the 2011 Plan or (b) tenth anniversary of the effective date of the 2011 Plan. Awards outstanding upon expiration of the 2011 Plan shall remain in effect until they have been exercised, terminated, or have expired. As of July 31, 2014, there were approximately 1,656,000 shares available for grant under the 2011 Plan. | |||||||||||||||||||||||||
The Company estimates the fair value of each stock option award on the measurement date using a binomial option pricing model. The fair value of awards is amortized to expense on a straight line basis over the requisite service period. The Company expenses restricted stock awards based on vesting requirements, primarily time elapsed. | |||||||||||||||||||||||||
Options granted pursuant to the plans may be either incentive stock options or non-statutory options The 2011 Plan provides for the issuance of stock options, restricted stock and restricted stock unit awards which generally vest over a two to four year period. A summary of the activity pursuant to the Company’s stock option plans for the years ended July 31, 2014, 2013, and 2012 is as follows: | |||||||||||||||||||||||||
2014 | 2013 | 2012 | |||||||||||||||||||||||
Options | Weighted - | Options | Weighted - | Options | Weighted - | ||||||||||||||||||||
Average | Average | Average | |||||||||||||||||||||||
Exercise | Exercise | Exercise | |||||||||||||||||||||||
Price | Price | Price | |||||||||||||||||||||||
Outstanding at beginning of year | 726,645 | $ | 10.39 | 736,490 | $ | 14.5 | 785,124 | $ | 14.53 | ||||||||||||||||
New Grants | 665,117 | $ | 2.77 | 336,817 | $ | 2.88 | — | $ | — | ||||||||||||||||
Expired | (236,852 | ) | $ | 15.8 | (346,662 | ) | $ | 11.82 | (48,634 | ) | $ | 15.05 | |||||||||||||
Outstanding at end of year | 1,155,910 | $ | 5.03 | 726,645 | $ | 10.39 | 736,490 | $ | 14.5 | ||||||||||||||||
Exercisable at end of year | 399,262 | $ | 7.66 | 389,828 | $ | 16.88 | 736,490 | $ | 14.5 | ||||||||||||||||
Weighted average fair value of options granted during year | $ | 0.9 | $ | 1.22 | — | ||||||||||||||||||||
The intrinsic value of stock option awards that vested during the fiscal year represents the value of the Company’s closing stock price on the last trading day of the fiscal year in excess of the exercise price multiplied by the number of options that vested. Total intrinsic value of options that vested and were exercisable during the fiscal years ended July 31, 2014, 2013, and 2012 was $425, $0 and $0, respectively. The intrinsic value of options outstanding at July 31, 2014, 2013, and 2012 was $1,915, $0 and $0, respectively. | |||||||||||||||||||||||||
On January 17, 2014, the Company awarded 267,797 options to two senior officers and the board of directors with an exercise price of $2.70 and a five year term, which vest annually over two years. The fair value of the options granted was $1.05 per share. The assumptions used to fair value this option award were as follows: expected life of 3.25 years, expected volatility 54.78%, a risk free interest rate of 0.90% and 0 dividend yield. As of July 31, 2014, 0 of these options were vested. Further on January 17, 2014, the Company awarded 95,729 options to executive officers with an exercise price of $2.70 and a five year term, which vest annually over three years. The fair value of the options granted was $1.10 per share. The assumptions used to fair value this option award were as follows: expected life of 3.5 years, expected volatility 55.45%, a risk free interest rate of 1.00% and 0 dividend yield. As of July 31, 2014, 0 of these options were vested. | |||||||||||||||||||||||||
On February 3, 2014, the Company awarded 20,000 options to an executive officer with an exercise price of $2.75 and a five year term, which vest annually over three years. The fair value of the options granted was $1.11 per share. The assumptions used to fair value this option award were as follows: expected life of 3.5 years, expected volatility 55.07%, risk free interest rate of 0.84% and 0 dividend yield. As of July 31, 2014, 0 of these options were vested. | |||||||||||||||||||||||||
The following table summarizes information for stock options outstanding at July 31, 2014: | |||||||||||||||||||||||||
Options outstanding and exercisable | |||||||||||||||||||||||||
Range of Exercise prices | Shares | Weighted- Average | Weighted- | ||||||||||||||||||||||
Remaining | Average Exercise | ||||||||||||||||||||||||
Contractual Life in | Price | ||||||||||||||||||||||||
years | |||||||||||||||||||||||||
$ 2.53 – 3.00 | 217,362 | 3.81 | $ | 2.84 | |||||||||||||||||||||
$12.99-17.66 | 181,900 | 0.41 | $ | 16.82 | |||||||||||||||||||||
399,262 | |||||||||||||||||||||||||
Restricted Stock Awards | |||||||||||||||||||||||||
During fiscal 2014, 2013 and 2012, the compensation committee of the Company’s board of directors approved grants of restricted stock and restricted stock unit awards (the “Awards”) to the Company’s directors, certain officers and certain employees under the 2011 or 2005 Plans. The Awards vest upon the recipient’s continued employment or director service ratably over either two, three or four years. Share-based compensation expense is based on the fair value of the award as measured on the grant date and is recorded over the vesting period on a straight-line basis. The Awards will be forfeited if the recipient ceases to be employed by or serve as a director of the Company, as defined in the Plans’ terms. The Awards settle in shares of the Company’s common stock on a one-for-one basis. | |||||||||||||||||||||||||
The following table summarizes the activity pursuant to restricted stock awards for the years ended July 31, | |||||||||||||||||||||||||
2014 | 2013 | 2012 | |||||||||||||||||||||||
Awards | Weighted - | Awards | Weighted - | Awards | Weighted - | ||||||||||||||||||||
Average | Average | Average | |||||||||||||||||||||||
Award Price | Award Price | Award Price | |||||||||||||||||||||||
Outstanding at beginning of year | 125,133 | $ | 3.45 | 257,583 | $ | 3.58 | 311,952 | $ | 4.84 | ||||||||||||||||
Awarded | 11,500 | $ | 4.77 | 39,000 | $ | 1.77 | 144,143 | $ | 2.51 | ||||||||||||||||
Vested | (82,971 | ) | $ | (2.70 | ) | (157,783 | ) | $ | (3.23 | ) | (174,638 | ) | $ | (4.85 | ) | ||||||||||
Forfeited | (11,160 | ) | $ | (1.70 | ) | (13,667 | ) | $ | (3.59 | ) | (23,874 | ) | $ | (4.30 | ) | ||||||||||
Outstanding (non-vested) at end of year | 42,502 | $ | 5.74 | 125,133 | $ | 3.45 | 257,583 | $ | 3.58 | ||||||||||||||||
Weighted average market value of awards granted during year | $ | 4.77 | $ | 1.77 | $ | 2.51 | |||||||||||||||||||
The fair value of the awards that vested during the years ended July 31, 2014, 2013 and 2012 was $253, $411 and $283, respectively. |
Employee_benefit_plan
Employee benefit plan | 12 Months Ended | ||||||||||||
Jul. 31, 2014 | |||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ' | ||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | ' | ||||||||||||
Note 11 - Employee benefit plan | |||||||||||||
The Company has a qualified Salary Reduction Profit Sharing Plan (the “Plan”) for eligible U.S. employees under Section 401(k) of the Internal Revenue Code. The Plan provides for voluntary employee contributions through salary reduction and voluntary employer contributions at the discretion of the Company. For the years ended July 31, 2014, 2013, and 2012, the Company authorized employer matched contributions of 50% of the employees’ contribution up to 10% of the employees’ compensation, payable in Enzo Biochem, Inc. common stock. The share-based 401(k) employer matched contribution was approximately $636, $643, and $649 in fiscal years 2014, 2013, and 2012, respectively. | |||||||||||||
The Company’s Swiss operations provide a pension plan named the Enzo Life Sciences (ELS) AG Vertrag - Nr. 601013, (the “Swiss Plan”) under the Swiss government’s social security system for Swiss employees. The current required minimum saving contribution is 13% for employees over age 25 and minimum annual investment return is 2%. Employees are required to contribute based on a formula and the Company’s Swiss operations make contributions of at least 50% of the employee contribution. The status of the Swiss Plan, which is substantially funded as of December 31, 2013, the latest plan year end, is as follows: | |||||||||||||
As of December 31, | 2013 | 2012 | 2011 | ||||||||||
Total Assets | $ | 2,531 | $ | 2,965 | $ | 3,247 | |||||||
Accumulated Benefit Obligation | $ | 2,697 | $ | 3,064 | $ | 3,224 | |||||||
Funded status | 94 | % | 97 | % | 99 | % | |||||||
Fiscal Year ended July 31, | 2013 | 2012 | 2011 | ||||||||||
Contributions | $ | 467 | $ | 521 | $ | 483 | |||||||
The Swiss Plan’s contract expires December 31, 2014 and currently the Company has no plans to change the current funding or plan design. No events have occurred that would impact the Swiss Plan status. |
Royalty_and_other_income
Royalty and other income | 12 Months Ended |
Jul. 31, 2014 | |
Royalty And Other Income [Text Block] [Abstract] | ' |
Royalty And Other Income [Text Block] | ' |
Note 12 - Royalty and other income | |
The Company has a license agreement with Qiagen that began in 2005, whereby the Company earns quarterly running royalties on the net sales of Qiagen products subject to the license until the expiration of the patent on April 24, 2018. During the years ended July 31, 2014, 2013 and 2012, the Company recorded royalty income under the agreement of approximately $4,408, $5,144 and $5,900, respectively, which is included in the Life Sciences segment. |
Commitments
Commitments | 12 Months Ended | ||||||
Jul. 31, 2014 | |||||||
Disclosure Text Block Supplement [Abstract] | ' | ||||||
Commitments Disclosure [Text Block] | ' | ||||||
Note 13 - Commitments | |||||||
Leases | |||||||
The Company leases equipment, office and laboratory space under several non-cancelable operating leases that expire between September 2014 and May 2023. Certain leases include renewal options and rent escalation clauses. An entity owned by certain executive officers/directors of the Company owns the building that the Company leases as its main facility for laboratory operations and certain research operations. In March 2005, the Company amended and extended the lease for 12 years. In addition to the minimum annual rentals of space, the lease is subject to annual increases, based on the consumer price index. Annual increases are limited to 3% per year. Rent expense for this lease, inclusive of real estate taxes, approximated $1,649, $1,605 and $1,556 during fiscal years 2014, 2013 and 2012, respectively. Total rent expense incurred by the Company during fiscal 2014, 2013 and 2012 for all its facilities was approximately $4,488, $4,354 and $4,378, respectively. | |||||||
Minimum future annual rentals under all non-cancelable operating leases, net of sublease rental income of $322, as of July 31, 2014, are as follows: | |||||||
Years ended July 31, | |||||||
2015 | 5,627 | ||||||
2016 | 4,999 | ||||||
2017 | 3,731 | ||||||
2018 | 2,306 | ||||||
2019 | 1,733 | ||||||
Thereafter | 1,106 | ||||||
$ | 19,502 | ||||||
Employment Agreements | |||||||
The Company has employment agreements with certain officers that are cancelable at any time but provide for severance pay in the event an officer is terminated by the Company without cause, as defined in the agreements. Unless cancelled earlier or with notice as defined, the agreement automatically renews for two years. Aggregate minimum compensation commitments, exclusive of any severance provisions, as of July 31, 2014 is $2,271. |
Contingencies
Contingencies | 12 Months Ended |
Jul. 31, 2014 | |
Loss Contingency [Abstract] | ' |
Contingencies Disclosure [Text Block] | ' |
Note 14 - Contingencies | |
On June 7, 2004, the Company and Enzo Life Sciences, Inc., filed suit in the United States District Court for the District of Connecticut against Applera Corporation and its wholly-owned subsidiary Tropix, Inc., which became Life Technologies, Inc. (NASDAQ:LIFE) and was acquired by Thermo Fisher Scientific, Inc. (NYSE:TMO) on February 3, 2014. The complaint alleged infringement of six patents relating to DNA sequencing systems, labeled nucleotide products, and other technology. Yale University is the owner of four of the patents and the Company is the exclusive licensee. These four patents are commonly referred to as the “Ward” patents. On November 12, 2012, a jury in New Haven found that one of these patents (United States Patent No. 5,449,667) was infringed and not proven invalid. The jury awarded $48.5 million for this infringement. On January 6, 2014, the judge awarded prejudgment interest of approximately $12.5 million and additional post-interest on the full amount will also be awarded starting November 7, 2012 until the total award is satisfied. The final award to Enzo could be reduced or be subject to possible claims from third parties. On February 3, 2014, Life Technologies filed a notice of appeal and there can be no assurance that the Company will be successful in this litigation. Even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact on the Company. | |
As of August 1, 2013, the Company, as plaintiff, was engaged in litigation in the United States District Court for the Southern District of New York against six parties (and certain of their related companies): Amersham plc, PerkinElmer, Inc., Molecular Probes, Inc., Orchid Biosciences, Inc., Affymetrix, Inc., and Roche Diagnostic GmbH (“Roche”). These cases were commenced at various times from October 2002 to June 2004. In each of the six cases, the Company had asserted similar (with some differences) causes of action against the defendants which can be generally described as contract, tort, fraud, and patent claims, except that no patent claims are asserted against Affymetrix. In the Roche case, Roche seeks a declaratory judgment of non-breach and patent invalidity against the Company. The cases were consolidated for pre-trial purposes in 2004 and there has been extensive discovery among the parties. In 2011, the defendants moved for summary judgment of non-infringement regarding the Company’s patent claims. In 2012, those motions were granted in part and denied in part. In December 2012, all six defendants moved for summary judgment on the Company’s non-patent claims. Additional discovery was taken and the Company responded to the motions in May 2013. On October 22, 2013, the Court granted Amersham’s motion for summary judgment. Thereafter, on November 26, 2013, the parties settled and dismissed the Amersham case. On October 28, 2013, the Court granted in part and denied in part PerkinElmer’s motion for summary judgment. By decisions dated December 6, 2013, the Court granted in part and denied in part the summary judgment by Roche and Affymetrix. A jury trial was been ordered in Roche’s case on a date to be determined. On the same date, the Court granted the summary judgment for the remaining two motions by Molecular Probes and Orchid. | |
On April 22, 2014, the Company as plaintiff finalized and executed a settlement agreement with Affymetrix, Inc. to settle a patent litigation lawsuit (the “Agreement”) in the amount of $5.1 million. Under terms of the Agreement, Affymetrix paid to the Company $4.3 million and paid to the Company’s attorneys $0.8 million, which is included in legal fees in the statements of operations for the year ended July 31, 2014. The amount of the settlement is included in the statement of operations under Legal settlements, net within the Life Science segment. | |
On June 20, 2014 the Company, as plaintiff finalized and executed a settlement agreement with PerkinElmer, Inc., and PerkinElmer Health Sciences, Inc. (formerly known as PerkinElmer Life Sciences, Inc.) (together, “PerkinElmer”), with respect to an action between the Company and PerkinElmer before the U.S. District Court, Southern District of New York, Case No 03-CV-3817. PerkinElmer paid $7.0 million in escrow pursuant to the agreement because of a former attorney’s motion requesting a charging lien for fees allegedly owed for past services rendered to the Company. Because the settlement proceeds are held in escrow, the Company did not include the settlement or any additional amounts which may be payable to the attorney in the financial statements as of and for the fiscal year ended July 31, 2014. | |
As previously disclosed, in 2012, the Company received a Subpoena Duces Tecum (the “Subpoena”) from the Department of Health and Human Services, Office of Inspector General (“OIG”). The Subpoena was issued as part of an investigation being conducted by the US Attorney’s Office for the Eastern District of New York in conjunction with the OIG. While a number of potential issues were raised initially by the government, the investigation came to focus primarily on an alleged failure to collect diagnosis codes from physicians who ordered tests through Enzo Clinical Labs. The time period initially covered by the investigation was from 2004 through 2011. In response to the Subpoena, the Company cooperated with the government. On September 22, 2014, the Company and the U.S. Department of Justice reached a settlement agreement to resolve this matter, in substantive form as disclosed in the Company’s fiscal quarter ended April 30, 2014. During the quarter ended April, 30, 2014, the Company recorded a charge of $2.0 million in the statement of operations under legal settlements, net within the Clinical Labs segment. The settlement amount will be paid with interest over a five-year period and as a result the Company recorded $0.4 million as other current liabilities and $1.6 million as a non-current liability at July 31, 2014. Under certain circumstances, the Company may be required to accelerate payments and/or pay up to an additional $1.5 million based upon (i) a favorable recovery and collection related to the judgment in the Life Technologies matter discussed above, (ii) receipt of additional capital greater than $10.0 million in a fiscal year (in that case, the Company is required to pay 20% of any amount over $10.0 million plus interest, or (iii) sale of the Company. The final settlement covers the time period 2004 - 2014. | |
The Company is party to other claims, legal actions, complaints, and contractual disputes that arise in the ordinary course of business. The Company believes that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on its financial position or results of operations. |
Segment_reporting
Segment reporting | 12 Months Ended | ||||||||||||||||||||
Jul. 31, 2014 | |||||||||||||||||||||
Segment Reporting [Abstract] | ' | ||||||||||||||||||||
Segment Reporting Disclosure [Text Block] | ' | ||||||||||||||||||||
Note 15 - Segment reporting | |||||||||||||||||||||
The Company has three reportable segments: Life Sciences, Clinical Labs and Therapeutics. The Company’s Life Sciences segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Labs segment provides diagnostic services to the health care community. The Company’s Therapeutics segment conducts research and development activities for therapeutic drug candidates. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative costs which are not allocable to the three reportable segments. | |||||||||||||||||||||
Legal fee expense incurred to defend the Company’s intellectual property and other general corporate matters are considered a component of the Other segment. Legal fee expense specific to other segments’ activities have been allocated to those segments. | |||||||||||||||||||||
Legal settlements, net, represent activities for which royalties would have been received in the Company’s Life Sciences segment and expenses related to an investigation within the Clinical Labs segment. | |||||||||||||||||||||
Management of the Company assesses assets on a consolidated basis only and therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. | |||||||||||||||||||||
The following financial information represents the operating results of the reportable segments of the Company: | |||||||||||||||||||||
Year ended July 31, 2014 | Clinical | Life | Therapeutics | Other | Consolidated | ||||||||||||||||
Labs | Sciences | ||||||||||||||||||||
Revenues: | |||||||||||||||||||||
Clinical laboratory services | $ | 58,689 | — | — | — | $ | 58,689 | ||||||||||||||
Product revenues | — | $ | 32,850 | — | — | 32,850 | |||||||||||||||
Royalty and license fee income | — | 4,408 | — | — | 4,408 | ||||||||||||||||
Total revenues | 58,689 | 37,258 | — | — | 95,947 | ||||||||||||||||
Operating expenses: | |||||||||||||||||||||
Cost of clinical laboratory services | 38,948 | — | — | — | 38,948 | ||||||||||||||||
Cost of product revenues | — | 15,320 | — | — | 15,320 | ||||||||||||||||
Research and development | 14 | 2,350 | $ | 777 | — | 3,141 | |||||||||||||||
Selling, general and administrative | 20,460 | 13,374 | — | $ | 7,967 | 41,801 | |||||||||||||||
Provision for uncollectible accounts receivable | 3,115 | (52 | ) | — | — | 3,063 | |||||||||||||||
Legal fee expense | 736 | 940 | — | 5,278 | 6,954 | ||||||||||||||||
Legal settlements, net | 2,000 | (5,100 | ) | (3,100 | ) | ||||||||||||||||
Total operating expenses | 65,273 | 26,832 | 777 | 13,245 | 106,127 | ||||||||||||||||
Operating (loss) income | (6,584 | ) | 10,426 | (777 | ) | (13,245 | ) | (10,180 | ) | ||||||||||||
Other income (expense) | |||||||||||||||||||||
Interest | (43 | ) | 9 | — | (174 | ) | (208 | ) | |||||||||||||
Other | 56 | 95 | — | 43 | 194 | ||||||||||||||||
Foreign exchange gain | — | 289 | — | — | 289 | ||||||||||||||||
(Loss) income before income taxes | $ | (6,571 | ) | $ | 10,819 | $ | (777 | ) | $ | (13,376 | ) | $ | (9,905 | ) | |||||||
Depreciation and amortization included above | $ | 1,415 | $ | 2,455 | $ | 7 | $ | 94 | $ | 3,971 | |||||||||||
Share-based compensation included in above: | |||||||||||||||||||||
Cost of clinical laboratory services | $ | 8 | $ | 1 | — | — | $ | 9 | |||||||||||||
Research and development | — | 1 | — | — | 1 | ||||||||||||||||
Selling, general and administrative | 36 | 6 | — | $ | 542 | 584 | |||||||||||||||
Total | $ | 44 | $ | 8 | — | $ | 542 | $ | 594 | ||||||||||||
Capital expenditures | $ | 643 | $ | 195 | — | — | $ | 838 | |||||||||||||
The following financial information represents the operating results of the reportable segments of the Company: | |||||||||||||||||||||
Year ended July 31, 2013 | Clinical | Life | Therapeutics | Other | Consolidated | ||||||||||||||||
Labs | Sciences | ||||||||||||||||||||
Revenues: | |||||||||||||||||||||
Clinical laboratory services | $ | 55,889 | — | — | — | $ | 55,889 | ||||||||||||||
Product revenues | — | $ | 32,526 | — | — | 32,526 | |||||||||||||||
Royalty and license fee income | — | 5,292 | — | — | 5,292 | ||||||||||||||||
Total revenues | 55,889 | 37,818 | — | — | 93,707 | ||||||||||||||||
Operating expenses: | |||||||||||||||||||||
Cost of clinical laboratory services | 38,251 | — | — | — | 38,251 | ||||||||||||||||
Cost of product revenues | — | 16,584 | — | — | 16,584 | ||||||||||||||||
Research and development | 294 | 2,356 | $ | 1,239 | — | 3,889 | |||||||||||||||
Selling, general and administrative | 19,942 | 15,511 | — | $ | 8,201 | 43,654 | |||||||||||||||
Provision for uncollectible accounts receivable | 4,232 | 264 | — | — | 4,496 | ||||||||||||||||
Legal fee expense | 316 | 57 | — | 5,440 | 5,813 | ||||||||||||||||
Total operating expenses | 63,035 | 34,772 | 1,239 | 13,641 | 112,687 | ||||||||||||||||
Operating (loss) income | (7,146 | ) | 3,046 | (1,239 | ) | (13,641 | ) | (18,980 | ) | ||||||||||||
Other income (expense) | |||||||||||||||||||||
Interest | (46 | ) | 13 | — | (21 | ) | (54 | ) | |||||||||||||
Other | 49 | (71 | ) | — | 27 | 5 | |||||||||||||||
Foreign exchange gain | — | 80 | — | — | 80 | ||||||||||||||||
(Loss) income before income taxes | $ | (7,143 | ) | $ | 3,066 | $ | (1,239 | ) | $ | (13,635 | ) | $ | (18,949 | ) | |||||||
Depreciation and amortization included above | $ | 1,377 | $ | 3,102 | $ | 22 | $ | 104 | $ | 4,605 | |||||||||||
Share-based compensation included in above: | |||||||||||||||||||||
Cost of clinical laboratory services | $ | 9 | 1 | — | — | $ | 10 | ||||||||||||||
Research and development | — | $ | 2 | — | — | 2 | |||||||||||||||
Selling, general and administrative | 36 | 10 | — | $ | 487 | 533 | |||||||||||||||
Total | $ | 45 | $ | 13 | — | $ | 487 | $ | 545 | ||||||||||||
Capital expenditures | $ | 757 | $ | 231 | — | — | $ | 988 | |||||||||||||
Year ended July 31, 2012 | Clinical | Life | Therapeutics | Other | Consolidated | ||||||||||||||||
Labs | Sciences | ||||||||||||||||||||
Revenues: | |||||||||||||||||||||
Clinical laboratory services | $ | 59,403 | — | — | — | $ | 59,403 | ||||||||||||||
Product revenues | — | $ | 37,722 | — | — | 37,722 | |||||||||||||||
Royalty and license fee income | — | 5,958 | — | — | 5,958 | ||||||||||||||||
Total revenues | 59,403 | 43,680 | — | — | 103,083 | ||||||||||||||||
Operating expenses: | |||||||||||||||||||||
Cost of clinical laboratory services | 36,305 | — | — | — | 36,305 | ||||||||||||||||
Cost of product revenues | — | 19,668 | — | — | 19,668 | ||||||||||||||||
Research and development | 299 | 4,308 | $ | 1,686 | — | 6,293 | |||||||||||||||
Selling, general and administrative | 20,856 | 18,305 | — | $ | 8,767 | 47,928 | |||||||||||||||
Provision for uncollectible accounts receivable | 4,987 | 117 | — | — | 5,104 | ||||||||||||||||
Legal fee expense | 262 | 536 | — | 2,926 | 3,724 | ||||||||||||||||
Impairment charges | — | 24,540 | — | — | 24,540 | ||||||||||||||||
Total operating expenses | 62,709 | 67,474 | 1,686 | 11,693 | 143,562 | ||||||||||||||||
Operating loss | (3,306 | ) | (23,794 | ) | (1,686 | ) | (11,693 | ) | (40,479 | ) | |||||||||||
Other income (expense) | |||||||||||||||||||||
Interest | (5 | ) | 23 | — | 3 | 21 | |||||||||||||||
Other | 28 | 27 | — | 22 | 77 | ||||||||||||||||
Foreign exchange loss | — | (540 | ) | — | — | (540 | ) | ||||||||||||||
Loss before income taxes | $ | (3,283 | ) | $ | (24,284 | ) | $ | (1,686 | ) | $ | (11,668 | ) | $ | (40,921 | ) | ||||||
Depreciation and amortization included above | $ | 1,092 | $ | 3,217 | $ | 43 | $ | 125 | $ | 4,477 | |||||||||||
Share-based compensation included in above: | |||||||||||||||||||||
Cost of clinical laboratory services | $ | 10 | — | — | $ | 10 | |||||||||||||||
Research and development | — | $ | 4 | — | — | 4 | |||||||||||||||
Selling, general and administrative | 49 | 59 | — | $ | 597 | 705 | |||||||||||||||
Total | $ | 59 | $ | 63 | — | $ | 597 | $ | 719 | ||||||||||||
Capital expenditures | $ | 921 | $ | 443 | — | — | $ | 1,364 | |||||||||||||
Geographic financial information is as follows: | |||||||||||||||||||||
Net sales to unaffiliated customers: | 2014 | 2013 | 2012 | ||||||||||||||||||
United States | $ | 84,389 | $ | 80,559 | $ | 87,776 | |||||||||||||||
Switzerland | 4,130 | 5,499 | 6,802 | ||||||||||||||||||
United Kingdom | 2,023 | 2,324 | 2,728 | ||||||||||||||||||
Other international countries | 5,405 | 5,325 | 5,777 | ||||||||||||||||||
Total | $ | 95,947 | $ | 93,707 | $ | 103,083 | |||||||||||||||
Long-lived assets at July 31, | |||||||||||||||||||||
United States | $ | 20,854 | $ | 23,136 | $ | 25,081 | |||||||||||||||
Switzerland | 1,629 | 1,984 | 2,223 | ||||||||||||||||||
United Kingdom | 462 | 491 | 618 | ||||||||||||||||||
Other international countries | 345 | 401 | 426 | ||||||||||||||||||
Total | $ | 23,290 | $ | 26,012 | $ | 28,348 | |||||||||||||||
The Company’s reportable segments are determined based on the services they perform, the products they sell, and the royalties and license fee income they earn, not on the geographic area in which they operate. The Company’s Clinical Labs segment operates 100% in the United States with all revenue derived there. The Life Sciences segment earns product revenue both in the United States and foreign countries and royalty and license fee income in the United States. The following is a summary of the Life Sciences segment revenues attributable to customers located in the United States and foreign countries: | |||||||||||||||||||||
2014 | 2013 | 2012 | |||||||||||||||||||
United States | $ | 25,700 | $ | 24,669 | $ | 28,372 | |||||||||||||||
Foreign countries | 11,558 | 13,149 | 15,308 | ||||||||||||||||||
$ | 37,258 | $ | 37,818 | $ | 43,680 | ||||||||||||||||
Summary_of_Selected_Quarterly_
Summary of Selected Quarterly Financial Data (unaudited) | 12 Months Ended | ||||||||||||||||
Jul. 31, 2014 | |||||||||||||||||
Quarterly Financial Information Disclosure [Abstract] | ' | ||||||||||||||||
Quarterly Financial Information [Text Block] | ' | ||||||||||||||||
Note 16 - Summary of Selected Quarterly Financial Data (unaudited) | |||||||||||||||||
The following table contains statement of operations information for each quarter of the years ended July 31, 2014 and 2013. The Company believes that the following information reflects all normal recurring adjustments necessary for a fair presentation of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period. | |||||||||||||||||
Unaudited quarterly financial data for fiscal 2014 and 2013 is summarized as follows: | |||||||||||||||||
Quarter Ended | |||||||||||||||||
Fiscal 2014 | October 31, | January 31, | April 30, | July 31, | |||||||||||||
2013 | 2014 | 2014 | 2014 | ||||||||||||||
Total revenues | $ | 24,134 | $ | 22,928 | $ | 23,978 | $ | 24,907 | |||||||||
Gross profit | 10,579 | 9,771 | 10,394 | 10,935 | |||||||||||||
Loss before income taxes | (2,725 | ) | (3,570 | ) | (448 | ) | (3,162 | ) | |||||||||
Net loss | (2,787 | ) | (3,566 | ) | (455 | ) | (3,169 | ) | |||||||||
Basic and diluted loss per common share | $ | (0.07 | ) | $ | (0.09 | ) | $ | (0.01 | ) | $ | (0.07 | ) | |||||
Quarter Ended | |||||||||||||||||
Fiscal 2013 | October 31, | January 31, | April 30, | July 31, | |||||||||||||
2012 | 2013 | 2013 | 2013 | ||||||||||||||
Total revenues | $ | 25,630 | $ | 22,210 | $ | 22,598 | $ | 23,269 | |||||||||
Gross profit | 11,736 | 8,642 | 9,048 | 9,446 | |||||||||||||
Loss before income taxes | (3,755 | ) | (5,854 | ) | (5,808 | ) | (3,532 | ) | |||||||||
Net loss | (3,691 | ) | (5,674 | ) | (5,770 | ) | (3,102 | ) | |||||||||
Basic and diluted loss per common share | $ | (0.09 | ) | $ | (0.14 | ) | $ | (0.15 | ) | $ | (0.08 | ) | |||||
SCHEDULE_II_VALUATION_AND_QUAL
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS | 12 Months Ended | |||||||||||||||||||
Jul. 31, 2014 | ||||||||||||||||||||
Valuation and Qualifying Accounts [Abstract] | ' | |||||||||||||||||||
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] | ' | |||||||||||||||||||
SCHEDULE II | ||||||||||||||||||||
VALUATION AND QUALIFYING ACCOUNTS | ||||||||||||||||||||
Years ended July 31, 2014, 2013 and 2012 | ||||||||||||||||||||
(in thousands) | ||||||||||||||||||||
Year ended | Description | Balance at | Charged | Charged | Deductions | Balance at | ||||||||||||||
July 31, | Beginning | to | to other | end of period | ||||||||||||||||
of period | costs | accounts | ||||||||||||||||||
and expenses | ||||||||||||||||||||
2014 | Allowance for doubtful accounts receivable | 2,707 | 3,063 | 3,628 | -1 | 2,142 | ||||||||||||||
2013 | Allowance for doubtful accounts receivable | 3,273 | 4,496 | 5,062 | -1 | 2,707 | ||||||||||||||
2012 | Allowance for doubtful accounts receivable | 3,488 | 5,104 | 5,319 | -1 | 3,273 | ||||||||||||||
2014 | Deferred tax valuation allowance | 47,623 | 1,842 | 49,465 | ||||||||||||||||
2013 | Deferred tax valuation allowance | 41,261 | 6,362 | 47,623 | ||||||||||||||||
2012 | Deferred tax valuation allowance | 32,920 | 8,341 | 41,261 | ||||||||||||||||
-1 | Write-off of uncollectible accounts receivable. | |||||||||||||||||||
Accounting_Policies_by_Policy_
Accounting Policies, by Policy (Policies) | 12 Months Ended | ||||||||||||||||||||||||||
Jul. 31, 2014 | |||||||||||||||||||||||||||
Accounting Policies [Abstract] | ' | ||||||||||||||||||||||||||
Nature of Business [Policy Text Block] | ' | ||||||||||||||||||||||||||
Nature of business | |||||||||||||||||||||||||||
Enzo Biochem, Inc. (the “Company”) is an integrated life science and biotechnology company engaged in research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally. The Company is conducting research and development activities in the development of therapeutic products based on the Company’s technology platform of genetic modulation and immune modulation. The Company also operates a clinical laboratory that offers and provides diagnostic medical testing services in the New York, New Jersey and Eastern Pennsylvania medical communities. The Company operates in three segments (see Note 15). | |||||||||||||||||||||||||||
Consolidation, Policy [Policy Text Block] | ' | ||||||||||||||||||||||||||
Principles of consolidation | |||||||||||||||||||||||||||
The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) and include the accounts of the Company and its wholly-owned subsidiaries, Enzo Clinical Labs, Inc., Enzo Life Sciences, Inc. (and its wholly-owned foreign subsidiaries), Enzo Therapeutics, Inc. and Enzo Realty LLC (“Realty”). All intercompany transactions and balances have been eliminated. | |||||||||||||||||||||||||||
Use of Estimates, Policy [Policy Text Block] | ' | ||||||||||||||||||||||||||
Use of Estimates | |||||||||||||||||||||||||||
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying footnotes. Actual results could differ from those estimates. | |||||||||||||||||||||||||||
Foreign Currency Transactions and Translations Policy [Policy Text Block] | ' | ||||||||||||||||||||||||||
Foreign Currency Translation/Transactions | |||||||||||||||||||||||||||
The Company has determined that the functional currency for its foreign subsidiaries is the local currency. For financial reporting purposes, assets and liabilities denominated in foreign currencies are translated at current exchange rates and profit and loss accounts are translated at weighted average exchange rates. Resulting translation gains and losses are included as a separate component of stockholders’ equity as accumulated other comprehensive income or loss. Gains or losses resulting from transactions entered into in other than the functional currency are recorded as foreign exchange gains and losses in the consolidated statements of operations. | |||||||||||||||||||||||||||
Cash and Cash Equivalents, Policy [Policy Text Block] | ' | ||||||||||||||||||||||||||
Cash and cash equivalents | |||||||||||||||||||||||||||
Cash and cash equivalents consist of demand deposits with banks and highly liquid money market funds.. At July 31, 2014 and 2013, the Company had cash and cash equivalents in foreign bank accounts of $1.1 million and $1.5 million, respectively. | |||||||||||||||||||||||||||
Fair Value of Financial Instruments, Policy [Policy Text Block] | ' | ||||||||||||||||||||||||||
Fair Values of Financial Instruments | |||||||||||||||||||||||||||
The recorded amounts of the Company’s cash and equivalents, receivables, loan payable, accounts payable and accrued liabilities approximate their fair values principally because of the short-term nature of these items. | |||||||||||||||||||||||||||
Concentration Risk, Credit Risk, Policy [Policy Text Block] | ' | ||||||||||||||||||||||||||
Concentration of credit risk | |||||||||||||||||||||||||||
Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents and accounts receivable. | |||||||||||||||||||||||||||
The Company believes the fair value of the aforementioned financial instruments approximates the cost due to the immediate or short-term nature of these items. | |||||||||||||||||||||||||||
Concentration of credit risk with respect to the Company’s Life Sciences segment is mitigated by the diversity of the Company’s clients and their dispersion across many different geographic regions. To reduce risk, the Company routinely assesses the financial strength of these customers and, consequently, believes that its accounts receivable credit exposure with respect to these customers is limited. | |||||||||||||||||||||||||||
The Company believes that the concentration of credit risk with respect to the Clinical Labs accounts receivable is mitigated by the diversity of third party payers that insure individuals. To reduce risk, the Company routinely assesses the financial strength of these payers and, consequently, believes that its accounts receivable credit risk exposure, with respect to these payers, is limited. While the Company also has receivables due from the Federal Medicare program, the Company does not believe that these receivables represent a credit risk since the Medicare program is funded by the federal government and payment is primarily dependent on our submitting the appropriate documentation. | |||||||||||||||||||||||||||
Accrual For Self-Funded Medical [Policy Text Block] | ' | ||||||||||||||||||||||||||
Accrual for Self-Funded Medical | |||||||||||||||||||||||||||
Accruals for self-funded medical insurance are determined based on a number of assumptions and factors, including historical payment trends, claims history and current estimates. These estimated liabilities are not discounted. If actual trends differ from these estimates, the financial results could be impacted. | |||||||||||||||||||||||||||
Revenue Recognition, Policy [Policy Text Block] | ' | ||||||||||||||||||||||||||
Revenue Recognition - Product revenues | |||||||||||||||||||||||||||
Revenues from product sales are recognized when the products are shipped and title transfers, the sales price is fixed or determinable and collectability is reasonably assured. | |||||||||||||||||||||||||||
Revenue Recognition, Services, Royalty Fees [Policy Text Block] | ' | ||||||||||||||||||||||||||
Royalties | |||||||||||||||||||||||||||
Royalty revenues are recorded in the period earned. Royalties received in advance of being earned are recorded as deferred revenues. | |||||||||||||||||||||||||||
Clinical Laboratory Services [Policy Text Block] | ' | ||||||||||||||||||||||||||
Clinical laboratory services | |||||||||||||||||||||||||||
Revenues from the Clinical Labs segment are recognized upon completion of the testing process for a specific patient and reported to the ordering physician. These revenues and the associated accounts receivable are based on gross amounts billed or billable for services rendered, net of a contractual adjustment, which is the difference between amounts billed to payers and the expected reimbursable settlements from such payers. | |||||||||||||||||||||||||||
The following table summarizes the Clinical Lab segment’s net revenues and revenue percentages by revenue category: | |||||||||||||||||||||||||||
Years Ended July 31, | |||||||||||||||||||||||||||
2014 | 2013 | 2012 | |||||||||||||||||||||||||
Revenue category | Amount | % | Amount | % | Amount | % | |||||||||||||||||||||
Third-party payers | $ | 29,509 | 50 | $ | 26,014 | 47 | $ | 29,616 | 50 | ||||||||||||||||||
Medicare | 12,815 | 22 | 12,497 | 22 | 12,658 | 21 | |||||||||||||||||||||
Patient self-pay | 11,204 | 19 | 12,172 | 22 | 11,895 | 20 | |||||||||||||||||||||
HMO’s | 5,161 | 9 | 5,206 | 9 | 5,234 | 9 | |||||||||||||||||||||
Total | $ | 58,689 | 100 | % | $ | 55,889 | 100 | % | $ | 59,403 | 100 | % | |||||||||||||||
The Company provides services to certain patients covered by various third-party payers, including the Federal Medicare program. Laws and regulations governing Medicare are complex and subject to interpretation for which action for noncompliance includes fines, penalties and exclusion from the Medicare programs (See Note 14). | |||||||||||||||||||||||||||
Other than the Medicare program, one provider whose programs are included in the “Third-party payers” and “Health Maintenance Organizations” (“HMO’s”) categories represent approximately 25%, 22% and 21% of the Clinical Labs segment net revenue for the years ended July 31, 2014, 2013 and 2012 respectively. | |||||||||||||||||||||||||||
Contractual Adjustments and Third Party Settlements, Policy [Policy Text Block] | ' | ||||||||||||||||||||||||||
Contractual Adjustment | |||||||||||||||||||||||||||
The Company’s estimate of contractual adjustment is based on significant assumptions and judgments, such as its interpretation of payer reimbursement policies, and bears the risk of change. The estimation process is based on the experience of amounts approved as reimbursable and ultimately settled by payers, versus the corresponding gross amount billed to the respective payers. The contractual adjustment is an estimate that reduces gross revenue based on gross billing rates to amounts expected to be approved and reimbursed. Gross billings are based on a standard fee schedule the Company sets for all third-party payers, including Medicare, HMO’s and managed care providers. The Company adjusts the contractual adjustment estimate quarterly, based on its evaluation of current and historical settlement experience with payers, industry reimbursement trends, and other relevant factors which include the monthly and quarterly review of: 1) current gross billings and receivables and reimbursement by payer, 2) current changes in third party arrangements and 3) the growth of in-network provider arrangements and managed care plans specific to our Company. | |||||||||||||||||||||||||||
During the years ended July 31, 2014, 2013 and 2012, the contractual adjustment percentages, determined using current and historical reimbursement statistics, were approximately 86%, 85% and 85%, respectively, of gross billings. | |||||||||||||||||||||||||||
Accounts Receivable And Allowance For Doubtful Accounts [Policy Text Block] | ' | ||||||||||||||||||||||||||
Accounts Receivable and Allowance for Doubtful Accounts | |||||||||||||||||||||||||||
Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period of the related revenue. | |||||||||||||||||||||||||||
For the Clinical Labs segment, the allowance for doubtful accounts represents amounts that the Company does not expect to collect after the Company has exhausted its collection procedures. The Company estimates its allowance for doubtful accounts in the period the related services are billed and adjusts the estimate in future accounting periods as necessary. It bases the estimate for the allowance on the evaluation of historical collection experience, the aging profile of accounts receivable, payer mix and other relevant factors. | |||||||||||||||||||||||||||
During the years ended July 31, 2014 and 2013, the Company determined an allowance for doubtful accounts for customers whose accounts receivable have been outstanding less than 210 days and either fully reserved or wrote off 100% of accounts receivable over 210 days, as it determined based on historical trends that those accounts were uncollectible, except for certain fully reserved balances, principally related to Medicare. These accounts have not been written off because the payer’s filing date deadline has not occurred or the collection process has not been exhausted. The Company adjusts the historical collection analysis for recoveries, if any, on an ongoing basis. | |||||||||||||||||||||||||||
The Company’s ability to collect outstanding receivables from third-party payers is critical to its operating performance and cash flows. The primary collection risk lies with uninsured patients or patients for whom primary insurance has paid but a patient portion remains outstanding. The Company also assesses the current state of its billing functions in order to identify any known collection issues and to assess the impact, if any, on the allowance estimates which involves judgment. The Company believes that the collectability of its receivables is directly linked to the quality of its billing processes, most notably, those related to obtaining the correct information in order to bill effectively for the services provided. Should circumstances change (e.g. shift in payer mix, decline in economic conditions or deterioration in aging of receivables), our estimates of net realizable value of receivables could be reduced by a material amount. | |||||||||||||||||||||||||||
The Clinical Labs segment’s net receivables are detailed by billing category and as a percent to its total net receivables. At July 31, 2014 and 2013, approximately 60% of the Company’s net accounts receivable relates to its Clinical Labs business, which operates in the New York, New Jersey, and Eastern Pennsylvania medical communities. | |||||||||||||||||||||||||||
The Life Sciences segment’s accounts receivable includes royalties receivable of $1.0 million and $1.2 million, as of July 31, 2014 and 2013, respectively, due from QIAGEN Gaithersburg Inc. (“Qiagen”) (see Note 12). | |||||||||||||||||||||||||||
The following is a table of the Company’s net accounts receivable by segment. | |||||||||||||||||||||||||||
31-Jul-14 | 31-Jul-13 | ||||||||||||||||||||||||||
Net accounts receivable by segment | Amount | % | Amount | % | |||||||||||||||||||||||
Clinical Labs (by billing category) | |||||||||||||||||||||||||||
Third party payers | $ | 3,499 | 46 | $ | 3,395 | 46 | |||||||||||||||||||||
Patient self-pay | 2,193 | 29 | 2,696 | 37 | |||||||||||||||||||||||
Medicare | 1,558 | 21 | 930 | 13 | |||||||||||||||||||||||
HMO’s | 280 | 4 | 300 | 4 | |||||||||||||||||||||||
Total Clinical Labs | 7,530 | 100 | % | 7,321 | 100 | % | |||||||||||||||||||||
Total Life Sciences | 4,940 | 4,967 | |||||||||||||||||||||||||
Total accounts receivable – net | $ | 12,470 | $ | 12,288 | |||||||||||||||||||||||
Changes in the Company’s allowance for doubtful accounts are as follows: | |||||||||||||||||||||||||||
31-Jul-14 | 31-Jul-13 | ||||||||||||||||||||||||||
Beginning balance | $ | 2,707 | $ | 3,273 | |||||||||||||||||||||||
Provision for doubtful accounts | 3,063 | 4,496 | |||||||||||||||||||||||||
Write-offs | (3,628 | ) | (5,062 | ) | |||||||||||||||||||||||
Ending balance | $ | 2,142 | $ | 2,707 | |||||||||||||||||||||||
Inventory, Policy [Policy Text Block] | ' | ||||||||||||||||||||||||||
Inventories | |||||||||||||||||||||||||||
The Company values inventory at the lower of cost (first-in, first-out) or market. Work-in-process and finished goods inventories consist of material, labor, and manufacturing overhead. Write downs of inventories to market value are based on a review of inventory quantities on hand and estimated sales forecasts based on sales history and anticipated future demand. Unanticipated changes in demand could have a significant impact on the value of our inventory and require additional write downs of inventory which would impact our results of operations. | |||||||||||||||||||||||||||
Property, Plant and Equipment, Policy [Policy Text Block] | ' | ||||||||||||||||||||||||||
Property, plant and equipment | |||||||||||||||||||||||||||
Property, plant and equipment is stated at cost, and depreciated on the straight-line basis over the estimated useful lives of the various asset classes as follows: building and building improvements: 15 - 30 years, and laboratory machinery and equipment and office furniture and computer equipment which range from 3 - 10 years. Leasehold improvements are amortized over the term of the related leases or estimated useful lives of the assets, whichever is shorter. | |||||||||||||||||||||||||||
Goodwill and Intangible Assets, Policy [Policy Text Block] | ' | ||||||||||||||||||||||||||
Goodwill and Intangible Assets | |||||||||||||||||||||||||||
Goodwill represents the excess of the cost of an acquisition over the fair value of the net assets acquired. | |||||||||||||||||||||||||||
Intangible assets (exclusive of patents), arose primarily from acquisitions, and primarily consist of customer relationships, trademarks, licenses, and website and database content. Finite-lived intangible assets are amortized according to their estimated useful lives, which range from 4 to 15 years. Indefinite-lived intangibles are not amortized and are evaluated each reporting period to determine whether events and circumstances continue to support their having an indefinite life. Indefinite-lived intangibles found to no longer have an indefinite life are evaluated for impairment and are then amortized over their remaining useful life as finite-lived intangible assets. Patents represent capitalized legal costs incurred in pursuing patent applications. When such applications result in an issued patent, the related capitalized costs are amortized over a ten year period or the life of the patent, whichever is shorter, using the straight-line method. The Company reviews its issued patents and pending patent applications, and if it determines to abandon a patent application or that an issued patent no longer has economic value, the unamortized balance in deferred patent costs relating to that patent is immediately expensed. | |||||||||||||||||||||||||||
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] | ' | ||||||||||||||||||||||||||
Impairment testing for Goodwill and Long-Lived Assets | |||||||||||||||||||||||||||
The Company tests goodwill and indefinite-lived intangible assets annually as of the first day of the fourth quarter, or more frequently if indicators of potential impairment exist. In assessing goodwill and indefinite-lived intangible assets for impairment, the Company has the option to first perform a qualitative assessment to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit or intangible asset is less than its carrying amount. If the Company determines that it is not more likely that not that the fair value of a reporting unit or intangible asset is less than its carrying amount, the Company is not required to perform any additional tests in assessing goodwill and indefinite-lived intangible assets for impairment. For goodwill, if the Company concludes otherwise or elects not to perform the qualitative assessment, then it is required to perform the first step of a two-step quantitative impairment review process. The first step of the quantitative impairment test requires the identification of the reporting units and comparison of the fair value of each of these reporting units to their respective carrying value. If the carrying value of the reporting unit is less than its fair value, no impairment exists and the second step is not performed. If the carrying value of the reporting unit is higher than its fair value, the second step must be performed to compute the amount of the goodwill impairment, if any. In the second step, the impairment is computed by comparing the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized for the excess. For indefinite-lived intangible assets, if the Company concludes otherwise or elects not to perform the qualitative assessment, then the fair value of the intangible asset is compared to its carrying value, and impairment is recognized for the excess of the carrying value over the fair value, if any. | |||||||||||||||||||||||||||
The Company performed a qualitative assessment in 2014 and a quantitative assessment in 2013 and concluded there were no impairments. The Company performed a quantitative assessment in fiscal 2012 and concluded goodwill and indefinite-lived intangible assets had been impaired (see Note 2). | |||||||||||||||||||||||||||
The Company reviews the recoverability of the carrying value of long-lived assets (including intangible assets with finite lives) for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. Should indicators of impairment exist, the carrying values of the assets are evaluated in relation to the operating performance and future undiscounted cash flows of the underlying business. The net book value of an asset is adjusted to fair value if its expected future undiscounted cash flow is less than its book value. There were 0 impairments in 2014, 2013 or 2012, exclusive of goodwill and indefinite-lived intangibles in 2012. | |||||||||||||||||||||||||||
Comprehensive Loss [Policy Text Block] | ' | ||||||||||||||||||||||||||
Comprehensive loss | |||||||||||||||||||||||||||
Comprehensive loss consists of the Company’s consolidated net loss and foreign currency translation adjustments. Foreign currency translation adjustments included in comprehensive loss were not tax effected as investments in international affiliates are deemed to be permanent. Accumulated other comprehensive income is a separate component of stockholders’ equity and consists of the cumulative foreign currency translation adjustments. | |||||||||||||||||||||||||||
Shipping and Handling Cost, Policy [Policy Text Block] | ' | ||||||||||||||||||||||||||
Shipping and Handling Costs | |||||||||||||||||||||||||||
Shipping and handling costs associated with the distribution of finished goods to customers are recorded in cost of goods sold. | |||||||||||||||||||||||||||
Research and Development Expense, Policy [Policy Text Block] | ' | ||||||||||||||||||||||||||
Research and Development | |||||||||||||||||||||||||||
Research and development costs are charged to expense as incurred. | |||||||||||||||||||||||||||
Advertising Costs, Policy [Policy Text Block] | ' | ||||||||||||||||||||||||||
Advertising | |||||||||||||||||||||||||||
All costs associated with advertising are expensed as incurred. Advertising expense, included in Selling, general and administrative expense, approximated $440, $302 and $237 for the years ended July 31, 2014, 2013 and 2012, respectively. | |||||||||||||||||||||||||||
Income Tax, Policy [Policy Text Block] | ' | ||||||||||||||||||||||||||
Income Taxes | |||||||||||||||||||||||||||
The Company accounts for income taxes under the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The liability method requires that any tax benefits recognized for net operating loss carry forwards and other items be reduced by a valuation allowance when it is more likely than not that the benefits may not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. | |||||||||||||||||||||||||||
It is the Company’s policy to provide for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. At July 31, 2014, the Company believes it has appropriately accounted for any unrecognized tax benefits. To the extent the Company prevails in matters for which a liability for an unrecognized tax benefit is established or is required to pay amounts in excess of the liability, the Company’s effective tax rate in a given financial statement period may be affected. | |||||||||||||||||||||||||||
Segment Reporting, Policy [Policy Text Block] | ' | ||||||||||||||||||||||||||
Segment Reporting | |||||||||||||||||||||||||||
The Company follows accounting pronouncements which establish standards for reporting information on operating segments in interim and annual financial statements. An enterprise is required to separately report information about each operating segment that engages in business activities from which the segment may earn revenues and incur expenses, whose separate operating results are regularly reviewed by the chief operating decision maker regarding allocation of resources and performance assessment and which exceed specific quantitative thresholds related to revenue and profit or loss. The Company’s operating activities are reported in three segments (see Note 15). | |||||||||||||||||||||||||||
Earnings Per Share, Policy [Policy Text Block] | ' | ||||||||||||||||||||||||||
Net income (loss) per share | |||||||||||||||||||||||||||
Basic net income (loss) per share represents net income (loss) divided by the weighted average number of common shares outstanding during the period. The dilutive effect of potential common shares, consisting of outstanding stock options and unvested restricted stock, is determined using the treasury stock method. Diluted weighted average shares outstanding for fiscal 2014, 2013 and 2012 do not include the potential common shares from stock options and unvested restricted stock because to do so would have been antidilutive and as such is the same as basic weighted average shares outstanding. The number of potential common shares (“in the money options”) and unvested restricted stock excluded from the calculation of diluted earnings per share for the years ended July 31, 2014, 2013, and 2012 was 159,000, 32,000, and 0, respectively. | |||||||||||||||||||||||||||
For the years ended July 31, 2014, 2013 and 2012, the effect of approximately 604,000, 727,000 and 736,000 respectively, of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. The following table sets forth the computation of basic and diluted net loss per share for the years ended July 31: | |||||||||||||||||||||||||||
2014 | 2013 | 2012 | |||||||||||||||||||||||||
Net loss | $ | (9,977 | ) | $ | (18,237 | ) | $ | (39,269 | ) | ||||||||||||||||||
Weighted-average common shares outstanding - Basic | 42,561 | 39,607 | 38,798 | ||||||||||||||||||||||||
Add: effect of dilutive stock options and restricted stock | — | — | — | ||||||||||||||||||||||||
Weighted-average common shares outstanding - Diluted | 42,561 | 39,607 | 38,798 | ||||||||||||||||||||||||
Net loss per share: | |||||||||||||||||||||||||||
Basic and diluted | $ | (0.23 | ) | $ | (0.46 | ) | $ | (1.01 | ) | ||||||||||||||||||
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] | ' | ||||||||||||||||||||||||||
Share-Based Compensation | |||||||||||||||||||||||||||
The Company records compensation expense associated with stock options and restricted stock based upon the fair value of stock based awards as measured at the grant date. The expense is recorded by amortizing the fair values on a straight line basis over the vesting period, adjusted for estimated forfeitures. | |||||||||||||||||||||||||||
For the years ended July 31, 2014, 2013 and 2012, share-based compensation expense relating to the fair value of stock options, restricted shares and restricted stock units was approximately $594, $545, and $719, respectively (see Note 10). 0 excess tax benefits were recognized for the year ended July 31, 2014, 2013 and 2012. | |||||||||||||||||||||||||||
The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statement of operations for the years ended July 31: | |||||||||||||||||||||||||||
2014 | 2013 | 2012 | |||||||||||||||||||||||||
Cost of clinical laboratory services | $ | 9 | $ | 10 | $ | 10 | |||||||||||||||||||||
Research and development | 1 | 2 | 4 | ||||||||||||||||||||||||
Selling, general and administrative | 584 | 533 | 705 | ||||||||||||||||||||||||
$ | 594 | $ | 545 | $ | 719 | ||||||||||||||||||||||
As of July 31, 2014, there was $462 of total unrecognized compensation cost related to non-vested share-based payment arrangements granted under the Company’s incentive stock plans, which will be recognized over a weighted average remaining life of approximately fourteen months. | |||||||||||||||||||||||||||
New Accounting Pronouncements, Policy [Policy Text Block] | ' | ||||||||||||||||||||||||||
Effect of new accounting pronouncements | |||||||||||||||||||||||||||
In May 2014, the Financial Accounting Standards Board issued ASU No. 2014-09, Revenue from Contracts with Customers: Topic 606, or ASU 2014-09. ASU 2014-09 amends the guidance for revenue recognition to replace numerous, industry-specific requirements and converges areas under this topic with those of the International Financial Reporting Standards. ASU 2014-09 implements a five-step process for customer contract revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include the capitalization and amortization of certain contract costs, ensuring the time value of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The amendments in ASU 2014-09 are effective for reporting periods beginning after December 15, 2016, and early adoption is prohibited. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. We are currently assessing the impact the adoption of ASU 2014-09 will have on the Company’s combined consolidated financial statements. | |||||||||||||||||||||||||||
In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of Unrecognized Tax Benefit When a Net Operating Loss Carryforward, A Similar Tax Loss, or a Tax Credit Carryforward Exists (A Consensus the FASB Emerging Issues Task Force). ASU 2013-11 requires an entity to present an unrecognized tax benefit as a reduction of a deferred tax asset for a net operating loss carryforward, or similar tax loss or tax credit carryforward, rather than as a liability when the uncertain tax position would reduce the net operating loss or other carryforward under the tax law of the applicable jurisdiction and the entity intends to use the deferred tax asset for that purpose. This amendment is effective prospectively but allows optional retrospective adoption (for all periods presented). We do not expect the adoption of this standard to have a material impact on our consolidated financial statements. | |||||||||||||||||||||||||||
In August 2014, the FABS issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. ASU 2014-15 will explicitly require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. We are currently evaluating the impact of the adoption of ASU 2014-15. |
Summary_of_significant_account1
Summary of significant accounting policies (Tables) | 12 Months Ended | ||||||||||||||||||||||||||
Jul. 31, 2014 | |||||||||||||||||||||||||||
Accounting Policies [Abstract] | ' | ||||||||||||||||||||||||||
Schedule Of Segment Revenue And Revenue Percentage [Table Text Block] | 'The following table summarizes the Clinical Lab segment’s net revenues and revenue percentages by revenue category: | ||||||||||||||||||||||||||
Years Ended July 31, | |||||||||||||||||||||||||||
2014 | 2013 | 2012 | |||||||||||||||||||||||||
Revenue category | Amount | % | Amount | % | Amount | % | |||||||||||||||||||||
Third-party payers | $ | 29,509 | 50 | $ | 26,014 | 47 | $ | 29,616 | 50 | ||||||||||||||||||
Medicare | 12,815 | 22 | 12,497 | 22 | 12,658 | 21 | |||||||||||||||||||||
Patient self-pay | 11,204 | 19 | 12,172 | 22 | 11,895 | 20 | |||||||||||||||||||||
HMO’s | 5,161 | 9 | 5,206 | 9 | 5,234 | 9 | |||||||||||||||||||||
Total | $ | 58,689 | 100 | % | $ | 55,889 | 100 | % | $ | 59,403 | 100 | % | |||||||||||||||
Schedule Of Accounts Receivable By Segment [Table Text Block] | 'The following is a table of the Company’s net accounts receivable by segment. | ||||||||||||||||||||||||||
31-Jul-14 | 31-Jul-13 | ||||||||||||||||||||||||||
Net accounts receivable by segment | Amount | % | Amount | % | |||||||||||||||||||||||
Clinical Labs (by billing category) | |||||||||||||||||||||||||||
Third party payers | $ | 3,499 | 46 | $ | 3,395 | 46 | |||||||||||||||||||||
Patient self-pay | 2,193 | 29 | 2,696 | 37 | |||||||||||||||||||||||
Medicare | 1,558 | 21 | 930 | 13 | |||||||||||||||||||||||
HMO’s | 280 | 4 | 300 | 4 | |||||||||||||||||||||||
Total Clinical Labs | 7,530 | 100 | % | 7,321 | 100 | % | |||||||||||||||||||||
Total Life Sciences | 4,940 | 4,967 | |||||||||||||||||||||||||
Total accounts receivable – net | $ | 12,470 | $ | 12,288 | |||||||||||||||||||||||
Schedule of Allowance for Doubtful Accounts Receivable [Table Text Block] | 'Changes in the Company’s allowance for doubtful accounts are as follows: | ||||||||||||||||||||||||||
31-Jul-14 | 31-Jul-13 | ||||||||||||||||||||||||||
Beginning balance | $ | 2,707 | $ | 3,273 | |||||||||||||||||||||||
Provision for doubtful accounts | 3,063 | 4,496 | |||||||||||||||||||||||||
Write-offs | (3,628 | ) | (5,062 | ) | |||||||||||||||||||||||
Ending balance | $ | 2,142 | $ | 2,707 | |||||||||||||||||||||||
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | 'The following table sets forth the computation of basic and diluted net loss per share for the years ended July 31: | ||||||||||||||||||||||||||
2014 | 2013 | 2012 | |||||||||||||||||||||||||
Net loss | $ | (9,977 | ) | $ | (18,237 | ) | $ | (39,269 | ) | ||||||||||||||||||
Weighted-average common shares outstanding - Basic | 42,561 | 39,607 | 38,798 | ||||||||||||||||||||||||
Add: effect of dilutive stock options and restricted stock | — | — | — | ||||||||||||||||||||||||
Weighted-average common shares outstanding - Diluted | 42,561 | 39,607 | 38,798 | ||||||||||||||||||||||||
Net loss per share: | |||||||||||||||||||||||||||
Basic and diluted | $ | (0.23 | ) | $ | (0.46 | ) | $ | (1.01 | ) | ||||||||||||||||||
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] | 'The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statement of operations for the years ended July 31: | ||||||||||||||||||||||||||
2014 | 2013 | 2012 | |||||||||||||||||||||||||
Cost of clinical laboratory services | $ | 9 | $ | 10 | $ | 10 | |||||||||||||||||||||
Research and development | 1 | 2 | 4 | ||||||||||||||||||||||||
Selling, general and administrative | 584 | 533 | 705 | ||||||||||||||||||||||||
$ | 594 | $ | 545 | $ | 719 |
Goodwill_and_intangible_assets1
Goodwill and intangible assets (Tables) | 12 Months Ended | |||||||||||||||||||||||||
Jul. 31, 2014 | ||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | ' | |||||||||||||||||||||||||
Schedule of Indefinite-Lived Intangible Assets [Table Text Block] | 'The Company’s change in the net carrying amount of intangible assets, all in the Life Sciences segment is as follows: | |||||||||||||||||||||||||
Gross | Accumulated | Net | ||||||||||||||||||||||||
Amortization | ||||||||||||||||||||||||||
31-Jul-12 | $ | 27,904 | (16,124 | ) | 11,780 | |||||||||||||||||||||
Amortization expense | — | (1,990 | ) | (1,990 | ) | |||||||||||||||||||||
Foreign currency translation | 310 | (157 | ) | 153 | ||||||||||||||||||||||
31-Jul-13 | $ | 28,214 | (18,271 | ) | 9,943 | |||||||||||||||||||||
Amortization expense | — | -1,840 | (1,840 | ) | ||||||||||||||||||||||
Foreign currency translation | 264 | (259 | ) | 5 | ||||||||||||||||||||||
31-Jul-14 | $ | 28,478 | (20,370 | ) | 8,108 | |||||||||||||||||||||
Schedule of Intangible Assets [Table Text Block] | 'Intangible assets, all finite-lived, consist of the following: | |||||||||||||||||||||||||
31-Jul-14 | 31-Jul-13 | |||||||||||||||||||||||||
Gross | Accumulated | Net | Gross | Accumulated | Net | |||||||||||||||||||||
Amortization | Amortization | |||||||||||||||||||||||||
Patents | $ | 11,027 | $ | (10,775 | ) | $ | 252 | $ | 11,027 | $ | (10,587 | ) | $ | 440 | ||||||||||||
Customer relationships | 12,602 | (6,565 | ) | 6,037 | 12,446 | (5,448 | ) | 6,998 | ||||||||||||||||||
Website and acquired content | 1,037 | (1,037 | ) | — | 1,026 | (980 | ) | 46 | ||||||||||||||||||
Licensed technology and other | 537 | (434 | ) | 103 | 513 | (382 | ) | 131 | ||||||||||||||||||
Trademarks, gives effect for impairment charge and reclassification to finite-lived as of May 1, 2012 | 3,275 | (1,559 | ) | 1,716 | 3,202 | (874 | ) | 2,328 | ||||||||||||||||||
Total | $ | 28,478 | $ | (20,370 | ) | $ | 8,108 | $ | 28,214 | $ | (18,271 | ) | $ | 9,943 | ||||||||||||
Schedule of Useful Lives For Acquisitions [Table Text Block] | 'At July 31, 2014 information with respect to the intangibles acquired is as follows: | |||||||||||||||||||||||||
Useful life | Weighted average | |||||||||||||||||||||||||
assigned | remaining useful life | |||||||||||||||||||||||||
Customer relationships | 8-15 years | 6 years | ||||||||||||||||||||||||
Trademarks | 5 years | 3 years | ||||||||||||||||||||||||
Other intangibles | 4-5 years | 1 years | ||||||||||||||||||||||||
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] | 'Estimated amortization expense related to these finite-lived intangible assets for the five succeeding fiscal years ending July 31 is as follows: | |||||||||||||||||||||||||
2015 | 1,630 | |||||||||||||||||||||||||
2016 | 1,620 | |||||||||||||||||||||||||
2017 | 1,508 | |||||||||||||||||||||||||
2018 | 1,141 | |||||||||||||||||||||||||
2019 | 827 |
Inventories_Tables
Inventories (Tables) | 12 Months Ended | ||||||||
Jul. 31, 2014 | |||||||||
Inventory Disclosure [Abstract] | ' | ||||||||
Schedule of Inventory, Current [Table Text Block] | 'Inventories consisted of the following at July 31: | ||||||||
2014 | 2013 | ||||||||
Raw materials | $ | 1,092 | $ | 922 | |||||
Work in process | 2,460 | 2,628 | |||||||
Finished products | 5,138 | 5,255 | |||||||
$ | 8,690 | $ | 8,805 |
Property_plant_and_equipment_T
Property, plant, and equipment (Tables) | 12 Months Ended | ||||||||
Jul. 31, 2014 | |||||||||
Property, Plant and Equipment [Abstract] | ' | ||||||||
Property, Plant and Equipment [Table Text Block] | 'At July 31, 2014 and 2013 property, plant, and equipment consist of: | ||||||||
2014 | 2013 | ||||||||
Building and building improvements | $ | 4,834 | $ | 4,751 | |||||
Machinery and equipment (includes asset under capital lease - see Note 9) | 7,125 | 6,922 | |||||||
Office furniture and computer equipment | 16,834 | 16,390 | |||||||
Leasehold improvements | 4,835 | 4,759 | |||||||
33,628 | 32,822 | ||||||||
Accumulated depreciation and amortization | (26,610 | ) | (24,917 | ) | |||||
7,018 | 7,905 | ||||||||
Land and land improvements | 712 | 712 | |||||||
$ | 7,730 | $ | 8,617 |
Income_taxes_Tables
Income taxes (Tables) | 12 Months Ended | ||||||||||||
Jul. 31, 2014 | |||||||||||||
Income Tax Disclosure [Abstract] | ' | ||||||||||||
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | 'The (provision) benefit for income taxes for fiscal years ended July 31 is as follows: | ||||||||||||
2014 | 2013 | 2012 | |||||||||||
Current (provision) benefit: | |||||||||||||
Federal | $ | — | $ | — | $ | — | |||||||
State and local | (68 | ) | (46 | ) | (49 | ) | |||||||
Foreign | (22 | ) | (1 | ) | (61 | ) | |||||||
Deferred benefit | 18 | 759 | 1,762 | ||||||||||
(Provision) benefit for income taxes | $ | (72 | ) | $ | 712 | $ | 1,652 | ||||||
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | 'Deferred tax assets and liabilities arise from temporary differences between the tax basis of assets | ||||||||||||
2014 | 2013 | ||||||||||||
Deferred tax assets: | |||||||||||||
Federal tax carryforward losses | $ | 35,352 | $ | 34,836 | |||||||||
Provision for uncollectible accounts receivable | 753 | 920 | |||||||||||
State and local tax carry forward losses | 2,604 | 3,791 | |||||||||||
Accrued royalties | 144 | 143 | |||||||||||
Stock compensation | 190 | 317 | |||||||||||
Depreciation | 618 | 625 | |||||||||||
Research and development and other tax credit carryforwards | 1,085 | 1,013 | |||||||||||
Foreign tax carryforward losses | 1,207 | 772 | |||||||||||
Intangibles | 2,970 | 2,980 | |||||||||||
Inventory | 2,194 | 1,249 | |||||||||||
Accrued expenses | 3,103 | 1,622 | |||||||||||
Other, net | 15 | 19 | |||||||||||
Deferred tax assets | 50,235 | 48,287 | |||||||||||
Deferred tax liabilities: | |||||||||||||
Deferred patent costs | (135 | ) | (132 | ) | |||||||||
Prepaid expenses | (671 | ) | (695 | ) | |||||||||
Unrealized foreign exchange | (118 | ) | — | ||||||||||
Other, net | (29 | ) | (37 | ) | |||||||||
Deferred tax liabilities | (953 | ) | (864 | ) | |||||||||
Net deferred tax assets (liabilities) before valuation allowance | 49,282 | 47,423 | |||||||||||
Less: valuation allowance | (49,465 | ) | (47,623 | ) | |||||||||
Net deferred tax liabilities | $ | (183 | ) | $ | (200 | ) | |||||||
Schedule of Deferred Tax Liabilities Included In Consolidated Balance Sheets [Table Text Block] | 'Net deferred tax liabilities are included in the consolidated balance sheets as of July 31 as follow | ||||||||||||
2014 | 2013 | ||||||||||||
Deferred taxes: | |||||||||||||
Current | $ | — | $ | — | |||||||||
Non-current | 183 | 200 | |||||||||||
$ | 183 | $ | 200 | ||||||||||
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] | 'The components of loss before income taxes consisted of the following for the years ended July 31: | ||||||||||||
2014 | 2013 | 2012 | |||||||||||
United States operations | $ | (8,702 | ) | $ | (15,419 | ) | $ | (31,817 | ) | ||||
International operations | (1,203 | ) | (3,530 | ) | (9,104 | ) | |||||||
Loss before taxes | $ | (9,905 | ) | $ | (18,949 | ) | $ | (40,921 | ) | ||||
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | 'The benefit (provision) for income taxes were at rates different from U.S. federal statutory rates for the following reasons for the years ended July 31: | ||||||||||||
2014 | 2013 | 2012 | |||||||||||
Federal statutory rate | 34 | % | 34 | % | 34 | % | |||||||
Penalties and other expenses not deductible for income tax return purposes | (6.6 | ) | (0.9 | ) | (0.5 | ) | |||||||
State income taxes, net of benefit of federal tax deduction | 0.2 | 2.5 | 0.9 | ||||||||||
Change in valuation allowance | (16.5 | ) | (32.7 | ) | (23.2 | ) | |||||||
Impairment of goodwill | — | — | (7.1 | ) | |||||||||
State tax law change | (12.3 | ) | — | — | |||||||||
Other | 0.5 | 0.9 | (0.1 | ) | |||||||||
(0.7 | )% | 3.8 | % | 4 | % |
Accrued_Liabilities_Other_Curr1
Accrued Liabilities, Other Current Liabilities and Other Liabilities (Tables) | 12 Months Ended | ||||||||
Jul. 31, 2014 | |||||||||
Payables and Accruals [Abstract] | ' | ||||||||
Schedule of Accrued Liabilities [Table Text Block] | 'At July 31 accrued liabilities consist of: | ||||||||
2014 | 2013 | ||||||||
Legal | $ | 4,721 | $ | 3,104 | |||||
Payroll, benefits, severance and commissions | 4,959 | 4,794 | |||||||
Research and development | 400 | 721 | |||||||
Professional fees | 638 | 863 | |||||||
Other | 2,199 | 2,294 | |||||||
$ | 12,917 | $ | 11,776 | ||||||
Schedule of Other Current Liabilities [Table Text Block] | 'At July 31 other current liabilities consist of: | ||||||||
2014 | 2013 | ||||||||
Accrued legal settlement – see Note 14 | $ | 400 | $ | — | |||||
Installment loans - see Note 9 | 241 | 182 | |||||||
Capital lease obligations - see Note 9 | 149 | $ | 149 | ||||||
$ | 790 | $ | 331 |
Other_liabilities_Tables
Other liabilities (Tables) | 12 Months Ended | ||||||||
Jul. 31, 2014 | |||||||||
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract] | ' | ||||||||
Schedule of Other Liabilities [Table Text Block] | 'At July 31 Other liabilities consist of: | ||||||||
2014 | 2013 | ||||||||
Accrued legal settlement – see Note 14 | $ | 1,600 | — | ||||||
Capital lease obligation | $ | 344 | $ | 505 | |||||
Installment loans | 369 | 269 | |||||||
$ | 2,313 | $ | 774 | ||||||
Schedule Of Maturities Of Long Term Debt and Capital Lease Obligation [Table Text Block] | 'Future minimum lease and loan payments are as follows: | ||||||||
Capital lease | Installment | ||||||||
loans | |||||||||
2015 | 149 | 241 | |||||||
2016 | 200 | 200 | |||||||
2017 | 191 | 160 | |||||||
2018 | — | 9 | |||||||
Total payments | 540 | 610 | |||||||
Less: imputed interest | (47 | ) | — | ||||||
Payments net of interest | 493 | 610 | |||||||
Less: current portion | (149 | ) | (241 | ) | |||||
Other liabilities - net | $ | 344 | $ | 369 |
Stockholders_Equity_Tables
Stockholders' Equity (Tables) | 12 Months Ended | ||||||||||||||||||||||||
Jul. 31, 2014 | |||||||||||||||||||||||||
Stockholders' Equity Note [Abstract] | ' | ||||||||||||||||||||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | 'A summary of the activity pursuant to the Company’s stock option plans for the years ended July 31, 2014, 2013, and 2012 is as follows: | ||||||||||||||||||||||||
2014 | 2013 | 2012 | |||||||||||||||||||||||
Options | Weighted - | Options | Weighted - | Options | Weighted - | ||||||||||||||||||||
Average | Average | Average | |||||||||||||||||||||||
Exercise | Exercise | Exercise | |||||||||||||||||||||||
Price | Price | Price | |||||||||||||||||||||||
Outstanding at beginning of year | 726,645 | $ | 10.39 | 736,490 | $ | 14.5 | 785,124 | $ | 14.53 | ||||||||||||||||
New Grants | 665,117 | $ | 2.77 | 336,817 | $ | 2.88 | — | $ | — | ||||||||||||||||
Expired | (236,852 | ) | $ | 15.8 | (346,662 | ) | $ | 11.82 | (48,634 | ) | $ | 15.05 | |||||||||||||
Outstanding at end of year | 1,155,910 | $ | 5.03 | 726,645 | $ | 10.39 | 736,490 | $ | 14.5 | ||||||||||||||||
Exercisable at end of year | 399,262 | $ | 7.66 | 389,828 | $ | 16.88 | 736,490 | $ | 14.5 | ||||||||||||||||
Weighted average fair value of options granted during year | $ | 0.9 | $ | 1.22 | — | ||||||||||||||||||||
Schedule of Share based Compensation Stock Options Activity Range of Exercise Prices [Table Text Block] | 'The following table summarizes information for stock options outstanding at July 31, 2014: | ||||||||||||||||||||||||
Options outstanding and exercisable | |||||||||||||||||||||||||
Range of Exercise prices | Shares | Weighted- Average | Weighted- | ||||||||||||||||||||||
Remaining | Average Exercise | ||||||||||||||||||||||||
Contractual Life in | Price | ||||||||||||||||||||||||
years | |||||||||||||||||||||||||
$ 2.53 – 3.00 | 217,362 | 3.81 | $ | 2.84 | |||||||||||||||||||||
$12.99-17.66 | 181,900 | 0.41 | $ | 16.82 | |||||||||||||||||||||
399,262 | |||||||||||||||||||||||||
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] | 'The following table summarizes the activity pursuant to restricted stock awards for the years ended July 31, | ||||||||||||||||||||||||
2014 | 2013 | 2012 | |||||||||||||||||||||||
Awards | Weighted - | Awards | Weighted - | Awards | Weighted - | ||||||||||||||||||||
Average | Average | Average | |||||||||||||||||||||||
Award Price | Award Price | Award Price | |||||||||||||||||||||||
Outstanding at beginning of year | 125,133 | $ | 3.45 | 257,583 | $ | 3.58 | 311,952 | $ | 4.84 | ||||||||||||||||
Awarded | 11,500 | $ | 4.77 | 39,000 | $ | 1.77 | 144,143 | $ | 2.51 | ||||||||||||||||
Vested | (82,971 | ) | $ | (2.70 | ) | (157,783 | ) | $ | (3.23 | ) | (174,638 | ) | $ | (4.85 | ) | ||||||||||
Forfeited | (11,160 | ) | $ | (1.70 | ) | (13,667 | ) | $ | (3.59 | ) | (23,874 | ) | $ | (4.30 | ) | ||||||||||
Outstanding (non-vested) at end of year | 42,502 | $ | 5.74 | 125,133 | $ | 3.45 | 257,583 | $ | 3.58 | ||||||||||||||||
Weighted average market value of awards granted during year | $ | 4.77 | $ | 1.77 | $ | 2.51 |
Employee_benefit_plan_Tables
Employee benefit plan (Tables) | 12 Months Ended | ||||||||||||
Jul. 31, 2014 | |||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ' | ||||||||||||
Schedule of Substantially Funded [Table Text Block] | 'The status of the Swiss Plan, which is substantially funded as of December 31, 2013, the latest plan year end, is as follows: | ||||||||||||
As of December 31, | 2013 | 2012 | 2011 | ||||||||||
Total Assets | $ | 2,531 | $ | 2,965 | $ | 3,247 | |||||||
Accumulated Benefit Obligation | $ | 2,697 | $ | 3,064 | $ | 3,224 | |||||||
Funded status | 94 | % | 97 | % | 99 | % | |||||||
Schedule of Contributions Plan [Table Text Block] | ' | ||||||||||||
Fiscal Year ended July 31, | 2013 | 2012 | 2011 | ||||||||||
Contributions | $ | 467 | $ | 521 | $ | 483 |
Commitments_Tables
Commitments (Tables) | 12 Months Ended | ||||||
Jul. 31, 2014 | |||||||
Disclosure Text Block Supplement [Abstract] | ' | ||||||
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] | 'Minimum future annual rentals under all non-cancelable operating leases, net of sublease rental income of $322, as of July 31, 2014, are as follows: | ||||||
Years ended July 31, | |||||||
2015 | 5,627 | ||||||
2016 | 4,999 | ||||||
2017 | 3,731 | ||||||
2018 | 2,306 | ||||||
2019 | 1,733 | ||||||
Thereafter | 1,106 | ||||||
$ | 19,502 |
Segment_reporting_Tables
Segment reporting (Tables) | 12 Months Ended | ||||||||||||||||||||
Jul. 31, 2014 | |||||||||||||||||||||
Segment Reporting [Abstract] | ' | ||||||||||||||||||||
Schedule of Segment Reporting Information, by Segment [Table Text Block] | 'The following financial information represents the operating results of the reportable segments of the Company: | ||||||||||||||||||||
Year ended July 31, 2014 | Clinical | Life | Therapeutics | Other | Consolidated | ||||||||||||||||
Labs | Sciences | ||||||||||||||||||||
Revenues: | |||||||||||||||||||||
Clinical laboratory services | $ | 58,689 | — | — | — | $ | 58,689 | ||||||||||||||
Product revenues | — | $ | 32,850 | — | — | 32,850 | |||||||||||||||
Royalty and license fee income | — | 4,408 | — | — | 4,408 | ||||||||||||||||
Total revenues | 58,689 | 37,258 | — | — | 95,947 | ||||||||||||||||
Operating expenses: | |||||||||||||||||||||
Cost of clinical laboratory services | 38,948 | — | — | — | 38,948 | ||||||||||||||||
Cost of product revenues | — | 15,320 | — | — | 15,320 | ||||||||||||||||
Research and development | 14 | 2,350 | $ | 777 | — | 3,141 | |||||||||||||||
Selling, general and administrative | 20,460 | 13,374 | — | $ | 7,967 | 41,801 | |||||||||||||||
Provision for uncollectible accounts receivable | 3,115 | (52 | ) | — | — | 3,063 | |||||||||||||||
Legal fee expense | 736 | 940 | — | 5,278 | 6,954 | ||||||||||||||||
Legal settlements, net | 2,000 | (5,100 | ) | (3,100 | ) | ||||||||||||||||
Total operating expenses | 65,273 | 26,832 | 777 | 13,245 | 106,127 | ||||||||||||||||
Operating (loss) income | (6,584 | ) | 10,426 | (777 | ) | (13,245 | ) | (10,180 | ) | ||||||||||||
Other income (expense) | |||||||||||||||||||||
Interest | (43 | ) | 9 | — | (174 | ) | (208 | ) | |||||||||||||
Other | 56 | 95 | — | 43 | 194 | ||||||||||||||||
Foreign exchange gain | — | 289 | — | — | 289 | ||||||||||||||||
(Loss) income before income taxes | $ | (6,571 | ) | $ | 10,819 | $ | (777 | ) | $ | (13,376 | ) | $ | (9,905 | ) | |||||||
Depreciation and amortization included above | $ | 1,415 | $ | 2,455 | $ | 7 | $ | 94 | $ | 3,971 | |||||||||||
Share-based compensation included in above: | |||||||||||||||||||||
Cost of clinical laboratory services | $ | 8 | $ | 1 | — | — | $ | 9 | |||||||||||||
Research and development | — | 1 | — | — | 1 | ||||||||||||||||
Selling, general and administrative | 36 | 6 | — | $ | 542 | 584 | |||||||||||||||
Total | $ | 44 | $ | 8 | — | $ | 542 | $ | 594 | ||||||||||||
Capital expenditures | $ | 643 | $ | 195 | — | — | $ | 838 | |||||||||||||
Year ended July 31, 2013 | Clinical | Life | Therapeutics | Other | Consolidated | ||||||||||||||||
Labs | Sciences | ||||||||||||||||||||
Revenues: | |||||||||||||||||||||
Clinical laboratory services | $ | 55,889 | — | — | — | $ | 55,889 | ||||||||||||||
Product revenues | — | $ | 32,526 | — | — | 32,526 | |||||||||||||||
Royalty and license fee income | — | 5,292 | — | — | 5,292 | ||||||||||||||||
Total revenues | 55,889 | 37,818 | — | — | 93,707 | ||||||||||||||||
Operating expenses: | |||||||||||||||||||||
Cost of clinical laboratory services | 38,251 | — | — | — | 38,251 | ||||||||||||||||
Cost of product revenues | — | 16,584 | — | — | 16,584 | ||||||||||||||||
Research and development | 294 | 2,356 | $ | 1,239 | — | 3,889 | |||||||||||||||
Selling, general and administrative | 19,942 | 15,511 | — | $ | 8,201 | 43,654 | |||||||||||||||
Provision for uncollectible accounts receivable | 4,232 | 264 | — | — | 4,496 | ||||||||||||||||
Legal fee expense | 316 | 57 | — | 5,440 | 5,813 | ||||||||||||||||
Total operating expenses | 63,035 | 34,772 | 1,239 | 13,641 | 112,687 | ||||||||||||||||
Operating (loss) income | (7,146 | ) | 3,046 | (1,239 | ) | (13,641 | ) | (18,980 | ) | ||||||||||||
Other income (expense) | |||||||||||||||||||||
Interest | (46 | ) | 13 | — | (21 | ) | (54 | ) | |||||||||||||
Other | 49 | (71 | ) | — | 27 | 5 | |||||||||||||||
Foreign exchange gain | — | 80 | — | — | 80 | ||||||||||||||||
(Loss) income before income taxes | $ | (7,143 | ) | $ | 3,066 | $ | (1,239 | ) | $ | (13,635 | ) | $ | (18,949 | ) | |||||||
Depreciation and amortization included above | $ | 1,377 | $ | 3,102 | $ | 22 | $ | 104 | $ | 4,605 | |||||||||||
Share-based compensation included in above: | |||||||||||||||||||||
Cost of clinical laboratory services | $ | 9 | 1 | — | — | $ | 10 | ||||||||||||||
Research and development | — | $ | 2 | — | — | 2 | |||||||||||||||
Selling, general and administrative | 36 | 10 | — | $ | 487 | 533 | |||||||||||||||
Total | $ | 45 | $ | 13 | — | $ | 487 | $ | 545 | ||||||||||||
Capital expenditures | $ | 757 | $ | 231 | — | — | $ | 988 | |||||||||||||
Year ended July 31, 2012 | Clinical | Life | Therapeutics | Other | Consolidated | ||||||||||||||||
Labs | Sciences | ||||||||||||||||||||
Revenues: | |||||||||||||||||||||
Clinical laboratory services | $ | 59,403 | — | — | — | $ | 59,403 | ||||||||||||||
Product revenues | — | $ | 37,722 | — | — | 37,722 | |||||||||||||||
Royalty and license fee income | — | 5,958 | — | — | 5,958 | ||||||||||||||||
Total revenues | 59,403 | 43,680 | — | — | 103,083 | ||||||||||||||||
Operating expenses: | |||||||||||||||||||||
Cost of clinical laboratory services | 36,305 | — | — | — | 36,305 | ||||||||||||||||
Cost of product revenues | — | 19,668 | — | — | 19,668 | ||||||||||||||||
Research and development | 299 | 4,308 | $ | 1,686 | — | 6,293 | |||||||||||||||
Selling, general and administrative | 20,856 | 18,305 | — | $ | 8,767 | 47,928 | |||||||||||||||
Provision for uncollectible accounts receivable | 4,987 | 117 | — | — | 5,104 | ||||||||||||||||
Legal fee expense | 262 | 536 | — | 2,926 | 3,724 | ||||||||||||||||
Impairment charges | — | 24,540 | — | — | 24,540 | ||||||||||||||||
Total operating expenses | 62,709 | 67,474 | 1,686 | 11,693 | 143,562 | ||||||||||||||||
Operating loss | (3,306 | ) | (23,794 | ) | (1,686 | ) | (11,693 | ) | (40,479 | ) | |||||||||||
Other income (expense) | |||||||||||||||||||||
Interest | (5 | ) | 23 | — | 3 | 21 | |||||||||||||||
Other | 28 | 27 | — | 22 | 77 | ||||||||||||||||
Foreign exchange loss | — | (540 | ) | — | — | (540 | ) | ||||||||||||||
Loss before income taxes | $ | (3,283 | ) | $ | (24,284 | ) | $ | (1,686 | ) | $ | (11,668 | ) | $ | (40,921 | ) | ||||||
Depreciation and amortization included above | $ | 1,092 | $ | 3,217 | $ | 43 | $ | 125 | $ | 4,477 | |||||||||||
Share-based compensation included in above: | |||||||||||||||||||||
Cost of clinical laboratory services | $ | 10 | — | — | $ | 10 | |||||||||||||||
Research and development | — | $ | 4 | — | — | 4 | |||||||||||||||
Selling, general and administrative | 49 | 59 | — | $ | 597 | 705 | |||||||||||||||
Total | $ | 59 | $ | 63 | — | $ | 597 | $ | 719 | ||||||||||||
Capital expenditures | $ | 921 | $ | 443 | — | — | $ | 1,364 | |||||||||||||
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] | 'Geographic financial information is as follows: | ||||||||||||||||||||
Net sales to unaffiliated customers: | 2014 | 2013 | 2012 | ||||||||||||||||||
United States | $ | 84,389 | $ | 80,559 | $ | 87,776 | |||||||||||||||
Switzerland | 4,130 | 5,499 | 6,802 | ||||||||||||||||||
United Kingdom | 2,023 | 2,324 | 2,728 | ||||||||||||||||||
Other international countries | 5,405 | 5,325 | 5,777 | ||||||||||||||||||
Total | $ | 95,947 | $ | 93,707 | $ | 103,083 | |||||||||||||||
Long-lived assets at July 31, | |||||||||||||||||||||
United States | $ | 20,854 | $ | 23,136 | $ | 25,081 | |||||||||||||||
Switzerland | 1,629 | 1,984 | 2,223 | ||||||||||||||||||
United Kingdom | 462 | 491 | 618 | ||||||||||||||||||
Other international countries | 345 | 401 | 426 | ||||||||||||||||||
Total | $ | 23,290 | $ | 26,012 | $ | 28,348 | |||||||||||||||
Schedule of Segment Revenue By Geographical [Table Text Block] | 'The following is a summary of the Life Sciences segment revenues attributable to customers located in the United States and foreign countries: | ||||||||||||||||||||
2014 | 2013 | 2012 | |||||||||||||||||||
United States | $ | 25,700 | $ | 24,669 | $ | 28,372 | |||||||||||||||
Foreign countries | 11,558 | 13,149 | 15,308 | ||||||||||||||||||
$ | 37,258 | $ | 37,818 | $ | 43,680 |
Summary_of_Selected_Quarterly_1
Summary of Selected Quarterly Financial Data (unaudited) (Tables) | 12 Months Ended | ||||||||||||||||
Jul. 31, 2014 | |||||||||||||||||
Quarterly Financial Information Disclosure [Abstract] | ' | ||||||||||||||||
Schedule of Quarterly Financial Information [Table Text Block] | 'Unaudited quarterly financial data for fiscal 2014 and 2013 is summarized as follows: | ||||||||||||||||
Quarter Ended | |||||||||||||||||
Fiscal 2014 | October 31, | January 31, | April 30, | July 31, | |||||||||||||
2013 | 2014 | 2014 | 2014 | ||||||||||||||
Total revenues | $ | 24,134 | $ | 22,928 | $ | 23,978 | $ | 24,907 | |||||||||
Gross profit | 10,579 | 9,771 | 10,394 | 10,935 | |||||||||||||
Loss before income taxes | (2,725 | ) | (3,570 | ) | (448 | ) | (3,162 | ) | |||||||||
Net loss | (2,787 | ) | (3,566 | ) | (455 | ) | (3,169 | ) | |||||||||
Basic and diluted loss per common share | $ | (0.07 | ) | $ | (0.09 | ) | $ | (0.01 | ) | $ | (0.07 | ) | |||||
Quarter Ended | |||||||||||||||||
Fiscal 2013 | October 31, | January 31, | April 30, | July 31, | |||||||||||||
2012 | 2013 | 2013 | 2013 | ||||||||||||||
Total revenues | $ | 25,630 | $ | 22,210 | $ | 22,598 | $ | 23,269 | |||||||||
Gross profit | 11,736 | 8,642 | 9,048 | 9,446 | |||||||||||||
Loss before income taxes | (3,755 | ) | (5,854 | ) | (5,808 | ) | (3,532 | ) | |||||||||
Net loss | (3,691 | ) | (5,674 | ) | (5,770 | ) | (3,102 | ) | |||||||||
Basic and diluted loss per common share | $ | (0.09 | ) | $ | (0.14 | ) | $ | (0.15 | ) | $ | (0.08 | ) |
SCHEDULE_II_VALUATION_AND_QUAL1
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS (Tables) | 12 Months Ended | |||||||||||||||||||
Jul. 31, 2014 | ||||||||||||||||||||
Valuation and Qualifying Accounts [Abstract] | ' | |||||||||||||||||||
Schedule of Valuation and Qualifying Accounts [Table Text Block] | ' | |||||||||||||||||||
Year ended | Description | Balance at | Charged | Charged | Deductions | Balance at | ||||||||||||||
July 31, | Beginning | to | to other | end of period | ||||||||||||||||
of period | costs | accounts | ||||||||||||||||||
and expenses | ||||||||||||||||||||
2014 | Allowance for doubtful accounts receivable | 2,707 | 3,063 | 3,628 | -1 | 2,142 | ||||||||||||||
2013 | Allowance for doubtful accounts receivable | 3,273 | 4,496 | 5,062 | -1 | 2,707 | ||||||||||||||
2012 | Allowance for doubtful accounts receivable | 3,488 | 5,104 | 5,319 | -1 | 3,273 | ||||||||||||||
2014 | Deferred tax valuation allowance | 47,623 | 1,842 | 49,465 | ||||||||||||||||
2013 | Deferred tax valuation allowance | 41,261 | 6,362 | 47,623 | ||||||||||||||||
2012 | Deferred tax valuation allowance | 32,920 | 8,341 | 41,261 | ||||||||||||||||
-1 | Write-off of uncollectible accounts receivable. |
Summary_of_significant_account2
Summary of significant accounting policies (Details) (USD $) | 12 Months Ended | |||
Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 | Jul. 31, 2011 | |
Summary of significant accounting policies (Details) [Line Items] | ' | ' | ' | ' |
Number of Operating Segments | 3 | ' | ' | ' |
Cash and Cash Equivalents, at Carrying Value | $17,455,000 | $9,007,000 | $15,076,000 | $14,161,000 |
Contractual Adjustment Percentage | 86.00% | 85.00% | 85.00% | ' |
Maximum Period for Allowance for Doubtful Accounts | '210 days | '210 days | ' | ' |
Percentage Of Account Receivable Over Specified Days | 100.00% | 100.00% | ' | ' |
Finite-Lived Intangible Asset, Useful Life | '10 years | ' | ' | ' |
Impairment of Long-Lived Assets Held-for-use | 0 | 0 | 0 | ' |
Indefinite-Lived Intangible Assets (Excluding Goodwill) | ' | ' | 0 | ' |
Advertising Expense | 440,000 | 302,000 | 237,000 | ' |
Share-based Compensation | 594,000 | 545,000 | 719,000 | ' |
Excess Tax Benefit from Share-based Compensation, Operating Activities | 0 | 0 | 0 | ' |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | 462,000 | ' | ' | ' |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | '14 months | ' | ' | ' |
Unvested Restricted Stock [Member] | ' | ' | ' | ' |
Summary of significant accounting policies (Details) [Line Items] | ' | ' | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares) | 159,000 | 32,000 | 0 | ' |
In the Money Stock Options [Member] | ' | ' | ' | ' |
Summary of significant accounting policies (Details) [Line Items] | ' | ' | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares) | 159,000 | 32,000 | 0 | ' |
Outstanding Options [Member] | ' | ' | ' | ' |
Summary of significant accounting policies (Details) [Line Items] | ' | ' | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares) | 604,000 | 727,000 | 736,000 | ' |
Building and Building Improvements [Member] | Minimum [Member] | ' | ' | ' | ' |
Summary of significant accounting policies (Details) [Line Items] | ' | ' | ' | ' |
Property, Plant and Equipment, Estimated Useful Lives | '15 | ' | ' | ' |
Building and Building Improvements [Member] | Maximum [Member] | ' | ' | ' | ' |
Summary of significant accounting policies (Details) [Line Items] | ' | ' | ' | ' |
Property, Plant and Equipment, Estimated Useful Lives | '30 | ' | ' | ' |
Machinery and Equipment [Member] | Minimum [Member] | ' | ' | ' | ' |
Summary of significant accounting policies (Details) [Line Items] | ' | ' | ' | ' |
Property, Plant and Equipment, Estimated Useful Lives | '3 | ' | ' | ' |
Machinery and Equipment [Member] | Maximum [Member] | ' | ' | ' | ' |
Summary of significant accounting policies (Details) [Line Items] | ' | ' | ' | ' |
Property, Plant and Equipment, Estimated Useful Lives | '10 | ' | ' | ' |
Clinical Labs [Member] | United Health Care of New York [Member] | ' | ' | ' | ' |
Summary of significant accounting policies (Details) [Line Items] | ' | ' | ' | ' |
Sales Revenue Services Net Percentage | 25.00% | 22.00% | 21.00% | ' |
Clinical Labs [Member] | ' | ' | ' | ' |
Summary of significant accounting policies (Details) [Line Items] | ' | ' | ' | ' |
Sales Revenue Services Net Percentage | 100.00% | 100.00% | 100.00% | ' |
Receivable Percentage | 60.00% | 60.00% | ' | ' |
Life Sciences [Member] | ' | ' | ' | ' |
Summary of significant accounting policies (Details) [Line Items] | ' | ' | ' | ' |
Royalties Receivable | 1,000,000 | 1,200,000 | ' | ' |
Foreign Bank [Member] | ' | ' | ' | ' |
Summary of significant accounting policies (Details) [Line Items] | ' | ' | ' | ' |
Cash and Cash Equivalents, at Carrying Value | $1,100,000 | $1,500,000 | ' | ' |
Minimum [Member] | ' | ' | ' | ' |
Summary of significant accounting policies (Details) [Line Items] | ' | ' | ' | ' |
Finite-Lived Intangible Asset, Useful Life | '4 years | ' | ' | ' |
Maximum [Member] | ' | ' | ' | ' |
Summary of significant accounting policies (Details) [Line Items] | ' | ' | ' | ' |
Finite-Lived Intangible Asset, Useful Life | '15 years | ' | ' | ' |
Summary_of_significant_account3
Summary of significant accounting policies (Details) - Segment's net revenues and revenue percentages (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 |
Summary of significant accounting policies (Details) - Segment's net revenues and revenue percentages [Line Items] | ' | ' | ' |
Sales Revenue Services Net | $58,689 | $55,889 | $59,403 |
Clinical Labs [Member] | Third-Party Payor [Member] | ' | ' | ' |
Summary of significant accounting policies (Details) - Segment's net revenues and revenue percentages [Line Items] | ' | ' | ' |
Sales Revenue Services Net | 29,509 | 26,014 | 29,616 |
Sales Revenue Services Net Percentage | 50.00% | 47.00% | 50.00% |
Clinical Labs [Member] | Medicare [Member] | ' | ' | ' |
Summary of significant accounting policies (Details) - Segment's net revenues and revenue percentages [Line Items] | ' | ' | ' |
Sales Revenue Services Net | 12,815 | 12,497 | 12,658 |
Sales Revenue Services Net Percentage | 22.00% | 22.00% | 21.00% |
Clinical Labs [Member] | Self-Pay [Member] | ' | ' | ' |
Summary of significant accounting policies (Details) - Segment's net revenues and revenue percentages [Line Items] | ' | ' | ' |
Sales Revenue Services Net | 11,204 | 12,172 | 11,895 |
Sales Revenue Services Net Percentage | 19.00% | 22.00% | 20.00% |
Clinical Labs [Member] | Health Maintenance Organizations [Member] | ' | ' | ' |
Summary of significant accounting policies (Details) - Segment's net revenues and revenue percentages [Line Items] | ' | ' | ' |
Sales Revenue Services Net | 5,161 | 5,206 | 5,234 |
Sales Revenue Services Net Percentage | 9.00% | 9.00% | 9.00% |
Clinical Labs [Member] | ' | ' | ' |
Summary of significant accounting policies (Details) - Segment's net revenues and revenue percentages [Line Items] | ' | ' | ' |
Sales Revenue Services Net | $58,689 | $55,889 | $59,403 |
Sales Revenue Services Net Percentage | 100.00% | 100.00% | 100.00% |
Summary_of_significant_account4
Summary of significant accounting policies (Details) - Net accounts receivable by segment (USD $) | Jul. 31, 2014 | Jul. 31, 2013 |
In Thousands, unless otherwise specified | ||
Summary of significant accounting policies (Details) - Net accounts receivable by segment [Line Items] | ' | ' |
Accounts Receivable Net Current | $12,470 | $12,288 |
Clinical Labs [Member] | Third-Party Payor [Member] | ' | ' |
Summary of significant accounting policies (Details) - Net accounts receivable by segment [Line Items] | ' | ' |
Accounts Receivable Net Current | 3,499 | 3,395 |
Accounts Receivable Net Current Percentage | 46.00% | 46.00% |
Clinical Labs [Member] | Self-Pay [Member] | ' | ' |
Summary of significant accounting policies (Details) - Net accounts receivable by segment [Line Items] | ' | ' |
Accounts Receivable Net Current | 2,193 | 2,696 |
Accounts Receivable Net Current Percentage | 29.00% | 37.00% |
Clinical Labs [Member] | Medicare [Member] | ' | ' |
Summary of significant accounting policies (Details) - Net accounts receivable by segment [Line Items] | ' | ' |
Accounts Receivable Net Current | 1,558 | 930 |
Accounts Receivable Net Current Percentage | 21.00% | 13.00% |
Clinical Labs [Member] | Health Maintenance Organizations [Member] | ' | ' |
Summary of significant accounting policies (Details) - Net accounts receivable by segment [Line Items] | ' | ' |
Accounts Receivable Net Current | 280 | 300 |
Accounts Receivable Net Current Percentage | 4.00% | 4.00% |
Clinical Labs [Member] | ' | ' |
Summary of significant accounting policies (Details) - Net accounts receivable by segment [Line Items] | ' | ' |
Accounts Receivable Net Current | 7,530 | 7,321 |
Accounts Receivable Net Current Percentage | 100.00% | 100.00% |
Life Sciences [Member] | ' | ' |
Summary of significant accounting policies (Details) - Net accounts receivable by segment [Line Items] | ' | ' |
Accounts Receivable Net Current | $4,940 | $4,967 |
Summary_of_significant_account5
Summary of significant accounting policies (Details) - Allowance for doubtful accounts (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 |
Allowance for doubtful accounts [Abstract] | ' | ' | ' |
Beginning balance | $2,707 | $3,273 | ' |
Provision for doubtful accounts | 3,063 | 4,496 | 5,104 |
Write-offs | -3,628 | -5,062 | ' |
Ending balance | $2,142 | $2,707 | $3,273 |
Summary_of_significant_account6
Summary of significant accounting policies (Details) - Computation of basic and diluted net loss per share (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
In Thousands, except Per Share data, unless otherwise specified | Jul. 31, 2014 | Apr. 30, 2014 | Jan. 31, 2014 | Oct. 31, 2013 | Jul. 31, 2013 | Apr. 30, 2013 | Jan. 31, 2013 | Oct. 31, 2012 | Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 |
Computation of basic and diluted net loss per share [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss (in Dollars) | ($3,169) | ($455) | ($3,566) | ($2,787) | ($3,102) | ($5,770) | ($5,674) | ($3,691) | ($9,977) | ($18,237) | ($39,269) |
Weighted-average common shares outstanding - Basic | ' | ' | ' | ' | ' | ' | ' | ' | 42,561 | 39,607 | 38,798 |
Weighted-average common shares outstanding - Diluted | ' | ' | ' | ' | ' | ' | ' | ' | 42,561 | 39,607 | 38,798 |
Net loss per share: | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Basic and diluted (in Dollars per share) | ($0.07) | ($0.01) | ($0.09) | ($0.07) | ($0.08) | ($0.15) | ($0.14) | ($0.09) | ($0.23) | ($0.46) | ($1.01) |
Summary_of_significant_account7
Summary of significant accounting policies (Details) - Amount of expense related to share-based payment arrangements (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 |
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ' | ' | ' |
Share Based Compensation | $594 | $545 | $719 |
Cost of Clinical Laboratory Services [Member] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ' | ' | ' |
Share Based Compensation | 9 | 10 | 10 |
Research and Development Expense [Member] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ' | ' | ' |
Share Based Compensation | 1 | 2 | 4 |
Selling, General and Administrative Expenses [Member] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ' | ' | ' |
Share Based Compensation | $584 | $533 | $705 |
Goodwill_and_intangible_assets2
Goodwill and intangible assets (Details) (USD $) | 1 Months Ended | 3 Months Ended | 12 Months Ended | 12 Months Ended | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||||||
31-May-14 | 31-May-13 | Jul. 31, 2012 | Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 | Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 | 31-May-12 | Jul. 31, 2012 | Jul. 31, 2014 | Jul. 31, 2014 | |
Clinical Labs [Member] | Clinical Labs [Member] | Enzo Life Sciences [Member] | Trademarks [Member] | Trademarks [Member] | Trademarks [Member] | Intangible Assets, Amortization Period [Member] | |||||||
Goodwill and intangible assets (Details) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Goodwill | ' | ' | ' | $7,452,000 | $7,452,000 | ' | $7,452,000 | $7,452,000 | ' | ' | ' | ' | ' |
Percentage Of Stock Price Result Of Decline Market Capitalization | ' | ' | 44.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Asset Impairment Charges | ' | ' | ' | ' | ' | 24,540,000 | ' | ' | 18,800,000 | ' | 5,700,000 | ' | ' |
Asset Impairment Charges Net of Taxes | ' | ' | ' | ' | ' | 22,400,000 | ' | ' | 18,000,000 | ' | 4,400,000 | ' | ' |
Finite-Lived Intangible Asset, Useful Life | ' | ' | ' | '10 years | ' | ' | ' | ' | ' | '5 years | ' | '5 years | '5 years |
Amortization of Intangible Assets | ' | ' | ' | 1,840,000 | 1,990,000 | 1,660,000 | ' | ' | ' | ' | ' | 600,000 | ' |
Finite-Lived Intangible Assets, Period Increase (Decrease) | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5,700,000 | ' | ' | ' |
Goodwill, Impairment Loss | $0 | $0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Goodwill_and_intangible_assets3
Goodwill and intangible assets (Details) - Schedule of indefinite-lived intangible assets (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 |
Indefinite-lived Intangible Assets [Line Items] | ' | ' | ' |
Gross | $28,478 | $28,214 | ' |
Accumulated Amortization | -20,370 | -18,271 | ' |
Net | 8,108 | 9,943 | ' |
Amortization expense, Accumulated Amortization | -1,840 | -1,990 | -1,660 |
Amortization expense, Net | -1,840 | -1,990 | -1,660 |
Life Sciences [Member] | ' | ' | ' |
Indefinite-lived Intangible Assets [Line Items] | ' | ' | ' |
Gross | 28,478 | 28,214 | 27,904 |
Accumulated Amortization | -20,370 | -18,271 | -16,124 |
Net | 8,108 | 9,943 | 11,780 |
Amortization expense, Accumulated Amortization | -1,840 | -1,990 | ' |
Amortization expense, Net | -1,840 | -1,990 | ' |
Foreign currency translation, Gross | 264 | 310 | ' |
Foreign currency translation, Accumulated Amortization | -259 | -157 | ' |
Foreign currency translation, Net | $5 | $153 | ' |
Goodwill_and_intangible_assets4
Goodwill and intangible assets (Details) - Schedule of intangible assets (USD $) | Jul. 31, 2014 | Jul. 31, 2013 |
In Thousands, unless otherwise specified | ||
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items] | ' | ' |
Finite-lived intangible assets, Gross | $28,478 | $28,214 |
Finite-lived intangible assets, Accumulated Amortization | -20,370 | -18,271 |
Finite-lived intangible assets, Net | 8,108 | 9,943 |
Patents [Member] | ' | ' |
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items] | ' | ' |
Finite-lived intangible assets, Gross | 11,027 | 11,027 |
Finite-lived intangible assets, Accumulated Amortization | -10,775 | -10,587 |
Finite-lived intangible assets, Net | 252 | 440 |
Customer Relationships [Member] | ' | ' |
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items] | ' | ' |
Finite-lived intangible assets, Gross | 12,602 | 12,446 |
Finite-lived intangible assets, Accumulated Amortization | -6,565 | -5,448 |
Finite-lived intangible assets, Net | 6,037 | 6,998 |
Website And Acquired Content [Member] | ' | ' |
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items] | ' | ' |
Finite-lived intangible assets, Gross | 1,037 | 1,026 |
Finite-lived intangible assets, Accumulated Amortization | -1,037 | -980 |
Finite-lived intangible assets, Net | ' | 46 |
Licensed Technology And Other [Member] | ' | ' |
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items] | ' | ' |
Finite-lived intangible assets, Gross | 537 | 513 |
Finite-lived intangible assets, Accumulated Amortization | -434 | -382 |
Finite-lived intangible assets, Net | 103 | 131 |
Trademarks [Member] | ' | ' |
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items] | ' | ' |
Finite-lived intangible assets, Gross | 3,275 | 3,202 |
Finite-lived intangible assets, Accumulated Amortization | -1,559 | -874 |
Finite-lived intangible assets, Net | $1,716 | $2,328 |
Goodwill_and_intangible_assets5
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions | 1 Months Ended | 12 Months Ended |
31-May-12 | Jul. 31, 2014 | |
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items] | ' | ' |
Useful life assigned | ' | '10 years |
Customer Relationships [Member] | Minimum [Member] | ' | ' |
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items] | ' | ' |
Useful life assigned | ' | '8 years |
Customer Relationships [Member] | Maximum [Member] | ' | ' |
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items] | ' | ' |
Useful life assigned | ' | '15 years |
Customer Relationships [Member] | ' | ' |
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items] | ' | ' |
Weighted average remaining useful life | ' | '6 years |
Trademarks [Member] | ' | ' |
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items] | ' | ' |
Useful life assigned | '5 years | '5 years |
Weighted average remaining useful life | ' | '3 years |
Other Intangible Assets [Member] | Minimum [Member] | ' | ' |
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items] | ' | ' |
Useful life assigned | ' | '4 years |
Other Intangible Assets [Member] | Maximum [Member] | ' | ' |
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items] | ' | ' |
Useful life assigned | ' | '5 years |
Other Intangible Assets [Member] | ' | ' |
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items] | ' | ' |
Weighted average remaining useful life | ' | '1 year |
Minimum [Member] | ' | ' |
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items] | ' | ' |
Useful life assigned | ' | '4 years |
Maximum [Member] | ' | ' |
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items] | ' | ' |
Useful life assigned | ' | '15 years |
Goodwill_and_intangible_assets6
Goodwill and intangible assets (Details) - schedule of finite-lived intangible assets, future amortization expense (USD $) | Jul. 31, 2014 |
In Thousands, unless otherwise specified | |
schedule of finite-lived intangible assets, future amortization expense [Abstract] | ' |
2015 | $1,630 |
2016 | 1,620 |
2017 | 1,508 |
2018 | 1,141 |
2019 | $827 |
Supplemental_disclosure_for_st1
Supplemental disclosure for statement of cash flows (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 |
Supplemental Cash Flow Elements [Abstract] | ' | ' | ' |
Income Taxes Paid | $44 | $46 | $70 |
Interest Paid | 208 | 69 | 5 |
Installment Loans Financed Amount | 392 | 365 | ' |
Capital Lease Obligation Cost Basis | ' | 765 | ' |
Adjustment to Additional Paid in Capital Stock Option Issued in Lieu of Cash Payment | $136 | ' | ' |
Inventories_Details_Schedule_o
Inventories (Details) - Schedule of inventory, current (USD $) | Jul. 31, 2014 | Jul. 31, 2013 |
In Thousands, unless otherwise specified | ||
Schedule of inventory, current [Abstract] | ' | ' |
Raw materials | $1,092 | $922 |
Work in process | 2,460 | 2,628 |
Finished products | 5,138 | 5,255 |
$8,690 | $8,805 |
Property_plant_and_equipment_D
Property, plant, and equipment (Details) - Schedule of Property, Plant And Equipment (USD $) | Jul. 31, 2014 | Jul. 31, 2013 |
In Thousands, unless otherwise specified | ||
Schedule of Property, Plant And Equipment [Abstract] | ' | ' |
Building and building improvements | $4,834 | $4,751 |
Machinery and equipment (includes asset under capital lease - see Note 9) | 7,125 | 6,922 |
Office furniture and computer equipment | 16,834 | 16,390 |
Leasehold improvements | 4,835 | 4,759 |
33,628 | 32,822 | |
Accumulated depreciation and amortization | -26,610 | -24,917 |
7,018 | 7,905 | |
Land and land improvements | 712 | 712 |
$7,730 | $8,617 |
Income_taxes_Details
Income taxes (Details) (USD $) | 12 Months Ended | |
Jul. 31, 2014 | Jul. 31, 2013 | |
Income taxes (Details) [Line Items] | ' | ' |
Deferred Tax Liabilities, Net | $183,000 | $200,000 |
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | 1,800,000 | 6,400,000 |
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration | 103,200,000 | ' |
Deferred Tax Assets Research and Development and Other Tax Credit Carryforwards | 1,085,000 | 1,013,000 |
Foreign Loss Carryforwards | 6,000,000 | ' |
Undistributed Earnings of Foreign Subsidiaries | 304,000 | ' |
Liability for Uncertain Tax Position | 0 | ' |
Domestic Tax Authority [Member] | Minimum [Member] | ' | ' |
Income taxes (Details) [Line Items] | ' | ' |
Operating Loss Carryforwards Expiration Year | '2018 | ' |
Domestic Tax Authority [Member] | Maximum [Member] | ' | ' |
Income taxes (Details) [Line Items] | ' | ' |
Operating Loss Carryforwards Expiration Year | '2034 | ' |
U.S. Federal Tax [Member] | ' | ' |
Income taxes (Details) [Line Items] | ' | ' |
Deferred Tax Assets Research and Development and Other Tax Credit Carryforwards | $1,000,000 | ' |
Research Tax Credit Carryforward [Member] | Minimum [Member] | ' | ' |
Income taxes (Details) [Line Items] | ' | ' |
Tax Credit Carryforward Expiration Year | '2025 | ' |
Research Tax Credit Carryforward [Member] | Maximum [Member] | ' | ' |
Income taxes (Details) [Line Items] | ' | ' |
Tax Credit Carryforward Expiration Year | '2034 | ' |
Minimum [Member] | ' | ' |
Income taxes (Details) [Line Items] | ' | ' |
Income Tax Examination, Year under Examination | '2011 | ' |
Maximum [Member] | ' | ' |
Income taxes (Details) [Line Items] | ' | ' |
Income Tax Examination, Year under Examination | '2013 | ' |
Income_taxes_Details_Provision
Income taxes (Details) - (Provision) benefit for income taxes (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 |
Current (provision) benefit: | ' | ' | ' |
State and local | ($68) | ($46) | ($49) |
Foreign | -22 | -1 | -61 |
Deferred benefit | 18 | 759 | 1,762 |
(Provision) benefit for income taxes | ($72) | $712 | $1,652 |
Income_taxes_Details_Deferred_
Income taxes (Details) - Deferred tax assets and liabilities (USD $) | Jul. 31, 2014 | Jul. 31, 2013 |
In Thousands, unless otherwise specified | ||
Deferred tax assets: | ' | ' |
Federal tax carryforward losses | $35,352 | $34,836 |
Provision for uncollectible accounts receivable | 753 | 920 |
State and local tax carry forward losses | 2,604 | 3,791 |
Accrued royalties | 144 | 143 |
Stock compensation | 190 | 317 |
Depreciation | 618 | 625 |
Research and development and other tax credit carryforwards | 1,085 | 1,013 |
Foreign tax carryforward losses | 1,207 | 772 |
Intangibles | 2,970 | 2,980 |
Inventory | 2,194 | 1,249 |
Accrued expenses | 3,103 | 1,622 |
Other, net | 15 | 19 |
Deferred tax assets | 50,235 | 48,287 |
Deferred tax liabilities: | ' | ' |
Deferred patent costs | -135 | -132 |
Prepaid expenses | -671 | -695 |
Unrealized foreign exchange | -118 | ' |
Other, net | -29 | -37 |
Deferred tax liabilities | -953 | -864 |
Net deferred tax assets (liabilities) before valuation allowance | 49,282 | 47,423 |
Less: valuation allowance | -49,465 | -47,623 |
Net deferred tax liabilities | ($183) | ($200) |
Income_taxes_Details_Net_defer
Income taxes (Details) - Net deferred tax liabilities are included in the consolidated balance sheets (USD $) | Jul. 31, 2014 | Jul. 31, 2013 |
In Thousands, unless otherwise specified | ||
Deferred taxes: | ' | ' |
Non-current | $183 | $200 |
$183 | $200 |
Income_taxes_Details_Component
Income taxes (Details) - Components of loss before income taxes (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
In Thousands, unless otherwise specified | Jul. 31, 2014 | Apr. 30, 2014 | Jan. 31, 2014 | Oct. 31, 2013 | Jul. 31, 2013 | Apr. 30, 2013 | Jan. 31, 2013 | Oct. 31, 2012 | Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 |
Income taxes (Details) - Components of loss before income taxes [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Loss before taxes | ($3,162) | ($448) | ($3,570) | ($2,725) | ($3,532) | ($5,808) | ($5,854) | ($3,755) | ($9,905) | ($18,949) | ($40,921) |
Domestic Tax Authority [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Income taxes (Details) - Components of loss before income taxes [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Loss before taxes | ' | ' | ' | ' | ' | ' | ' | ' | -8,702 | -15,419 | -31,817 |
Foreign Tax Authority [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Income taxes (Details) - Components of loss before income taxes [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Loss before taxes | ' | ' | ' | ' | ' | ' | ' | ' | ($1,203) | ($3,530) | ($9,104) |
Income_taxes_Details_Benefit_p
Income taxes (Details) - Benefit (provision) for income taxes were at rates different from U.S. federal statutory rates | 12 Months Ended | ||
Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 | |
Benefit (provision) for income taxes were at rates different from U.S. federal statutory rates [Abstract] | ' | ' | ' |
Federal statutory rate | 34.00% | 34.00% | 34.00% |
Penalties and other expenses not deductible for income tax return purposes | -6.60% | -0.90% | -0.50% |
State income taxes, net of benefit of federal tax deduction | 0.20% | 2.50% | 0.90% |
Change in valuation allowance | -16.50% | -32.70% | -23.20% |
Impairment of goodwill | ' | ' | -7.10% |
State tax law change | -12.30% | ' | ' |
Other | 0.50% | 0.90% | -0.10% |
-0.70% | 3.80% | 4.00% |
Loan_Payable_Details
Loan Payable (Details) (USD $) | 12 Months Ended | |
Jul. 31, 2014 | Jul. 31, 2013 | |
Debt Disclosure [Abstract] | ' | ' |
Line of Credit Facility Expiration Month and Year | 'December 2016 | ' |
Line of Credit Facility, Maximum Borrowing Capacity | $8,000,000 | ' |
Line of Credit Facility Additional Borrowings Capacity | 4,000,000 | ' |
Unamortized Debt Issuance Expense | 281,000 | ' |
LIBOR Rate Period | '3 months | ' |
Debt Instrument, Description of Variable Rate Basis | 'three month LIBOR rate, with a floor of 1.25% plus an applicable margin of 4.0% | ' |
Debt Instrument, Basis Spread on Variable Rate | 1.25% | ' |
Debt Instrument Margin on Variable Rate | 4.00% | ' |
Debt Instrument Increase in Interest Rate on Default | 3.00% | ' |
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage | 0.50% | ' |
Line of Credit Facility Minimum Borrowings | 2,000,000 | ' |
Long-term Line of Credit | 3,013,000 | 3,264,000 |
Line of Credit Facility, Remaining Borrowing Capacity | $2,700,000 | ' |
Accrued_Liabilities_Other_Curr2
Accrued Liabilities, Other Current Liabilities and Other Liabilities (Details) (USD $) | Jul. 31, 2014 | Jul. 31, 2013 |
In Millions, unless otherwise specified | ||
Payables and Accruals [Abstract] | ' | ' |
Self Insurance Reserve, Current | $0.20 | $0.20 |
Accrued_Liabilities_Other_Curr3
Accrued Liabilities, Other Current Liabilities and Other Liabilities (Details) - Accrued liabilities (USD $) | Jul. 31, 2014 | Jul. 31, 2013 |
In Thousands, unless otherwise specified | ||
Accrued liabilities [Abstract] | ' | ' |
Legal | $4,721 | $3,104 |
Payroll, benefits, severance and commissions | 4,959 | 4,794 |
Research and development | 400 | 721 |
Professional fees | 638 | 863 |
Other | 2,199 | 2,294 |
$12,917 | $11,776 |
Accrued_Liabilities_Other_Curr4
Accrued Liabilities, Other Current Liabilities and Other Liabilities (Details) - Other current liabilities (USD $) | Jul. 31, 2014 | Jul. 31, 2013 |
In Thousands, unless otherwise specified | ||
Accrued Liabilities, Other Current Liabilities and Other Liabilities (Details) - Other current liabilities [Line Items] | ' | ' |
Other Liabilities Current | $790 | $331 |
Accrued Legal Settlement [Member] | ' | ' |
Accrued Liabilities, Other Current Liabilities and Other Liabilities (Details) - Other current liabilities [Line Items] | ' | ' |
Other Liabilities Current | 400 | ' |
Installment Loans [Member] | ' | ' |
Accrued Liabilities, Other Current Liabilities and Other Liabilities (Details) - Other current liabilities [Line Items] | ' | ' |
Other Liabilities Current | 241 | 182 |
Capital Lease Obligations [Member] | ' | ' |
Accrued Liabilities, Other Current Liabilities and Other Liabilities (Details) - Other current liabilities [Line Items] | ' | ' |
Other Liabilities Current | $149 | $149 |
Other_liabilities_Details
Other liabilities (Details) (USD $) | Jul. 31, 2014 | Jul. 31, 2013 |
In Thousands, unless otherwise specified | ||
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract] | ' | ' |
Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation (in Dollars) | $330 | ' |
Short-term Debt, Weighted Average Interest Rate | 2.87% | 4.50% |
Other_liabilities_Details_Sche
Other liabilities (Details) - Schedule of other current liabilities (USD $) | Jul. 31, 2014 | Jul. 31, 2013 |
In Thousands, unless otherwise specified | ||
Other liabilities (Details) - Schedule of other current liabilities [Line Items] | ' | ' |
Other liabilities | $2,313 | $774 |
Accrued Legal Settlement [Member] | ' | ' |
Other liabilities (Details) - Schedule of other current liabilities [Line Items] | ' | ' |
Other liabilities | 1,600 | ' |
Capital Lease Obligations [Member] | ' | ' |
Other liabilities (Details) - Schedule of other current liabilities [Line Items] | ' | ' |
Other liabilities | 344 | 505 |
Installment Loans [Member] | ' | ' |
Other liabilities (Details) - Schedule of other current liabilities [Line Items] | ' | ' |
Other liabilities | $369 | $269 |
Other_liabilities_Details_Sche1
Other liabilities (Details) - Schedule of future minimum lease and loan payments (USD $) | Jul. 31, 2014 |
In Thousands, unless otherwise specified | |
Schedule of future minimum lease and loan payments [Abstract] | ' |
2015 | $149 |
2015 | 241 |
2016 | 200 |
2016 | 200 |
2017 | 191 |
2017 | 160 |
2018 | 9 |
Total payments | 540 |
Total payments | 610 |
Less: imputed interest | -47 |
Payments net of interest | 493 |
Payments net of interest | 610 |
Less: current portion | -149 |
Less: current portion | -241 |
Other liabilities - net | 344 |
Other liabilities - net | $369 |
Stockholders_Equity_Details
Stockholders' Equity (Details) (USD $) | 12 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | |||||||||||||||||
Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 | Jan. 17, 2014 | Mar. 28, 2013 | Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 | Jul. 31, 2013 | Jul. 31, 2012 | Jul. 31, 2013 | Jul. 31, 2012 | Jul. 31, 2014 | Jul. 31, 2014 | Jul. 31, 2014 | Jan. 17, 2014 | Jul. 31, 2014 | Feb. 03, 2014 | Jan. 17, 2014 | Jul. 31, 2014 | Jul. 31, 2014 | Jul. 31, 2014 | Jan. 14, 2011 | |
Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Treasury Stock [Member] | Treasury Stock [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | 2011 Plan [Member] | Minimum [Member] | Maximum [Member] | Senior Officers and Board of Directors [Member] | Senior Officers and Board of Directors [Member] | Executive Officers [Member] | Executive Officers [Member] | Executive Officers [Member] | 2005 Plan [Member] | 2011 Plan [Member] | 2011 Plan [Member] | ||||||
Stockholders' Equity (Details) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common Stock, Par or Stated Value Per Share (in Dollars per share) | $0.01 | $0.01 | ' | ' | $0.01 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Maximum Offering Price Under Sales Agreement (in Shares) | ' | ' | ' | 20,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of Commission Payable on Equity Offering | 3.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock Issued During Period, Shares, New Issues (in Shares) | ' | 906,715 | ' | ' | ' | 3,421,176 | 906,715 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Average Sale Price of Stock (in Dollars per share) | $3.48 | $2.26 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Proceeds from Issuance of Common Stock | $11,542,000 | $1,825,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock Offering and Commissions Expenses | 357,000 | 224,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock Issued During Period, Shares, Employee Benefit Plan (in Shares) | 165,646 | 9,419 | ' | ' | ' | 165,646 | 9,419 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Payments of Stock Issuance Costs | ' | ' | ' | ' | ' | 636,000 | 27,000 | ' | 616,000 | 649,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock Issued During Period Shares Acquisition Earn Out (in Shares) | ' | ' | ' | ' | ' | ' | ' | 275,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fair Value of Stock Issued for Acquisition Earn Out | ' | ' | ' | ' | ' | ' | ' | 500,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock Issued During Period, Shares, Treasury Stock Reissued (in Shares) | ' | ' | ' | ' | ' | ' | ' | ' | 216,556 | 233,458 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock Issued During Period, Value, Treasury Stock Reissued | ' | 616,000 | 649,000 | ' | ' | ' | ' | ' | 3,074,000 | 3,313,000 | -2,458,000 | -2,664,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,000,000 | ' | ' |
Share Based Compensation Arrangement by Share Based Payment Award Number of Additional Awards to be Granted (in Shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' |
Share Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units (in Shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,000,000 |
Number of Shares of Common Stock Remain Available for Issuance as Option for Plan Termination (in Shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,656,000 | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '2 years | '4 years | '2 years | ' | '3 years | '3 years | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | 425,000 | 0 | 0 | ' | ' | 253,000 | 411,000 | 283 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | 1,915 | 0 | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares) | 665,117 | 336,817 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 267,797 | ' | 20,000 | 95,729 | ' | ' | ' | ' |
Number of Officers | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2 | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $2.77 | $2.88 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $2.70 | ' | $2.75 | $2.70 | ' | ' | ' | ' |
Share Based Compensation Arrangement by Share Based Payment Award Options Term | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '5 years | ' | '5 years | '5 years | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share) | $0.90 | $1.22 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $1.05 | ' | $1.11 | $1.10 | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '3 years 3 months | ' | '3 years 6 months | '3 years 6 months | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 54.78% | ' | 55.07% | 55.45% | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0.90% | ' | 0.84% | 1.00% | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0 | ' | $0 | $0 | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in Shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' | 0 | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights | 'The Awards vest upon the recipient’s continued employment or director service ratably over either two, three or four years. | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stockholders_Equity_Details_Sc
Stockholders' Equity (Details) - Schedule of stock option plans (USD $) | 12 Months Ended | ||
Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 | |
Schedule of stock option plans [Abstract] | ' | ' | ' |
Outstanding at beginning of year (in Shares) | 726,645 | 736,490 | 785,124 |
Outstanding at beginning of year | $10.39 | $14.50 | $14.53 |
New Grants (in Shares) | 665,117 | 336,817 | ' |
New Grants | $2.77 | $2.88 | ' |
Expired (in Shares) | -236,852 | -346,662 | -48,634 |
Expired | $15.80 | $11.82 | $15.05 |
Outstanding at end of year (in Shares) | 1,155,910 | 726,645 | 736,490 |
Outstanding at end of year | $5.03 | $10.39 | $14.50 |
Exercisable at end of year (in Shares) | 399,262 | 389,828 | 736,490 |
Exercisable at end of year | $7.66 | $16.88 | $14.50 |
Weighted average fair value of options granted during year | $0.90 | $1.22 | ' |
Stockholders_Equity_Details_Sc1
Stockholders' Equity (Details) - Schedule of stock options outstanding (USD $) | Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 | Jul. 31, 2011 | Jul. 31, 2014 | Jul. 31, 2014 |
Exercise Price Range 1 [Member] | Exercise Price Range 2 [Member] | |||||
Stockholders' Equity (Details) - Schedule of stock options outstanding [Line Items] | ' | ' | ' | ' | ' | ' |
Range of Exercise prices | ' | ' | ' | ' | $2.53 | $12.99 |
Range of Exercise prices | ' | ' | ' | ' | $3 | $17.66 |
Shares (in Shares) | 399,262 | 389,828 | 736,490 | ' | 217,362 | 181,900 |
Weighted-Average Remaining Contractual Life in years | ' | ' | ' | ' | '3 years 295 days | '149 days |
Weighted Average Exercise price (in Dollars per share) | $5.03 | $10.39 | $14.50 | $14.53 | $2.84 | $16.82 |
Stockholders_Equity_Details_Sc2
Stockholders' Equity (Details) - Schedule of restricted stock awards (USD $) | 12 Months Ended | ||
Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 | |
Schedule of restricted stock awards [Abstract] | ' | ' | ' |
Outstanding at beginning of year (in Shares) | 125,133 | 257,583 | 311,952 |
Outstanding at beginning of year | $3.45 | $3.58 | $4.84 |
Awarded | $4.77 | $1.77 | $2.51 |
Awarded (in Shares) | 11,500 | 39,000 | 144,143 |
Vested (in Shares) | -82,971 | -157,783 | -174,638 |
Vested | ($2.70) | ($3.23) | ($4.85) |
Forfeited (in Shares) | -11,160 | -13,667 | -23,874 |
Forfeited | ($1.70) | ($3.59) | ($4.30) |
Outstanding (non-vested) at end of year (in Shares) | 42,502 | 125,133 | 257,583 |
Outstanding (non-vested) at end of year | $5.74 | $3.45 | $3.58 |
Weighted average market value of awards granted during year | $4.77 | $1.77 | $2.51 |
Employee_benefit_plan_Details
Employee benefit plan (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 |
Employee benefit plan (Details) [Line Items] | ' | ' | ' |
Employer Matched Contributions Percentage Of The Employees Contribution | 50.00% | 50.00% | 50.00% |
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent | 10.00% | 10.00% | 10.00% |
Share Based 401k Employer Match Expense (in Dollars) | $636 | $643 | $649 |
Defined Contribution Plan Minimum Annual Contribution Percent | 13.00% | ' | ' |
Minimum Age of Employee for Saving Contribution | '25 years | ' | ' |
Defined Benefit Plan Minimum Annual Investment Return Percentage | 2.00% | ' | ' |
Defined Contribution Pension Plan Expiration Date | 31-Dec-14 | ' | ' |
Swiss Employees [Member] | ' | ' | ' |
Employee benefit plan (Details) [Line Items] | ' | ' | ' |
Employer Matched Contributions Percentage Of The Employees Contribution | 50.00% | ' | ' |
Employee_benefit_plan_Details_
Employee benefit plan (Details) - Schedule of substantially funded (USD $) | Jul. 31, 2014 | Dec. 31, 2013 | Jul. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
In Thousands, unless otherwise specified | |||||
Schedule of substantially funded [Abstract] | ' | ' | ' | ' | ' |
Total Assets | $64,411 | $2,531 | $58,958 | $2,965 | $3,247 |
Accumulated Benefit Obligation | ' | $2,697 | ' | $3,064 | $3,224 |
Funded status | ' | 94.00% | ' | 97.00% | 99.00% |
Employee_benefit_plan_Details_1
Employee benefit plan (Details) - Schedule of contrubutions plan (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Jul. 31, 2013 | Jul. 31, 2012 | Jul. 31, 2011 |
Schedule of contrubutions plan [Abstract] | ' | ' | ' |
Contributions | $467 | $521 | $483 |
Royalty_and_other_income_Detai
Royalty and other income (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 |
Royalty and other income (Details) [Line Items] | ' | ' | ' |
Patent Expiration Date | 24-Apr-18 | ' | ' |
Life Sciences [Member] | ' | ' | ' |
Royalty and other income (Details) [Line Items] | ' | ' | ' |
Royalty Revenue | $4,408 | $5,144 | $5,900 |
Commitments_Details
Commitments (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 |
Commitments (Details) [Line Items] | ' | ' | ' |
Description Of Operating Leases | 'The Company leases equipment, office and laboratory space under several non-cancelable operating leases that expire between September 2014 and May 2023. Certain leases include renewal options and rent escalation clauses. An entity owned by certain executive officers/directors of the Company owns the building that the Company leases as its main facility for laboratory operations and certain research operations. In March 2005, the Company amended and extended the lease for 12 years. In addition to the minimum annual rentals of space, the lease is subject to annual increases, based on the consumer price index. Annual increases are limited to 3% per year | ' | ' |
Lease Extension Period | '12 years | ' | ' |
Maximum Annual Rental Increase Percentage | 3.00% | ' | ' |
Rent expense Including Real Estate Taxes | $1,649 | $1,605 | $1,556 |
Operating Leases, Rent Expense | 4,488 | 4,354 | 4,378 |
Operating Leases, Rent Expense, Sublease Rentals | 322 | ' | ' |
Agreement Renew Period | '2 years | ' | ' |
Other Commitment, Due in Next Twelve Months | $2,271 | ' | ' |
Minimum [Member] | ' | ' | ' |
Commitments (Details) [Line Items] | ' | ' | ' |
Lease Expiration Month and Year | 'September 2014 | ' | ' |
Maximum [Member] | ' | ' | ' |
Commitments (Details) [Line Items] | ' | ' | ' |
Lease Expiration Month and Year | 'May 2023 | ' | ' |
Commitments_Details_Schedule_o
Commitments (Details) - Schedule of future minimum rental payments for operating leases (USD $) | Jul. 31, 2014 |
In Thousands, unless otherwise specified | |
Schedule of future minimum rental payments for operating leases [Abstract] | ' |
2015 | $5,627 |
2016 | 4,999 |
2017 | 3,731 |
2018 | 2,306 |
2019 | 1,733 |
Thereafter | 1,106 |
$19,502 |
Contingencies_Details
Contingencies (Details) (USD $) | 1 Months Ended | 12 Months Ended | 21 Months Ended | 1 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | ||||
In Millions, unless otherwise specified | Nov. 30, 2012 | Jun. 30, 2004 | Jul. 31, 2014 | Jun. 30, 2004 | Jul. 31, 2014 | Apr. 22, 2014 | Jul. 31, 2014 | Jul. 31, 2014 | Apr. 30, 2014 | Jul. 31, 2014 | Jun. 20, 2014 |
Indemnification Agreement [Member] | Agreement [Member] | Subpoena [Member] | Subpoena [Member] | Subpoena [Member] | Subpoena [Member] | Perkin Elmer [Member] | |||||
Affymetrix Inc [Member] | Minimum [Member] | Maximum [Member] | |||||||||
Contingencies (Details) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Gain Contingency, Patents Allegedly Infringed upon, Number | ' | 6 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of Licensee Patents | ' | ' | 4 | ' | ' | ' | ' | ' | ' | ' | ' |
Gain Contingency, Patents Found Not Infringed upon, Number | 1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Gain Contingency, Unrecorded Amount | ' | ' | ' | ' | $48.50 | ' | ' | ' | ' | ' | ' |
Gain Contingencies Prejudgement Interest | ' | ' | 12.5 | ' | ' | ' | ' | ' | ' | ' | ' |
Loss Contingency, Number of Defendants | ' | ' | 6 | ' | ' | ' | ' | ' | ' | ' | ' |
Loss Contingency, New Claims Filed, Number | ' | ' | ' | 6 | ' | ' | ' | ' | ' | ' | ' |
Litigation Settlement, Amount | ' | ' | ' | ' | ' | 5.1 | ' | ' | ' | ' | ' |
Proceeds from Legal Settlements | ' | ' | ' | ' | ' | 4.3 | ' | ' | ' | ' | ' |
Litigation Settlement, Expense | ' | ' | ' | ' | ' | 0.8 | ' | ' | ' | ' | ' |
Escrow Deposit | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 7 |
Investigation Period | ' | ' | ' | ' | ' | ' | ' | ' | ' | 'The time period initially covered by the investigation was from 2004 through 2011. | ' |
Estimated Litigation Settlement Amount | ' | ' | ' | ' | ' | ' | ' | ' | 2 | ' | ' |
Period Over Which Settlement Amount Has to Be Paid | ' | ' | ' | ' | ' | ' | ' | ' | '5 years | ' | ' |
Estimated Litigation Liability, Current | ' | ' | 10 | ' | ' | ' | ' | ' | ' | 0.4 | ' |
Estimated Litigation Liability, Noncurrent | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1.6 | ' |
Additional Payment of Litigation Settlement Amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1.5 | ' |
Amount of Additional Capital Receipt Condition for Litigation Settlement | ' | ' | ' | ' | ' | ' | $10 | ' | ' | ' | ' |
Percentage of Additional Payment of Litigation Settlement Amount over Additional Capital Receipt | ' | ' | ' | ' | ' | ' | ' | ' | ' | 20.00% | ' |
Litigation Settlement Period | ' | ' | ' | ' | ' | ' | '2004 | '2014 | ' | ' | ' |
Segment_reporting_Details
Segment reporting (Details) | 12 Months Ended |
Jul. 31, 2014 | |
Segment Reporting [Abstract] | ' |
Number of Reportable Segments | 3 |
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount | 100.00% |
Segment_reporting_Details_Sche
Segment reporting (Details) - Schedule of segment reporting information, by segment (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 |
Revenues: | ' | ' | ' |
Clinical laboratory services | $58,689 | $55,889 | $59,403 |
Product revenues | 32,850 | 32,526 | 37,722 |
Royalty and license fee income | 4,408 | 5,292 | 5,958 |
Total revenues | 95,947 | 93,707 | 103,083 |
Operating expenses: | ' | ' | ' |
Cost of clinical laboratory services | 38,948 | 38,251 | 36,305 |
Cost of product revenues | 15,320 | 16,584 | 19,668 |
Research and development | 3,141 | 3,889 | 6,293 |
Selling, general and administrative | 41,801 | 43,654 | 47,928 |
Provision for uncollectible accounts receivable | 3,063 | 4,496 | 5,104 |
Legal fee expense | 6,954 | 5,813 | 3,724 |
Impairment charges | ' | ' | 24,540 |
Legal settlements, net | -3,100 | ' | ' |
Operating (loss) income | -10,180 | -18,980 | -40,479 |
Other income (expense) | ' | ' | ' |
Other | 194 | 5 | 77 |
Foreign exchange gain | 289 | 80 | -540 |
Cost of Clinical Laboratory Services [Member] | Clinical Labs [Member] | ' | ' | ' |
Share-based compensation included in above: | ' | ' | ' |
Share-based compensation | 8 | 9 | 10 |
Cost of Clinical Laboratory Services [Member] | Life Sciences [Member] | ' | ' | ' |
Share-based compensation included in above: | ' | ' | ' |
Share-based compensation | 1 | 1 | ' |
Cost of Clinical Laboratory Services [Member] | Consolidated [Member] | ' | ' | ' |
Share-based compensation included in above: | ' | ' | ' |
Share-based compensation | 9 | 10 | 10 |
Research and Development Expense [Member] | Life Sciences [Member] | ' | ' | ' |
Share-based compensation included in above: | ' | ' | ' |
Share-based compensation | 1 | 2 | 4 |
Research and Development Expense [Member] | Consolidated [Member] | ' | ' | ' |
Share-based compensation included in above: | ' | ' | ' |
Share-based compensation | 1 | 2 | 4 |
Selling, General and Administrative Expenses [Member] | Clinical Labs [Member] | ' | ' | ' |
Share-based compensation included in above: | ' | ' | ' |
Share-based compensation | 36 | 36 | 49 |
Selling, General and Administrative Expenses [Member] | Life Sciences [Member] | ' | ' | ' |
Share-based compensation included in above: | ' | ' | ' |
Share-based compensation | 6 | 10 | 59 |
Selling, General and Administrative Expenses [Member] | Other Segments [Member] | ' | ' | ' |
Share-based compensation included in above: | ' | ' | ' |
Share-based compensation | 542 | 487 | 597 |
Selling, General and Administrative Expenses [Member] | Consolidated [Member] | ' | ' | ' |
Share-based compensation included in above: | ' | ' | ' |
Share-based compensation | 584 | 533 | 705 |
Total [Member] | Clinical Labs [Member] | ' | ' | ' |
Share-based compensation included in above: | ' | ' | ' |
Share-based compensation | 44 | 45 | 59 |
Total [Member] | Life Sciences [Member] | ' | ' | ' |
Share-based compensation included in above: | ' | ' | ' |
Share-based compensation | 8 | 13 | 63 |
Total [Member] | Other Segments [Member] | ' | ' | ' |
Share-based compensation included in above: | ' | ' | ' |
Share-based compensation | 542 | 487 | 597 |
Total [Member] | Consolidated [Member] | ' | ' | ' |
Share-based compensation included in above: | ' | ' | ' |
Share-based compensation | 594 | 545 | 719 |
Clinical Labs [Member] | ' | ' | ' |
Revenues: | ' | ' | ' |
Clinical laboratory services | 58,689 | 55,889 | 59,403 |
Total revenues | 58,689 | 55,889 | 59,403 |
Operating expenses: | ' | ' | ' |
Cost of clinical laboratory services | 38,948 | 38,251 | 36,305 |
Research and development | 14 | 294 | 299 |
Selling, general and administrative | 20,460 | 19,942 | 20,856 |
Provision for uncollectible accounts receivable | 3,115 | 4,232 | 4,987 |
Legal fee expense | 736 | 316 | 262 |
Legal settlements, net | 2,000 | ' | ' |
Total operating expenses | 65,273 | 63,035 | 62,709 |
Operating (loss) income | -6,584 | -7,146 | -3,306 |
Other income (expense) | ' | ' | ' |
Interest | -43 | -46 | -5 |
Other | 56 | 49 | 28 |
(Loss) income before income taxes | -6,571 | -7,143 | -3,283 |
Depreciation and amortization included above | 1,415 | 1,377 | 1,092 |
Share-based compensation included in above: | ' | ' | ' |
Capital expenditures | 643 | 757 | 921 |
Life Sciences [Member] | ' | ' | ' |
Revenues: | ' | ' | ' |
Product revenues | 32,850 | 32,526 | 37,722 |
Royalty and license fee income | 4,408 | 5,292 | 5,958 |
Total revenues | 37,258 | 37,818 | 43,680 |
Operating expenses: | ' | ' | ' |
Cost of product revenues | 15,320 | 16,584 | 19,668 |
Research and development | 2,350 | 2,356 | 4,308 |
Selling, general and administrative | 13,374 | 15,511 | 18,305 |
Provision for uncollectible accounts receivable | -52 | 264 | 117 |
Legal fee expense | 940 | 57 | 536 |
Impairment charges | ' | ' | 24,540 |
Legal settlements, net | -5,100 | ' | ' |
Total operating expenses | 26,832 | 34,772 | 67,474 |
Operating (loss) income | 10,426 | 3,046 | -23,794 |
Other income (expense) | ' | ' | ' |
Interest | 9 | 13 | 23 |
Other | 95 | -71 | 27 |
Foreign exchange gain | 289 | 80 | -540 |
(Loss) income before income taxes | 10,819 | 3,066 | -24,284 |
Depreciation and amortization included above | 2,455 | 3,102 | 3,217 |
Share-based compensation included in above: | ' | ' | ' |
Capital expenditures | 195 | 231 | 443 |
Therapeutics [Member] | ' | ' | ' |
Operating expenses: | ' | ' | ' |
Research and development | 777 | 1,239 | 1,686 |
Total operating expenses | 777 | 1,239 | 1,686 |
Operating (loss) income | -777 | -1,239 | -1,686 |
Other income (expense) | ' | ' | ' |
(Loss) income before income taxes | -777 | -1,239 | -1,686 |
Depreciation and amortization included above | 7 | 22 | 43 |
Other Segments [Member] | ' | ' | ' |
Operating expenses: | ' | ' | ' |
Selling, general and administrative | 7,967 | 8,201 | 8,767 |
Legal fee expense | 5,278 | 5,440 | 2,926 |
Total operating expenses | 13,245 | 13,641 | 11,693 |
Operating (loss) income | -13,245 | -13,641 | -11,693 |
Other income (expense) | ' | ' | ' |
Interest | -174 | -21 | 3 |
Other | 43 | 27 | 22 |
(Loss) income before income taxes | -13,376 | -13,635 | -11,668 |
Depreciation and amortization included above | 94 | 104 | 125 |
Consolidated [Member] | ' | ' | ' |
Revenues: | ' | ' | ' |
Clinical laboratory services | 58,689 | 55,889 | 59,403 |
Product revenues | 32,850 | 32,526 | 37,722 |
Royalty and license fee income | 4,408 | 5,292 | 5,958 |
Total revenues | 95,947 | 93,707 | 103,083 |
Operating expenses: | ' | ' | ' |
Cost of clinical laboratory services | 38,948 | 38,251 | 36,305 |
Cost of product revenues | 15,320 | 16,584 | 19,668 |
Research and development | 3,141 | 3,889 | 6,293 |
Selling, general and administrative | 41,801 | 43,654 | 47,928 |
Provision for uncollectible accounts receivable | 3,063 | 4,496 | 5,104 |
Legal fee expense | 6,954 | 5,813 | 3,724 |
Impairment charges | ' | ' | 24,540 |
Legal settlements, net | -3,100 | ' | ' |
Total operating expenses | 106,127 | 112,687 | 143,562 |
Operating (loss) income | -10,180 | -18,980 | -40,479 |
Other income (expense) | ' | ' | ' |
Interest | -208 | -54 | 21 |
Other | 194 | 5 | 77 |
Foreign exchange gain | 289 | 80 | -540 |
(Loss) income before income taxes | -9,905 | -18,949 | -40,921 |
Depreciation and amortization included above | 3,971 | 4,605 | 4,477 |
Share-based compensation included in above: | ' | ' | ' |
Capital expenditures | $838 | $988 | $1,364 |
Segment_reporting_Details_Geog
Segment reporting (Details) - Geographic financial information (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 |
Revenues from External Customers and Long-Lived Assets [Line Items] | ' | ' | ' |
Net sales to unaffiliated customers | $95,947 | $93,707 | $103,083 |
Long-lived assets at July 31, | ' | ' | ' |
Long-lived assets | 23,290 | 26,012 | 28,348 |
UNITED STATES | ' | ' | ' |
Revenues from External Customers and Long-Lived Assets [Line Items] | ' | ' | ' |
Net sales to unaffiliated customers | 84,389 | 80,559 | 87,776 |
Long-lived assets at July 31, | ' | ' | ' |
Long-lived assets | 20,854 | 23,136 | 25,081 |
SWITZERLAND | ' | ' | ' |
Revenues from External Customers and Long-Lived Assets [Line Items] | ' | ' | ' |
Net sales to unaffiliated customers | 4,130 | 5,499 | 6,802 |
Long-lived assets at July 31, | ' | ' | ' |
Long-lived assets | 1,629 | 1,984 | 2,223 |
UNITED KINGDOM | ' | ' | ' |
Revenues from External Customers and Long-Lived Assets [Line Items] | ' | ' | ' |
Net sales to unaffiliated customers | 2,023 | 2,324 | 2,728 |
Long-lived assets at July 31, | ' | ' | ' |
Long-lived assets | 462 | 491 | 618 |
Other International Countries [Member] | ' | ' | ' |
Revenues from External Customers and Long-Lived Assets [Line Items] | ' | ' | ' |
Net sales to unaffiliated customers | 5,405 | 5,325 | 5,777 |
Long-lived assets at July 31, | ' | ' | ' |
Long-lived assets | $345 | $401 | $426 |
Segment_reporting_Details_Sche1
Segment reporting (Details) - Schedule of segment revenue by geographical (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 |
Segment reporting (Details) - Schedule of segment revenue by geographical [Line Items] | ' | ' | ' |
Sales Revenue Net | $95,947 | $93,707 | $103,083 |
Life Sciences [Member] | UNITED STATES | ' | ' | ' |
Segment reporting (Details) - Schedule of segment revenue by geographical [Line Items] | ' | ' | ' |
Sales Revenue Net | 25,700 | 24,669 | 28,372 |
Life Sciences [Member] | Foreign Countries [Member] | ' | ' | ' |
Segment reporting (Details) - Schedule of segment revenue by geographical [Line Items] | ' | ' | ' |
Sales Revenue Net | 11,558 | 13,149 | 15,308 |
Life Sciences [Member] | ' | ' | ' |
Segment reporting (Details) - Schedule of segment revenue by geographical [Line Items] | ' | ' | ' |
Sales Revenue Net | 37,258 | 37,818 | 43,680 |
UNITED STATES | ' | ' | ' |
Segment reporting (Details) - Schedule of segment revenue by geographical [Line Items] | ' | ' | ' |
Sales Revenue Net | $84,389 | $80,559 | $87,776 |
Summary_of_Selected_Quarterly_2
Summary of Selected Quarterly Financial Data (unaudited) (Details) - Quarterly Financial Data (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
In Thousands, except Per Share data, unless otherwise specified | Jul. 31, 2014 | Apr. 30, 2014 | Jan. 31, 2014 | Oct. 31, 2013 | Jul. 31, 2013 | Apr. 30, 2013 | Jan. 31, 2013 | Oct. 31, 2012 | Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 |
Quarterly Financial Data [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total revenues | $24,907 | $23,978 | $22,928 | $24,134 | $23,269 | $22,598 | $22,210 | $25,630 | ' | ' | ' |
Gross profit | 10,935 | 10,394 | 9,771 | 10,579 | 9,446 | 9,048 | 8,642 | 11,736 | ' | ' | ' |
Loss before income taxes | -3,162 | -448 | -3,570 | -2,725 | -3,532 | -5,808 | -5,854 | -3,755 | -9,905 | -18,949 | -40,921 |
Net loss | ($3,169) | ($455) | ($3,566) | ($2,787) | ($3,102) | ($5,770) | ($5,674) | ($3,691) | ($9,977) | ($18,237) | ($39,269) |
Basic and diluted loss per common share (in Dollars per share) | ($0.07) | ($0.01) | ($0.09) | ($0.07) | ($0.08) | ($0.15) | ($0.14) | ($0.09) | ($0.23) | ($0.46) | ($1.01) |
SCHEDULE_II_VALUATION_AND_QUAL2
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS (Details) - Schedule of Valuation and Qualifying Accounts (USD $) | 12 Months Ended | |||||
In Thousands, unless otherwise specified | Jul. 31, 2014 | Jul. 31, 2013 | Jul. 31, 2012 | |||
Allowance for Doubtful Accounts [Member] | ' | ' | ' | |||
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS (Details) - Schedule of Valuation and Qualifying Accounts [Line Items] | ' | ' | ' | |||
Balance at Beginning of period | $2,707 | $3,273 | $3,488 | |||
Charged to costs and expenses | 3,063 | 4,496 | 5,104 | |||
Deductions | 3,628 | [1] | 5,062 | [1] | 5,319 | [1] |
Balance at end of period | 2,142 | 2,707 | 3,273 | |||
Valuation Allowance of Deferred Tax Assets [Member] | ' | ' | ' | |||
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS (Details) - Schedule of Valuation and Qualifying Accounts [Line Items] | ' | ' | ' | |||
Balance at Beginning of period | 47,623 | 41,261 | 32,920 | |||
Charged to costs and expenses | 1,842 | 6,362 | 8,341 | |||
Balance at end of period | $49,465 | $47,623 | $41,261 | |||
[1] | Write-off of uncollectible accounts receivable. |